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Abstract 	
The rapid detection of pathogenic organisms to ensure appropriate 
administration of treatment remains a global healthcare challenge. This is becoming 
increasingly difficult, as identification of the organism alone is no longer enough, 
with the rise of drug resistance amongst many pathogens it is becoming increasingly 
important that both the pathogen and drug resistance are identified. 
Currently, rapid identification can be achieved through a variety of techniques. 
However, many of these techniques are expensive, require extensive sample 
preparation, or highly trained personnel to run with results often not rapidly available. 
This leaves health care professionals to make point-of-care treatment decisions based 
on symptoms without any indication of drug resistance. The use of carbohydrate 
microarrays for pathogen detection has been identified as both a method for detection 
but also as a basis for identifying new drug targets. This exploits the initial protein-
carbohydrate interaction that many pathogens utilise in the initial stages of infection. 
However, the use of microarrays is also challenging, as highly sensitive identification 
of pathogens often requires expensive or synthetically challenging oligosaccharides or 
coupling with a highly sensitive detection method thus limiting its point of care 
application. 
Herein we describe the coupling of a facile surface chemistry for glycan 
addition with a powerful statistical algorithm to improve the sensitivity of a cheap 
monosaccharide functionalised surface without using expensive detection 
methodologies. This technique was then applied to the detection and identification of 
toxic lectins, bacterial samples and finally the life-stage specific detection of 
Plasmodium falciparum (one of the parasites responsible for human malaria). In this 
last case, drug resistance related to carbohydrate binding profile was also observed.  
	 1	
Chapter 1 
 
1.2 Introduction 
Carbohydrates in the glycocalyx, which surrounds almost all cells, mediate a 
multitude of biological processes through protein-carbohydrate interactions. The 
glycocalyx is also important for many diseases and can reflect disease states, such as 
cancer, through aberrant glycosylation patterns. Many pathogens also utilise proteins 
to interact with carbohydrates as an important step in pathogenicity.  
 
Protein-carbohydrate interactions are exploited by Vibrio cholerae in order to mediate 
toxin binding thus causing cholera infection, which results in the death of around 
100,000 people a year.1 Malaria is estimated to kill one child in Africa every 8 
minutes. It is caused by infection with parasites of the Plasmodium spp. and initial 
binding and internalisation of Plasmodium falciparum is mediated by a lectin-like 
protein. Protein-carbohydrate interactions are also crucial for infection with Influenza 
A and for the direct binding of pathogenic strains of Escherichia coli to give but a few 
examples.2 
 
Many of the current detection methodologies for these pathogens are complex or too 
expensive for robust point-of-care diagnostics and as such, increasing the resolution 
of current cheap and facile methods without the use of expensive detection systems is 
an important area of research for point-of-care pathogen detection. 
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1.2.1 Carbohydrates 
Carbohydrates were once described as a molecule “in search of a function”3 and 
thought to be less information rich than proteins.4 The importance of carbohydrate 
signalling has also been underestimated previously.5 However, in the last 20 years 
their role in complex biological processes; such as cell-cell communication, 
immunity, cell differentiation and fertilisation, has come to light and it is now known 
that carbohydrates play a crucial role in many processes.4 This has contributed to the 
delay in generating techniques for their study when compared to DNA and protein 
techniques and many challenges remain in the study of carbohydrates. 
 
Unlike proteins and DNA, carbohydrate synthesis is not trivial, it is possible to 
remove carbohydrate chains from cells but most procedures require multiple 
chromatographic or purification steps. In nature, sugar chain synthesis requires 
multiple enzymes and highly complex synthesis pathways and whilst there has been 
some success in the production of synthetic oligosaccharides the process is often 
laborious involving many protection and deprotection steps.6-10 Generation of the 
carbohydrate structures found in bacteria is further complicated by the presence of 
different glycosylation enzymes and their ability to utilise a larger library of 
monosaccharides than mammalian cells resulting in the production of even more 
complex structures.5  
 
1.2.2 Glycan complexity 
Carbohydrates are now regarded as being unsurpassed in their structural diversity, 
which makes them challenging to study.5 Only ten monosaccharides are utilised in 
	 3	
mammalian cells but that is enough to potentially generate ten million different 
tetrasaccharides.3  
 
The monosaccharides are themselves able to exist as different enantiomers known as 
D- and L- depending on the spatial configuration around the chiral carbon (Figure 
1.1A) and as different anomers depending on the configuration on the anomeric 
carbon (Figure 1.1B). The complexity of glycans goes beyond just the number of 
available monosaccharide building blocks, with chain lengths ranging from single 
monosaccharide units through to polysaccharides containing 500,000 sugar units.  
 
Figure 1.1 D- and L- optical isomers (left and right respectively) are determined by 
the arrangement around the chiral carbon (A). Monosaccharides can also exist as 
different anomers such as α and β glucose (left and right respectively). This is defined 
as the direction of the hydroxyl group on the anomeric carbon relative to the 
configuration around the chiral carbon (B). 
 
Glycosidic linkages between monomers allow the formation of large glycan chains 
and these linkages can also show differences in both stereo- and regiochemistry 
adding another layer of complexity to glycan chains. Differences in stereochemistry 
occur whereby either an α or a β linkage can occur. An example of this difference is 
	 4	
shown by maltose and cellobiose, both of which are disaccharides of D-glucose 
(Figure 1.2). 
 
Figure 1.2 The glycosidic linkage between monosaccharides can show differences in 
stereochemistry with either an α linkage, such as that maltose, or a β linkage as in 
cellobiose (left and right respectively). 
 
Differences in regiochemistry can also occur as the glycosidic bond can form between 
any of the hydroxyl groups as demonstrated by maltose and trehalose (Figure 1.3). 
These chains can also be highly branched utilising both α and β linkages. Often 3D 
structure of the carbohydrate, density, linker to the cell and topological arrangement 
all have to be maintained for recognition to occur.  
 
Figure 1.3 The glycosidic linkage can also show differences in regiochemistry as the 
linkage can form between any of the hydroxyl groups in the monosaccharide 
(examples shown are maltose and α, α-trehalose, left and right respectively). 
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After assembly by glycosyltransferases the glycan complexity is further increased by 
site-specific modifications of the monosaccharide units within a glycan chain. This 
modification can include sulfation, acylation or epimerisation of glucuronic acid to 
iduronic acid (Figure 1.4).  
 
 
Figure 1.4 Epimerisation of glucuronic acid (left) to iduronic acid (right) is a 
common mammalian monosaccharide modification. 
1.2.3 Mammalian Glycocalyx 
 
Carbohydrates are covalently linked to membrane proteins and lipids to form a dense 
glycocalyx (Figure 1.5). Cell surface glycans are positioned optimally to mediate cell-
cell interactions and protect the cell from the extracellular environment.11, 12 They also 
act as recognition elements and binding sites for a multitude of other components and 
are crucial for preventing non-specific protein-protein interactions.13, 14 
 
Figure 1.5 Electron microscopy image of a cross section of a rat myocardial capillary 
showing the glycocalyx of the endothelial cells (reprinted with permission from 
reference 15). 
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The diversity of the glycans present in the glycocalyx is determined by the 
mammalian glycome. The glycome is comprised of ten key mammalian 
monosaccharides (Figure 1.6), which are added to other molecules in a non-template 
driven process mediated by the expression of several different glycosyltransferases 
(several of which have tissue specific isoforms).16-18 
 
 
Figure 1.6 The ten mammalian monosaccharides displayed using standard 
consortium for functional glycomics (CFG) nomenclature.19 
 
Whilst the theoretical glycospace (which is the number of all the possible 
combinations of monosaccharides) is vast only a small subspace is actually used in 
mammals20 and it is thought that there are only around 2000 different mammalian 
glycans with many highly conserved core structures.19 Prokaryotes utilise many more 
than ten monosaccharides and use a much larger subspace of their theoretical glycome 
as their outer membrane has to protect the cell from many harsh and changing 
environments.20 
 
 
 
Galactose N-acetyl galactosamineGlucose Mannose
N-acetyl glucosamine Sialic acid 
(N-acetyl neuraminic acid)
Glucuronic acid
Fucose
Xylose Iduronic acid
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1.2.4 Glycosylation in disease susceptibility 
As the glycocalyx is crucial in the interactions of a cell with its environment it plays a 
crucial role in disease susceptibility and pathogen interaction. For example, the ABO 
blood system is determined by differences in antigenic oligosaccharides on the 
surface of red blood cells (RBCs, Figure 1.7). Serological subgroups are further 
defined by the number of oligosaccharides per RBC highlighting the importance of 
both the specific antigen and the distribution of those antigens.21, 22 Whilst the 
biological role of the system remains a mystery, anthropological studies on the 
population and geographic distributions of blood groups indicate that they may be 
related to group susceptibility to certain disease.21 It is known that blood group 
determines susceptibility to or severity of diseases such as small pox, cholera and 
malaria.23-25 The susceptibility of people with different blood groups to malaria is 
thought to be due to the invasion of the pathogen into uninfected RBCs.25 It has been 
hypothesised that the individual variation of glycans on the surface of human tissues 
is a result of a selection pressure caused by past endemic or epidemic pathogens.21 
 
	 8	
 
Figure 1.7 Serological blood groups are determined by oligosaccharides on the 
surface of red blood cells. Oligosaccharides shown are depicted using the standard 
CFG nomenclature.19 
 
 
1.2.5 Altered glycosylation in disease states 
 
Differences in glycosylation have been detected in diseased tissue and many different 
cancer cells. It is thought that changes in the expression of glycosyltransferases and 
glycosidases result in the changes in the glycans found on the surfaces of tumour 
cells, it has also been suggested that these differences affect interactions between 
lectins at the tumour surface which in turn determines a tumour’s metastatic 
potential.4, 26 
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Cancer cells show a number of differential glycosylation patterns but these changes 
tend to be a specific set of permeations that result in malignant transformation and 
tumour progression. These changes have been selected for as a form of 
‘microevolution’. Most notable are the differences in glycosylation of mucins.27 
Mucins are large glycoproteins found on the surfaces of endothelial cells. They are 
also secreted by healthy cells into the lumens of organs in order to limit adhesion of 
pathogens (Figure 1.7B).21 However, in tumours they have been found to be over-
expressed28 and a number of changes occur; firstly incomplete glycosylation of the 
mucins occurs resulting in truncated glycan patterns29 or increased sialic acid 
moieties.30 These truncated mucins can generate an immune response. The secreted 
mucins are also truncated and in some instances there is a total loss of glycosylation 
and the protein backbones are just secreted (Figure 1.8A). 
 
The altered topology of the tumour itself means that the mucins are added to all 
surfaces of the cells whereas normally they are only expressed on the surface facing 
the lumen. It also results in mucins being secreted into places other than the lumen 
and can be secreted into the blood stream (Figure 1.8A). As in healthy cells, the 
mucins can still act in an anti-adhesion capacity but in cancerous tissue they can 
prevent the adhesion of cancer cells to neighbouring cancer cells resulting in cell 
migration and subsequently tumour metastases (Figure 1.8A).30 
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Figure 1.8 Glycosylation and secretion of mucins is altered in tumours (A) compared 
to normal tissue (B). 
 
Other cancer-associated glycosylation changes include the increased β1-6 branching 
of N-linked glycans,31 increased addition of sialic acid to surface glycans and 
polysialylation,32 increased presentation of ligands specific to selectins33 and 
increased presentation of sialylated blood-group associated glycans on cell surfaces 
(e.g. Lewisx glycans).34 Incomplete synthesis and altered expression of blood-group 
associated glycans coupled with the loss of normal AB blood group glycan expression 
is associated with poorer clinical outcome.35 
 
Metastases
A B
Lumen
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Other diseases are also characterised by glycosylation differences. Mutations in 
certain glycosyltransferases will result in differences in glycosylation associated with 
many congenital diseases including galactosemia, muscle-eye brain disease and 
congenital muscular dystrophy.18 Glycoforms (isoforms of a protein that differ only in 
glycosylation) of immunoglobulin-γ antibodies have been associated with rheumatoid 
arthritis.36 Overexpression of mucins has also been associated with many chronic lung 
conditions including asthma, chronic-obstructive pulmonary disease, bronchitis and 
cystic fibrosis.37 
 
 
1.2.6 Protein-Carbohydrate Interactions 
	
Protein-carbohydrate interactions mediate many crucial biological processes including 
(but not limited to); cell-cell communication, fertilisation, pathogen recognition and 
response, protein folding and both passive and innate immunity.6, 26 All known 
organisms are covered by either free or bound glycan structures and proteins known 
as lectins bind to these carbohydrates during signal transduction.21 These interactions 
are typically weak with a dissociation constant (Kd) typically between 10-3 and 10-6 M. 
This is overcome in nature by presentation of multiple copies of the carbohydrate 
structures on the cells. The increase in affinity in binding is greater than the sum of 
the individual binding events that take place and this is known as the cluster glycoside 
effect.38    
 
This multivalent interaction means that many lectins have multiple binding subunits, 
which can interact with the surface in one of two manners; either the bind-and-slide39 
method or face-to-face binding40 (Figure 1.9). In the bind-and-slide model, a 
multivalent lectin will bind at one point and then once this complex dissociates the 
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lectin will slide along until it binds to another region and in the face-to-face model the 
subunits of the multivalent lectin face in opposite directions to each other and thus 
can engage in crosslinking.41 Graded affinity binding can also increase the binding of 
a lectin to a surface where one subunit interacts with the native version of the ligand 
and other subunits interact more weakly with truncated versions of the ligand in order 
to increase the avidity of the binding event.42  
 
 
Figure 1.9 Mechanisms for multivalent binding can be achieved by either binding of 
a multivalent protein which then dissociates and binds to the next ligand effectively 
sliding along the chain of saccharides with each binding event essentially increasing 
the residence time of the protein within the area of the ligand (A) or through face to 
face binding of multiple dimers binding to multiple ligands on a surface (B). 
 
 
 
Bind-and-slide Face-to-face
A B
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1.2.7 Pathogen exploitation 
 
The carbohydrates on a cell surface determine everything from blood type to disease 
susceptibility and they are often exploited by pathogens (Figure 1.10).21 This 
exploitation falls in to three broad categories; mimicry of the host glycome to avoid 
detection and eradication by the host immune system, adhesion of the pathogen as a 
crucial step in infection or for internalisation, and production of lectins similar to 
those produced by the host’s immune system in order to produce an immune-
compromised niche for the pathogen. 
 
Figure 1.10 Protein-carbohydrate interactions are crucial for many biological 
processes including pathogen-associated adhesion. 
Bacterial adhesion
Toxin adhesion
Cell-cell adhesion
Viral adhesion
Fungal adhesion
Phage adhesion
Parasite adhesion
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1.2.7.1 Host glycome mimicry 
Pathogenic bacteria often find themselves in a “dual glycan speedway” where they 
evolve to avoid phage recognition but also detection by the host.43, 44 One mechanism 
by which they avoid host recognition is through mimicry of the host glycome and 
many species have evolved a variety of mechanisms for doing this. In general, many 
human pathogens have a glycome that is very similar to the mammalian glycome.20 
This avoids triggering the immune system by introducing antigenic glycans such as 
the non-mammalian monosaccharide D-galactofuranose, which is found in 
Mycobacterium tuberculosis in arabinogalactan chains and has been shown to be 
highly antigenic.45 
 
Many mammalian glycans are either fucosylated or contain a sialic acid cap. This cap 
forms a crucial part of protecting host cells from the immune system. They mediate 
the binding of Factor H (which protects the host cells from attack by the complement 
immune system)46 and also engage siglecs, which are sialic acid binding 
immunoglobulin-like lectins. Siglecs are known to have an inhibitory affect on 
immune cells thus protecting the cell they are bound to from the immune response.47 
As sialic acid mediates both of these processes it would be extremely beneficial for 
pathogenic organisms to adopt the sialic acid cap into their glycans to offer protection 
from the host immune system. Indeed, strains of Haemophilus influenza that have 
sialic acid incorporated in their glycome were shown to be more resistant to 
complement-mediated killing by human serum. Mutation of the gene controlling 
sialylation resulted in loss of sialic acid residues and a marked reduction in the 
tolerance to human serum.48 A similar affect has been shown in pathogenic Neisseria 
spp. where sialylation of the lipopolysaccharide renders the bacteria resistant to 
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killing by human serum.49 Whilst sialic acid is used in both of these examples not all 
bacteria have evolved to use it but many of those that have not will utilise bacterial 
mimics of sialic acid.50-52 
 
L-fucose is another important terminal monosaccharide in mammalian glycans but 
this is only found in low abundance amongst bacterial species.20 The exception to this 
is one class of bacterial species, which contain L-fucose in high abundance; and 
includes the pathogenic bacteria Helicobacter pylori, which contains large 
proportions of fucosylated Lewis A glycans in order to mimic the host glycome and 
avoid an immune response.53 
 
Not all bacterial classes mimic the mammalian glycome, for example actinobacteria 
contain a large number of actinobacter specific monosaccharide residues.20 This class 
contains a number of specialised soil bacteria crucial for nitrogen fixation or other 
elements of the soil cycle but also includes a number of human pathogens from the 
class of Mycobacterium including M. tuberculosis.54 As already mentioned, this 
species utilises D-galactofuranose to form antigenic arabinogalactan. M. tuberculosis 
also contains very few sialic acid mimics and thus its glycome is a poor mimic of the 
host glycome but, in this instance, mimicry is less important for pathogen survival as 
M. tuberculosis is an intracellular pathogen.20 
 
Many pathogenic bacterial species mimic the host glycome, at least in part, to avoid 
detection by the immune system or to aid in the binding of immunosuppressant lectins 
present in the host. Those that do not mimic the host or poorly mimic the host are 
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often intracellular based pathogens and thus do not experience the same selection 
pressures to evolve a glycome more similar to that of the host. 
 
1.2.7.2 Toxin adhesion 
 
As all cells are glycosylated, many pathogens exploit this glycosylation to mediate 
binding and internalisation of toxins. Cholera is caused by cell internalisation of a 
toxin produced by the bacteria Vibrio cholerae.55, 56 The toxin is an AB5 toxin, and is 
made up of one subunit that causes cell damage by constitutively activating a protein 
resulting in the excretion of ions from the cell into the lumen of the small intestine 
(Figure 1.11A) and five lectin subunits (Figure 1.11B) that bind the 
monosialyltetrahexosylganglioside (GM1) found on endothelial cells in the small 
intestine.57 
 
Figure 1.11 Crystal structures of cholera toxin which contains one enzymatic A 
subunit shown in grey (A) and five glycan binding B subunits (B).58 
 
A B
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Ricin is a highly toxic lectin extracted from the seeds of the Ricinus communis plant. 
This toxin is an AB toxin and thus contains one glycan binding targeting domain (the 
B subunit) and an enzymatic A subunit. The targeting domain mediates the binding to 
galactose-rich glycans on the cell surface and upon binding the toxin is internalised by 
the cell. Once inside the cell the A subunit and the B subunit are cleaved at the 
disulphide bond (shown in yellow Figure 1.12) and the A subunit cleaves an adenine 
residue from the 28S ribosome effectively halting protein synthesis and triggering cell 
death.59 Whilst somewhere between 106 and 108 molecules of ricin will bind to the 
cell surface, few will make it into the cytosol but entry of just a single A subunit of 
ricin is sufficient to deactivate 1500 ribosome molecules per second.60 
 
Figure 1.12 Crystal structure of Ricin, which is comprised of one A subunit (red) and 
a carbohydrate binding B subunit (blue). A disulphide bond connects the A subunit 
and the B subunit (yellow).61 
 
Lectins are also found in many vegetables and consumption of improperly cooked 
vegetables can result in acute gastrointestinal (GI) tract distress.62 Any plant lectins 
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that are not degraded during digestion can bind to the endothelial cells in the 
intestines and are often toxic.63 Whilst in humans the affects tend to be nausea, 
vomiting and diarrhoea, long term consumption (in animal models) has been 
associated with endothelial cell necrosis and increased cell turn over.64 Upon 
incubation of healthy cultured endothelial cells with plant based lectins, mitogenesis65 
and inhibition of exocytosis is observed.66 Many of the endothelial cells in the GI tract 
experience mechanical stress resulting in damage to the plasma membrane.67 Healthy 
cells can rapidly repair this damage.68 However, lectin binding to these damaged cells 
inhibits this healing mechanism and results in cell necrosis and it has been proposed 
that this is responsible for plant-based food poisoning.69 
 
1.2.7.3 Virus attachment 
 
Many viruses exploit protein-carbohydrate interactions for the initial adhesion phase 
but by far the most studied example is that of hemagglutinin found in influenza A and 
B. This lectin is co-localised as trimmers onto the viral surface and mediates binding 
to the underlying surfaces through sialic acid terminated glycans. After binding, the 
viral envelope fuses to the cell membrane, the virus is internalised and replication 
occurs.  
Viral specificity is determined by the linkage of the sialic acid to the terminal glycan 
and this differs between species; avian species have α(2-3) linked residues (Figure 
1.13A), humans have predominantly α(2-6) linkages (Figure 1.13B) and porcine 
species have both α(2-3) and α(2-6) (Figure 1.13C). As such avian flu binds strongest 
to α(2-3) linked sialic acid residues and human strains of influenza A binds 
predominantly to α(2-6) linked sialic acid residues. In order for an avian influenza 
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virus to infect a human it must first infect a porcine species at the same time as either 
a porcine or human strain in order for the avian species to recombine with either the 
human or porcine viral DNA that allows binding to α(2-6) linked sialic acids. 
 
Figure 1.13 Avian tissue glycans are terminated by α(2-3) linked sialic acids (A), 
human tissue glycans are predominantly terminated by α(2-6) linked sialic acids (B) 
and porcine tissue glycans are terminated by a mixture of α(2-3) and α(2-6) linked 
sialic acids (C). 
 
Interestingly, the carbohydrate binding properties of viruses are not limited to 
mammalian viruses but are also found amongst bacteriophage (which are viruses that 
target bacteria). The bacteriophage PL-1, which infects Lactobacillus casei was found 
to interact specifically with L-rhamonosyl residues in the lipopolysaccharide chains 
which cover the surface of this bacteria. Addition of a lectin capable of binding L-
rhamanose resulted in a dose-dependent inhibition in phage absorption by this 
bacterial species.70 
 
1.2.7.4 Bacterial adhesion and biofilm formation 
 
Lectins play a crucial role in bacterial adhesion and colonisation both by pathogenic 
bacteria to host cells and subsequent biofilm formation, but also in symbiotic 
relationships where bacteria bind to plants and confer nitrogen-fixing properties. 
A B C
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During bacterial infection, a single bacterial cell will bind to the underlying host cell 
surface. The initial adhesion phase is often a protein-carbohydrate interaction either 
through bacterial adhesins binding to host glycans or vice versa. 
 
 
Figure 1.14 Schematic depicting bacterial biofilm formation. The example shown is 
the bacterial adhesin FimH interacting with a mannose rich tetrasaccharide. 
 
For example the adhesin FimH is a crucial virulence factor found in uropathogenic 
Escherichia coli strains.71, 72 FimH is found on the end of fimbrae and mediates the 
binding to mannose rich glycans on the cell surface (Figure 1.14). A combination of 
the adhesins present on the bacterial surface will define the range of susceptible 
tissues, which will differ between species and strains within the same species. For 
example, E. coli strains containing type 1 pili are responsible for initial colonisation 
and infection of the bladder whereas those that possess P-pili result in infection of the 
kidney through binding to glycans.2 Loss or inhibition of these adhesins can prevent 
infection and strains that lack adhesins are non-pathogenic. 
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In the opposite case, binding of the symbiotic Rhizobium spp. to the root hairs of 
plants is mediated by polysaccharides on the bacterial cell (either the 
exopolysaccharide, the lipopolysaccharide or the capsular polysaccharide depending 
on the species). For example, on the roots of the Dutch clover plant (Trifolium repens) 
the protein trifoliin is expressed.73 Trifoliin is a lectin that binds the 
exopolysaccharide of Rhizobium trifolii.74 Colonisation of the plant’s roots by the 
bacteria is the formation of a symbiotic relationship that gives the plant nitrogen-
fixing properties. 
 
1.2.7.5 Parasite exploitation  
 
Many parasites are known to exploit protein-carbohydrate interactions during 
infection. The production of parasite specific lectins are thought to play a role in 
down-regulating the immune response upon parasite infection to create an immune-
compromised niche for the parasite to live in. A lectin-like protein is also thought to 
play a key role in Plasmodium falciparum (one of the species that results in human 
malaria) infiltration of red blood cells. 
 
Generation of an immune-compromised niche involve interactions with host c-type 
lectins. C-type lectins are calcium dependent lectins that play a crucial role in the 
mammalian immune system; encompassing molecules such as collectins (crucial for 
innate bacterial and viral recognition),75 selectins (crucial for mediating adhesion of 
leukocytes at the site of inflammation)33 and Natural Killer cell receptors (which bind 
to major histocompatability complex class 1 (MHC 1) molecules on cells to prevent 
	 22	
lysis and provide triggers for cell death upon detection of altered MHC 1 molecules)76 
to name but a few. Many parasites are known to produce c-type lectins upon infection 
or have had putative c-type lectin domains identified in their genome. Necator 
americanus77 and Nippostrongylus brasiliensis78 are both gastrointestinal worms with 
N. americanus a human pathogen and N. brasiliensis a rodent-specific parasite. Both 
of these parasites have been shown to produce c-type lectins, which show binding 
properties similar to mammalian selectins. It is thought that these play a role in 
suppressing the immune system during parasite infection.78 The parasitic nematode 
Toxocara canis also secretes a glycoprotein, which has been shown to bind to 
mammalian cell surface glycans in a Ca2+ dependent manner and is thought to play a 
role in immune suppression.79, 80 
 
Lectins have also been shown to have a more direct role in parasite infection. During 
infection with Plasmodium falciparum it has been shown that a lectin-like protein is 
involved in binding of the parasite to the surface of the red blood cells prior to 
internalisation of the parasite. This process was prevented upon the addition of high 
concentrations of N-Acetyl-D-Glucosamine to the media.81 Many of the parasite-
derived proteins that are expressed on the surface of an infected red blood cell (during 
a late stage in the infection process) have also been shown to contain putative 
carbohydrate binding domains.82, 83 
 
1.2.7.6 Exploitation by Fungi 
 
Lectins play an important role in the adhesion of pathogenic fungi and has been 
shown to occur in many species including Chryosporium keratinophilum,84 
Macrophomina phaseolina,85 and Anixiopsis stercoraria.86 Of particular interest is 
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Aspergillus fumigatus, which is the most prevalent airborne fungal pathogen of the 
developed world and causes life-threatening infections in immune-compromised 
people.87 Infection involves the inhalation of conidia followed by adherence to the 
lung surface and then germination. This adhesion is known to be sialic acid dependent 
but many other lectins are also present on the surface of the fungi and play an 
important role in adhesion including a fucose binding lectin.88 
 
1.2.8 Disease prevention 
 
The prevalence of protein-carbohydrate interactions in pathogen mechanisms makes 
them an important target for disease prevention in the form of carbohydrate vaccine 
targets, new bacterial species-specific antibiotic targets and anti-adhesion therapy. 
These will now be addressed. 
 
1.2.8.1 Carbohydrate vaccine targets 
 
Despite many pathogens mimicking the host glycome, many still have pathogen 
specific oligosaccharide presentations, which could provide targets suitable for 
carbohydrate-based vaccines. For example, the antigenic response to arabinogalatan 
from M. tuberculosis is a potential vaccine candidate as the component 
galactofuranose is not present in mammalian cells; this minimising the chance of 
generating an autoimmune response.20 Monoclonal antibodies have been generated 
that are directed at the cluster presented mannose-rich oligosaccharides present on 
human immunodeficiency virus (HIV) glycoprotein 120 and new broadly neutralizing 
carbohydrate based antibodies have also been extracted from patients.89, 90 A 
carbohydrate specific immune response to the Streptococcus pneumonia bacteria has 
also been generated in mice in response to gold nanoparticles coated with a T-helper 
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peptide and the tetrasaccharide repeating unit of the S. pneumoniae capsular 
polysaccharide.91 
 
Protein conjugated carbohydrate vaccines have also been developed for H. influenza 
type b, where meningitis caused by this bacteria has been eradicated in areas with a 
vaccine program.92 A species specific tetrasaccharide has also been identified for 
Bacillus anthracis93 and administration of this allowed the generation of antibodies 
specific to this bacteria although more work needs to be done to develop this into a 
usable vaccine against anthrax.94 Proteins conjugated to the P. falciparum specific 
glycophosphatidylinositol (GPI) hexasaccharide have also been developed as a 
potential conjugate vaccine. This vaccine conferred reduced mortality to malaria in 
mice without any cross-reactivity with human GPI although more work to develop 
this is still on going.95 
 
Carbohydrate vaccines are also being pursued as an anti-cancer treatment by utilising 
antibodies produced by the aberrant glycosylation of mucins on tumour cells. This 
involved the coupling of the sialylated Tn antigen (where the Tn Antigen is just N-
Acetyl-D-Galactosamine coupled to a serine or a threonine residue) that is produced 
on aberrant mucins. This vaccine was able to generate a humoral and a cellular 
immune response to the cancer cells.96  
 
1.2.8.2 Pathogen specific glycosyltransferase targets 
 
As glycosylation is a process involving the expression of many glycosyltransferases 
and the existence of non-mammalian monosaccharides there will be pathogen specific 
glycosyltransferases. Drugs that target these enzymes may make the pathogen more 
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susceptible to the host’s immune system by removing its ability to mimic host glycan 
presentation on its surface or by reducing its pathogenicity through other mechanisms.  
 
Neuraminidases play a crucial role in influenza infection. Influenza particles adhere to 
the cell surface through adhesion to sialic acid residues. Upon creation of a new virus 
particle, the viral neuraminidase clips the terminal sialic acid residue from the cellular 
glycan thus allowing release of the viral particle from the cell surface where it can 
then go on and infect other cells.97 This process is the target of neuraminidase 
inhibitors such as oseltamivir and zanamivir although resistance to such drugs is 
becoming more widespread.  
 
V. cholerae can also produce a bacterial neuraminidase and this capability is found 
amongst all strains that cause the most severe cholera infection.98 The role of this 
neuraminidase is to clip sialic acid residues from glycans on the cell surface in order 
to truncate the glycans to form GM1 (the natural binding ligand of the cholera 
toxin).99, 100 This increases the cellular presentation of the cholera toxin binding ligand 
thereby increasing the amount of toxin binding and causing increased disease 
severity.101 Inhibition of this neuraminidase could reduce disease severity in severe 
cholera infections. 
 
As previously mentioned, the presence of sialic acid terminated glycans play a crucial 
role in the protection of H. influenza and Neisseria spp. from the complement immune 
system. As such, inhibition of the enzymes responsible for addition of the sialic acid 
cap to the glycans on the surface of these bacteria will make them more susceptible to 
killing by the immune system and offers a potential drug target (vide infra). 
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1.2.8.3 Anti-adhesion therapy 
 
For those pathogens that have an essential carbohydrate mediated adhesion phase 
(Figure 1.15A), anti-adhesion therapy has potential for prevention of infection and 
treatment of disease. Many examples of carbohydrate based anti-adhesion compounds 
exist, but some examples include the use of glycopolymers for the inhibition of 
cholera toxin binding102, 103 and for the specific inhibition of fimbriated (and thus 
pathogenic) strains of E. coli.104 105 This mechanism is also used in nature to protect 
cells from bacterial infection, mucins which are found on the surface of epithelial 
cells are also secreted thus trapping pathogens before they can invade the underlying 
tissue (Figure 1.15B).21, 106 
 
Figure 1.15 Schematic depicting anti-adhesion therapy. (A) Normally a bacteria will 
bind to the underlying cell glycans resulting in infection (B) whereas a drug or a 
mucin that mimcs these glycans can prevent binding and thus prevent infection. 
 
A
B
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Infection
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A form of anti-adhesion therapy has also been proposed for the prevention of cancer 
metastases. Many cancer cells contain regions of aberrant glycosylation, one common 
modification is the presence of many selectin ligands. This would mask the cancer 
cells from the immune system as selectins are used to suppress the immune system 
and prevent it from attacking host cells. Several compounds have been designed to 
mimic the glycan-binding domain of selectins in order to prevent binding of selectins 
to tumour cells.107-109 
 
1.2.8.4 Carbohydrate based drugs 
 
Carbohydrates also form the basis of a number of other drug compounds including a 
number of antibiotics such as kanamycin, vancomycin and teicoplannin.110 Heparin 
and related compounds such as dermatan sulphate form the basis of many anti-
thrombotic agents.111, 112 Glycoproteins have been used as enzyme replacement 
therapy in patients with Hurler and Hurler-Scheie forms of mucopolysaccharidosis 
I.113 
 
1.2.9 Pathogen detection 
 
As differential carbohydrate binding and glycosylation are often present in disease 
states or determine tissue specificity of pathogens they can be used as a detection 
mechanism too. Detection of disease specific glycosylation can be used in the 
detection of cancers or the presence of pathogens mimicking the host glycome and 
detection of pathogen specific lectins (either as secreted toxins or surface localised) 
can aid in the identification of pathogens. 
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1.2.9.1 Host detection of pathogen mimicry 
 
Whilst many pathogens mimic the host glycome in the presentation of the glycans on 
their cell surface, the host immune system contains mechanisms for identifying 
mimicry. For example, sulfation is a site-specific modification that is common in 
mammals but very rare amongst bacterial species. Sulfation tends to occur on 
glycosaminoglycans and these sulfation events are recognised by immune lectins, 
which identify cells containing these compounds as belonging to the host. The 
sulfation of these glycans coupled with the epimerisation of glucuronic acid to 
iduronic acid allow host immune lectins to distinguish between host proteins and 
pathogen mimics.20 
 
1.2.9.2 Detection of disease specific glycosylation 
 
Disease specific changes in glycosylation can be detected through the use of labelled 
lectins or carbohydrate specific antibodies and many applications of this has been 
shown.  
 
Lectins have been used for the staining of tissue in the detection of cancer for many 
years and hundreds of examples exist in the literature, to take but one example, the 
staining of tissue samples with the plant lectin leukoagglutinin (L-PHA) was able to 
detect cancerous cells through binding to the aberrant β(1-6) linkages present in 
oligosaccharides on their surfaces. Not only did L-PHA binding increase with 
cancerous tissues when compared to normal, but this increase was found to correlate 
with the pathological stage of the disease.114 
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Recently lectin microarrays have been used in the differentiation of gastric cancer 
tissue sections from gastric ulcers,115 quantum dot conjugated lectins have been used 
for the evaluation of the glycophenotype of breast cancer116 and a recombinant fungal 
lectin has been used in the detection of aberrant cancer associated glycosylation in 
tissue samples where the lectins were able to specifically bind cancer cells (reducing 
the risk of false positives).117  
 
Not only has lectin binding been used to determine the cancerous state of tissues but 
this information has been used to inform treatment by identifying crucial cancer 
antigens. Lectin coated nanoparticles have also been shown to enhance drug delivery 
to the brain after intranasal administration of a drug with the aim of combatting 
Alzheimer’s disease.118 
 
Cancerous secretion of mucins into the bloodstream has been used as a marker for 
cancer through detection with monoclonal antibodies and many glycan-specific 
cancer-associated antibodies can be found in the blood of patients with cancer and 
these can be used for detection. Whilst many of these antibodies have become 
potential therapeutic targets their use may be limited by the high level of mucins 
coated in their glycan targets, which are secreted into the blood by cancerous tissues 
and thus would compete with tissue bound glycans for the drug.31 
 
1.2.9.3 Detection of pathogen specific lectins 
 
Many methods for detection of pathogen specific lectins have been explored in the 
literature. Glycan functionalised magnetic particles have been used for the detection 
of cancerous cells using magnetic resonance imaging119, galabiose functionalised 
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magnetic particles for the detection of Streptococcus suis (a zoonotic pathogen),2, 120 
mannose conjugated gold nanoparticles for the detection of FimH positive (and thus 
pathogenic) strains of E. coli104 and label-free real-time detection of lectins down to 
femtogram levels has also been achieved through the conjugation of unmodified 
carbohydrates to silicon nanowires.121  
 
Whilst those examples were all particle based, carbohydrate microarrays were first 
used for mapping epitopes of HIV-related antibodies which has now been used to 
inform vaccine design.122-125 They have also been used for the detection of food-based 
bacterial pathogens for which standard culturing methods are challenging. This 
methodology coupled a mono- and di-saccharide based microarray with surface 
plasmon resonance for a real-time label-free output.126 Detection and typing of 
bacteria in the blood has also been achieved127 along with; detection of 
oligosaccharide binding of avian and human influenza strains128, identification of 
antibodies that protect against severe malaria129 and epitope mapping of tumour-
associated antigens.130 
 
However, many of the techniques that are currently available for pathogen detection 
either have poor sensitivity as they utilise monosaccharides or those that are based on 
monosaccharides that have good sensitivity are often coupled to expensive detection 
methods such as surface plasmon resonance, mass spectrometry or quartz crystal 
microbalance. Long-chain oligosaccharides are often used as sensors in order to 
increase the sensitivity of detection systems but these are expensive or difficult to 
synthesise. Many other techniques require either expensive or synthetically 
challenging modified glycans for attachment to probes or complex and robust surface 
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chemistry. Whilst non-carbohydrate based-detection systems exist, many utilise 
proteomic or antibody based detection methods that require preparation, storage, 
expensive detection equipment or highly trained staff to implement and they are not 
always suitable for robust point-of-care diagnostics. 
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1.3 Summary 
Whilst carbohydrates were previously thought of as lacking information density, they 
are now regarded as being unsurpassed in terms of structural diversity. Carbohydrates 
are covalently linked to membrane proteins and lipids to form a dense glycocalyx and 
whilst there are only ten mammalian monosaccharides it is thought that there are over 
2000 different glycans present in the mammalian glycocalyx. 
 
The glycocalyx is important for mediating many biological processes through protein 
carbohydrate interactions and also reflects disease states through aberrant 
glycosylation, such as the glycosylation patterns seen in mucins on cancerous cells. 
As they are crucial for many biological processes, protein carbohydrate interactions 
are also exploited by many pathogens during the initial stages of infection. They 
determine the binding of viral particles prior to cell internalisation, fungal cells, whole 
bacterial cells and their toxins and the initial binding of some parasites. 
 
The mammalian glycocalyx also determines the binding of immune system lectins, 
which protect host cells from destruction by the immune system. As such, mimicry of 
the mammalian glycome to escape the host immune system is also prevalent amongst 
pathogens, with mimicry seen across a number of bacterial species to one degree or 
another. Those species that do not mimic the host glycome and thus express bacterial 
specific glycans on their surface are often intracellular pathogens or have developed 
other mechanisms of protection against the immune system. 
 
Pathogen specific glycans and lectins form a mechanism for both the prevention of 
disease states and pathogen detection. Currently, carbohydrate based vaccines are 
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being developed (or in some cases already exist) and anti-adhesion therapy 
compounds are being developed for a number of different pathogenic organisms.  
 
In terms of detection through glycan interactions, lectin staining of tissue samples in 
search of differential glycosylation patterns in disease states is a technique that has 
existed for many years and the detection of glycoproteins with aberrant glycosylation 
patterns or glycan specific antibodies is routinely used in testing for the presence of 
certain cancers. Conversely, the detection of pathogen specific lectins has also been 
used to develop many sensors for disease although currently many of the techniques 
require either complex oligosaccharide ligands which can be difficult to produce in 
large quantities and are expensive. These ligands can provide a very pathogen specific 
on/off response in terms of detection, where as monosaccharides which are readily 
available in large quantities can be used for much broader detection of multiple 
pathogens but with poor sensitivity and resolution unless coupled with expensive 
detection methods. 
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1.4 Aims and Thesis summary 
 
Considering the above, the thesis aimed to couple unmodified readily available 
monosaccharides, facile surface functionalisation chemistry and a simple processing 
based methodology for improving the resolution in binding profiles without having to 
use expensive equipment or challenging techniques. This would then be used as a 
facile sensor for the detection of a multitude of pathogenic organisms. 
 
In Chapter 2 the information and binding profiles that are readily available through 
the Consortium for Functional Glycomics were utilised as a trial dataset to explore the 
information density that can be achieved when assessing carbohydrate-binding 
profiles. Furthermore, the power of two statistical techniques was assessed in order to 
improve the resolution of the information contained in monosaccharide binding 
profiles alone. Chapter 3 then develops a facile surface coupling chemistry for the 
production of a cheap carbohydrate based assay. The key aim was to develop a simple 
methodology that showed specificity of binding but utilised unmodified saccharides 
for surface attachment in order for the technique to be cheap. 
 
The combined approach of a monosaccharide surface coupled with a statistical 
analysis was then used in the detection of a variety of pathogens. In Chapter 4, the 
discrimination of pathogenic lectins of similar binding specificities was achieved 
through ratiometric profiling of binding to a variety of monosaccharides. Chapter 5 
then further develops this approach to allow the discrimination of bacterial species in 
order to improve point-of-care diagnostics. This chapter looked at the discrimination 
of a variety of bacteria including Mycobacterium smegmatis, Mycobacterium 
marinum and Pseudomonas putida, the first two being model organisms for 
	 35	
Mycobacterium tuberculosis (the causative agent of tuberculosis) and P. putida being 
a model organism for Pseudomonas aeruginosa which is a common cause of 
pneumonia in cystic fibrosis patients. 
 
In Chapter 6, the potential of differential glycan binding by red blood cells infected 
with Plasmodium falciparum is described. P. falciparum is one of the parasites 
responsible for human malaria and is one of the main causes of global death from 
disease. With the spread of resistance to one of the main front line treatment drugs on 
the rise and microscopy remaining the gold standard for malaria diagnosis, the 
development of novel, facile and cheap diagnostics techniques that provide 
information about drug resistance is becoming an important area of research. 
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Chapter 2 
 
The power and challenges of glycomics 
databases and the use of statistical tools in 
the extraction of crucial binding 
information; opportunities for chemists and 
biologists. 
 
 
 
2.1 Abstract 
Large amounts of lectin binding data are readily available in databases. However, 
considering the complex nature of carbohydrates it comes as no surprise that 
accessing and extracting information from these databases can be challenging. 
Despite the amount of data available, this information is also rarely used to inform 
experiments. As such this chapter highlights the complexity of the information 
available and also assesses the potential uses for this information in aiding in 
experimental design. Several statistical methodologies for the analysis of this data are 
also explored.  
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2.2 Introduction 
Glycomics is faced with many unique challenges when compared to either proteomics 
or genomics mainly due to the complexity of the system being studied. Genomics 
involves the study of either DNA or RNA, which comprise four main building blocks. 
Proteomics analyses proteins, which are chains of amino acids of which there are 20 
whereas there are 10 mammalian monosaccharides and even more found exclusively 
in bacterial species. Monosaccharides also have multiple attachment points, α or β 
conformations and are arranged in far more complex structures that those seen in 
either DNA or proteins. The building blocks in DNA, RNA and proteins can only be 
arranged in a linear manner whereas glycans often contain branched structures thus 
adding a further layer of complexity. 
 
Further to the structural complexity of glycans themselves, there are additional 
challenges in the study of both glycosylation and protein-carbohydrate interactions. 
Glycosylation is not a template-driven process and is the product of the expression of 
multiple glycosyltransferases, which can have tissue specific isoforms leading to a 
wide variety in glycosylation and the degree of glycosylation between different 
tissues (Figure 2.1).1-3 These different glycans can then interact with proteins but 
again these interactions are complex. Proteins that interact with carbohydrates make 
use of multivalency in order to overcome the naturally weak interactions.4 Thus the 
properties of a protein-carbohydrate interaction will change dependent on the density 
of the target glycan.5 This is then further complicated by the presence of graded 
affinity amongst these proteins, this means that the presence of the target glycan at 
low density can be overcome by additional weaker interactions of the protein with 
derivatives of the target carbohydrate chain. 
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Figure 2.1 Mass spectrum showing tissue differences in both the amount of 
glycosylation and the nature of N-linked glycans, extracted from the consortium for 
functional glycomics (CFG) for A) human spleen tissue and B) human small bowel 
tissue. All glycan structures are depicted using standard CFG nomenclature.6 
 
Given the complexity of glycan systems it is hardly surprising that the databases of 
information are themselves complicated and can often be challenging to use. There 
are many databases that consider only a small aspect of glycomics, for example 
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GlycomeDB,7 which contains glycan structures including three-dimensional structural 
information and GlycoGene, which contains information about genes associated with 
glycan synthesis. Many other databases incorporate a much more integrative approach 
such as the consortium for functional glycomics (CFG), which contains information 
relating to the gene expression of glycosyltransferases and glycan binding proteins, 
phenotypic analysis of transgenic mice, mass spectrometry analysis of glycans 
isolated from various cell and tissue types and the screening of glycan affinity of 
proteins using a carbohydrate microarray approach.8  
 
 
Figure 2.2 Many databases utilise their own nomenclature to represent glycans. A) 
Shows the CarbBank, IUPAC and CFG representation of the pentasaccharide 
component of monosialyltetrahexosylganglioside (GM1) and B) the standard CFG 
nomenclature for all 10 mammalian monosaccharides. 
 
Nomenclature Example
CarbBank
IUPAC
(6R) - 5 -Ace t am i do - 3 , 5 - d i d e oxy - 6 - [ ( 1R , 2R ) - 1 , 2 , 3 -
trihydroxypropyl]-β-L-threo-hex-2-ulopyranonosyl-(2-3)-[β-D-
ga l a c t opy r anosy l - ( 1 -3 ) - 2 - a ce t am ido -2 -deoxy -β -D -
galactopyranosyl-(1-4)]-β-D-galactopyranosyl-(1-3)-D-
glucopyranose
CFG
b-D-Galp-(1-3)-b-D-GalpNAc-(1-4)+
b-D-Galp-(1-4)-b-D-Glcp
a-D-Neup5Ac-(2-3)+
A
Galactose N-acetyl galactosamineGlucose Mannose
N-acetyl glucosamine Sialic acid 
(N-acetyl neuraminic acid)
B
Glucuronic acid
Fucose
Xylose Iduronic acid
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Using the output of one database as input information for another can also be 
challenging, as there is no uniform method for representing the structure of 
carbohydrates (Figure 2.2A) and many of the databases utilise their own 
nomenclature (Figure 2.2B). This means that after exporting information from one 
database the nomenclature will have to be changed in order to import into another 
database. This can be extremely time consuming. The differences in nomenclature can 
also make comparing information from two different databases challenging. 
 
The CFG contains the most comprehensive information on the binding profile of 
glycan binding proteins with genomic, proteomic and glycomic information about 
every protein. All data is available in a processed and summarised format, raw data 
and experimental protocols are also available. Not only are there binding profiles for 
single proteins but there are also profiles for antibodies, viruses and whole bacterial 
cells. The binding profile to over 200 different glycans is stored for each, with the 
glycans themselves ranging from monosaccharides to branched oligosaccharides. 
These profiles were generated through the use of specialised carbohydrate 
microarrays comprising of glycans attached to an amino linker and covalently printed 
on N-hydroxysuccinimide activated glass slides.8 
 
The wealth of information on protein and whole cell interactions with glycans can 
indicate the function of poorly understood proteins, and the mechanisms through 
which pathogenic lectins may have their function. This in turn can give the likely cell 
specificity of these lectins. Understanding mechanisms of action can be further 
utilised to guide inhibitor design and aid in the identification of lectins and whole 
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bacteria based on a ‘bar code’ approach. This approach requires only information 
about binding profiles for lectin identification. 
 
Unfortunately much of the information in the CFG database is rarely used. As such 
we aim to show some of the information that can be extracted from this database to 
highlight the wealth of this resource for a variety of applications. Here, the power of 
this information in terms of aiding inhibitor design, sample classification and 
elucidating function based on binding profiles is highlighted. Some of the limitations 
of the information contained within these databases in terms of experimentally 
reproducing the data will be assessed. 
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2.3 Results and discussion 	
2.3.1 Toxin modes of action 
Cholera toxin (CTx) is the toxic lectin produced by the bacteria Vibrio cholerae when 
it enters the small intestine. It is binding and internalisation of this lectin that results 
in constitutive activation of sodium channels in small intestine endothelial cells which 
then causes the symptoms associated with cholera infection.9, 10 Ricin (RCA) is 
another toxic lectin, which is found in the seeds of the castor oil plant, binding and 
internalisation of this toxic lectin results in cell death.  
 
Figure 2.3 Crystal structures of the CTx (left) and RCA (right) highlighting the 
enzymatic domain shown in red and the carbohydrate-targeting domain shown in 
blue. Both structures are from the PDB with codes of 1XTC11 and 2AAI12 for cholera 
and ricin respectively. 
 
Both of these lectins comprise an enzymatic domain and a targeting carbohydrate 
binding domain (Figure 2.3). Without binding of the targeting domain to 
carbohydrates on cell surfaces, the enzymatic subunit would not be internalised and 
the cell would not be affected; this forms the principle behind anti-adhesion therapy. 
Comparison of the carbohydrate binding regions of these toxins highlights the range 
of carbohydrates, which can result in toxin binding. This gives an indication of the 
cells that may be affected by binding. Binding of a subunit to a highly specific 
Enzymatic domain
Targeting domain
	 53	
oligosaccharide chain, as displayed by the b subunit of cholera toxin (CTxB, Figure 
2.4), can be indicative of a very specific cellular target. The moiety that is strongly 
bound in this instance is the GM1 pentasaccharide (other moieties that show strong 
binding are truncated versions of this glycan), which is located on intestinal 
endothelial cells, the site of adhesion and internalisation of this toxin.13 
 
Figure 2.4 Binding profiles of cholera toxin (red) and ricin (black) to a variety of 
carbohydrate surfaces, all data extracted from the consortium for functional glycomics 
(the concentration for both is 10 µg.mL-1) and binding is shown as a percentage 
relative to the maximum binding glycan. Fluorescence data is for all structures 
containing a terminal β-galactose residue.6 
 
In comparison, the binding profile of the ricin targeting domain (RCA120, a non-toxic 
derivative of RCA) shows a much broader range of targets (Figure 2.4). All the 
glycans that are bound contain a terminal β-galactose moiety and this is the unit that is 
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required for ricin binding. As this is the only real similarity between the glycans that 
are strongly bound it indicates that ricin can target a wide range of carbohydrate 
chains as long as they contain a terminal β-galactose and as such could potentially 
target a wide variety of cells. Indeed ricin can affect any cell in the body. Upon 
binding the toxin enters the cell through endocytosis and the enzymatic A subunit is 
cleaved from the targeting B subunit. The A subunit then binds to the ribosome, 
halting protein synthesis and causing cell death.14 
 
Whilst the modes of action of both these toxins have long been known, many of the 
lectins in the data base have been poorly studied or are difficult to obtain. These 
profiles could aid in the elucidation of the mode through which these lectins act. This 
is important for both lectins that are toxic or that play a role as part of a greater 
signalling pathway within an organism. Furthermore understanding modes of action 
can be used in the confirmation of proteomics studies in which putative glycan 
binding domains are identified. 
 
2.3.2 Inhibitor design 
Binding profiles can also be used to generate information that can be used in the 
design of inhibitors for targeted anti adhesion therapy. Upon identification of a toxin 
that binds a highly specific oligosaccharide, the binding profiles of truncated and 
modified versions of that oligosaccharide can be compared in order to identify which 
components are essential for binding. This can be used to aid in the production of 
inhibitors that are designed to mimic the target on the cell surface without using the 
cell surface glycan. This is vital as other native lectins in the body may use this glycan 
for signalling and as such would be affected by the inhibitor. 
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As has been shown, CTxB shows highly specific binding to the GM1 pentasaccharide 
(Figure 2.5). The binding profiles of a variety of truncated and modified versions of 
this glycan can guide the production of cholera toxin specific inhibitors. 
 
Figure 2.5 Structure of GM1 with the sugar backbone pictured in black and the side 
chain shown in blue (A). For comparison GM1 is also pictured using standard CFG 
nomenclature (B). 
 
If we consider just the sugar backbone of GM1 (shown in black, Figure 2.5A), then 
we can base an inhibitor on anything from a monosaccharide up to a tetrasaccharide. 
The difference in binding to the terminal monosaccharide and the full tetrasaccharide 
(Table 2.1) is very small but the price difference in buying a monosaccharide and a 
tetrasaccharide is considerable. In order to form cheap inhibitors of cholera toxin, the 
terminal galactose residue is an attractive starting compound. 
 
The terminal galactose has been combined with a variety of different scaffolds to 
generate a number of multivalent inhibitors of cholera toxin.15-17 However, a number 
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of other lectins within the body, such as galectins, also work through binding to 
galactose moieties and a more specific inhibitor is needed. Adaption of the linker 
length between the galactose and the scaffold has been show to drastically improve 
the specificity of an inhibitor to cholera toxin when compared to another galactose 
binding lectin.18 This was due to the deep binding pocket that cholera toxin has when 
compared to the surface exposed binding site for the other lectin. Thus galactose 
coupled with the appropriate length linker can form a good mimic of the GM1 sugar 
backbone.  
 
Table 2.1 Table showing the relative fluorescence binding (RFU) of CTxB 
(concentration of 10 µg.mL-1) to a variety of structures that represent either a 
modified or truncated version of GM1. Both a general name and the CFG structure 
are shown for both structures. IC50 values were determined by plotting the 
fluorescence data for a number of concentrations (all extracted from the consortium 
for functional glycomics database) and the apparent Kd (Kdapp) is calculated as 
described by Orsoz and Ovadi.19 
 
However, if we consider the binding profile, the difference in binding between the 
GM1 sugar backbone and the full GM1 glycan is significant (Table 2.1). The only 
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difference in sequence between these glycans is the sialic acid side-chain, which sits 
in a hydrophobic binding pocket in the cholera toxin. Binding of the side chain on its 
own to cholera toxin is very poor. When coupled to the GM1 backbone the strength of 
binding is much greater than the sum of two individual component parts.  
 
The importance of the side-chain is further highlighted by the large drop off observed 
in binding when the side chain is increased in length. The increase in the apparent 
dissociation constant (Kdapp) indicates that the sialic acid side chain is crucial for 
cholera toxin binding (Table 2.1). In fact GM1 with one additional side-chain sialic 
acid is found naturally on cell surfaces and severe cholera strains have evolved to 
secret a neuraminidase which clips this sialic acid, converting it into GM1 in order to 
increase the number of binding targets available to the cholera toxin.20 
 
Figure 2.6 Crystal structure of GM1 bound to one CTxB as extracted from the PDB 
(A). A simplified version of A is shown using standardised CFG nomenclature (B). A 
schematic representation of the polymer inhibitor showing the proposed position of 
the hydrophobic secondary binding motif (C). 
 
This observation can then be used to further guide the development of cholera toxin 
inhibitors. Polymers that contained a terminal galactose residue, coupled with the 
A B C
GM1/CTxB GM1/CTxB (simplified) Polymer/CTxB
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idealised linker length for CTxB inhibition were further modified to test a variety of 
hydrophobic side chain compounds as demonstrated in Figure 2.6. Addition of a 
hydrophobic side group resulted in increased specificity for the inhibitor to CTxB 
(when compared to another galactose binding lectin).21  
 
2.3.3 Identification of lectins from a carbohydrate binding ‘bar code’ 
Many lectins are toxic and rapid identification of the toxin responsible for an infection 
can expedite treatment and save lives. Each lectin will have a unique binding 
fingerprint on the carbohydrate microarray (like a ‘bar code’) and this could be used 
as a tool for the rapid identification of toxins in samples. 
 
A sample data set of 20 bacterial lectins with 6 replicates of every sample was 
extracted from the consortium for functional glycomics database in order to examine 
the possibility of lectin identification based on binding profiles. For each of the 
bacterial lectins, the binding intensity to a sample of 13 monosaccharides was 
extracted. Monosaccharides were selected as these are cheap and readily available and 
so, whilst they might be more challenging in discrimination of a bar code, they are the 
simplest platform for any identification sensor. 
 
As can be seen from the raw binding profiles, identification of a single lectin based 
purely on its binding to these monosaccharides would be extremely challenging 
(Figure 2.7). However, there are a number of powerful statistics techniques available 
for the further analysis of this data, which may allow prediction of lectin samples. 
Two of those techniques, linear discriminant analysis and random forest, will now be 
explored and their identification power assessed. 
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Figure 2.7 Relative binding profiles of 20 bacterial lectins to 13 monosaccharides as 
extracted from the consortium for functional glycomics. All monosaccharides are 
represented by their unique identifying code as used by the CFG. 
 
2.3.3.1 Linear discriminant analysis 
Linear discriminant analysis (LDA) is a clustering based machine-learning algorithm 
that can be used as a predictive tool for identifying group membership in unknown 
samples. Other clustering approaches such as principal component analysis focus on 
clustering data based on global variation rather than variation between groups. In 
comparison, linear discriminant analysis minimises variation between points within 
the same group whilst maximising variation between groups in order to allow better 
discrimination between groups (Figure 2.8). LDA has been previously used in the 
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identification of proteins based on binding to polymers and the identification of 
bacteria.22, 23 
 
Figure 2.8 Example of linear discriminant analysis. A) Example of an initial data set 
segregated into two classes and showing an unknown sample for classification (the 
red diamond). By considering the x and y co-ordinates of the unknown sample it 
could be classified as belonging to either group. LDA takes this initial data set and 
transforms it to minimise the variation within each class whilst maximising the 
variation between classes to produce a model (B). When the x and y co-ordinates of 
the unknown sample are once more considered it can clearly be classified as 
belonging to the green class with much higher confidence.  
 
One of the main challenges with this technique is the risk of overfitting (Figure 2.9, 
right), which results in a model that shows perfect discrimination for all groups 
submitted in the training matrix, but results in an excessively complex model that 
lacks the predictive capacity to classify new data. The opposite of this situation is also 
possible, in that too few components are retained (to avoid overfitting) and useful 
information is lost so the model lacks enough information to accurately describe the 
relationship (Figure 2.9, left). As a result the use of this technique requires many 
validation steps in order to find the perfect point, between being too complicated 
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(overfitting) and losing too much information (underfitting), known as the ‘goldilocks 
point’ (Figure 3.9, centre). 
 
Figure 2.9 A model (represented by a purple line) can be fitted to data (navy 
diamonds) in order to describe the underlying relationship between x and y (centre). 
During underfitting, insufficient information is retained in the model and thus the 
model poorly describes the relationship (left). During overfitting, too much 
information is retained and whilst the model perfectly describes the data points it is 
excessively complex. Both underfitting and overfitting can result in the inability of 
the model to accurately predict a new point in the data. 
 
Use of the previous data set (of 20 bacterial lectins, bound to 13 monosaccharide 
surfaces and 6 repeats for each lectin) was used as a training matrix for linear 
discriminant analysis. Cross-validation was performed in order to identify a suitable 
number of principal components (PCs) to retain in the final model (the ‘goldilocks’ 
number), this technique splits the data into two data sets; a training set (which 
contains 90 % of the original data) and a validation set (containing 10 % of the 
original data). The validation set is changed through random sampling and is 
classified by the model produced from the training set (with the number of retained 
principle components varied). This procedure is repeated 30 times for every number 
of retained principal components. For this data set 6 principal components were 
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selected as this explained most of the variation in the data (Figure 2.10A) and it 
achieved the highest successful prediction outcome score with the least number of 
PCs (Figure 2.10B). 
 
Figure 2.10 Variance explained by each principle component in the linear 
discriminant model (A). The successful prediction outcome when a validation data set 
is predicted from a model produced based on a training data set, the validation data 
set is randomly selected for 30 repeats and the number of principal components 
retained is varied (B). The variance explained by each of the linear discriminants for a 
model based on 6 principal components (C). The percentage of correct reassignment 
of a sample to its group by the LDA model produced in a ‘leave-one-out’ manner (D). 
 
As only 6 principal components were retained, it was possible to retain all of the 
linear discriminants to produce the final model (for large numbers of principal 
components the model then becomes too complex to retain all of the linear 
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discriminants) and all linear discriminants contained a reasonable amount of 
information (Figure 2.10C). The validity of the model was then assessed using a 
‘leave-one-out’ validation procedure in which every data point is left out of the model 
in an iterative process and the model is used to classify any points not used to 
generate the model. The model was able to correctly identify 76 % of all the samples 
analysed with several of the lectin groups scoring 100 % accuracy (Figure 2.10D). 
Whilst this is not a particularly high predictive power, it could be further improved by 
extending the analysis to include di- and oligosaccharides. 
 
2.3.3.2 Random forest 
Random forest is another classification technique that is generally assumed to be 
more powerful than linear discriminant analysis in terms of group identification. This 
analysis involves the production of multiple classification and regression trees based 
upon a random subsection of the data, each tree is also perturbed by a small amount in 
order to account for variance in any input data. In classification of a sample, each of 
the trees is used to classify the sample with the output determined as the majority 
class identified by the trees. This procedure has the benefit that it reduces the 
possibility of overfitting (where the model produced fits both the data and the 
underlying ‘noise’ in the dataset), which can be a problem when using LDA, by 
allowing variation within the model. It also copes with non-linearity in the data 
(where as LDA can only produce discriminants that are combined in a linear manner). 
This technique has previously been used for the prediction of disease risk and the 
identification of colon cancer biomarkers from microarray data.24, 25 
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Random forest was applied to the previous data set of 20 bacterial lectins on 13 
monosaccharide surfaces (with 6 repeats for each lectin on every surface). This 
technique is generally thought to be more powerful a classification tool than LDA and 
as expected in a ‘leave-one-out’ analysis it correctly assigned samples to their lectin 
group in 77.5 % of all samples thus making it appear marginally more accurate than 
the 76 % achieved through LDA. However, the correct assignment when broken 
down to the individual lectins was worse than that achieved with LDA- whilst some 
of the lectins showed higher correct predictions with this technique, all samples for 
two of the lectin groups assessed were incorrectly classified (Figure 2.11). 
 
 
Figure 2.11 The percentage of correct reassignment of a sample to its group by the 
random forest model produced in a ‘leave-one-out’ manner. 
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2.3.4 Challenges when using database profiles 
There are a number of challenges associated with using data from databases such as 
the consortium for functional glycomics. The CFG database includes attachment of a 
variety of glycans with a variety of spacers, which can impact on binding. The 
database entries are also produced by a variety of different laboratories, worldwide 
and, whilst all the detection values are fluorescence, the actual detection methods vary 
for some of the samples tested. This can have a significant impact on the binding 
profiles so only those with identical detection methods should be compared. 
Extraction of the data itself from the database can also be very challenging. 
  
2.3.4.1 Spacer effect 
The consortium for functional glycomics utilises a very large library of glycans (~ 
200 glycans) on their surface. They also use a number of spacers in order to achieve 
surface attachment. Many of the glycans are attached using a number of different 
spacers but not all spacers are available for all gylcans. This presents a unique 
problem, in that the spacer itself can affect lectin binding.  
 
For many of the spacers coupled to carbohydrates there is little difference between 
lectin binding to the same glycan utilising different spacers. But, for some lectins, 
there are large differences between spacers for the same glycan, and only for certain 
glycans (i.e. it is not a universal affect for that lectin). For example, changing the 
spacer from Sp0 (-CH2CH2NH2) to Sp9 (-CH2CH2CH2CH2CH2NH2) resulted in a 
two-fold increase in IC50 for cholera toxin binding to the demonstrated 
hexasaccharide (Figure 2.12). This effect is unsurprising as it is also used in nature to 
modulate binding to glycophospholipids where the binding strength to the 
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carbohydrate moiety can be affected by the fatty acid chain.26 Whilst the effect of the 
spacer could provide information about the depth of the binding pocket or other 
characteristics it does create a problem when comparing glycan binding between 
lectins as the affect of the spacer on binding can be significant. 
 
Figure 2.12 The relative fluorescence for various concentrations of cholera toxin 
(CTxB) binding to the displayed glycan for spacer 0 and spacer 9 was extracted from 
the CFG database. Binding to the glycan attached to spacer 0 (Sp0) showed stronger 
binding than binding to the same glycan to spacer 9 (Sp9) with IC50 values of 1.8 nM 
and 4.5 nM respectively.  
 
The presence of different spacers means that the data in the CFG can only be 
compared with lectin binding using a CFG microarray or binding onto a surface 
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functionalised in an identical way. Even the use of identical spacers on a different 
surface may produce different results as density of surface functionalisation can 
impact on lectin binding (as they often rely on multivalent interactions).  
 
2.3.4.2 Data comparison 
Other than the affect of the spacer, there are many other aspects that limit the use of 
the CFG database for lectin comparisons. Many of the entries in the database utilise 
different labelling or detection protocols, which may affect the detection limit of the 
assay. Only those with identical labelling protocols should really be compared and 
even then the labelling efficiency itself needs to be considered as this can vary 
drastically between proteins.27  
 
Fluorescent labelling of proteins has also been shown to impact upon glycan binding 
profiles of certain proteins and thus data within this database should not be compared 
to label free techniques and may not be an accurate representation of natural binding 
of the protein.28  
 
Extraction of entries themselves can be challenging as several of the entries are in a 
non-standard format and thus extraction of the data can be laborious. Once the 
extraction is complete then further formatting of the data may be required depending 
on future analysis protocols. A standardised array for all glycans and a standard 
visualisation technique could ensure that all data are comparable between 
experiments. 
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2.4 Conclusion 
 
In this chapter, we have demonstrated that large amounts of lectin binding 
information is readily available from databases such as the consortium for functional 
glycomics. This data can be used to highlight important elements involved in binding 
of a lectin to a known glycan, which can then be used to inform inhibitor design for 
anti-adhesion therapy. 
 
Powerful statistics tools such as random forest and linear discriminant analysis 
coupled with the information within these databases highlights the potential for using 
large data sets to assist in classification of unknown lectin samples based on their 
binding profiles. This could then be used to identify toxic environmental lectins, such 
as cholera toxin and ricin based on binding alone, which is currently challenging, as 
samples may be contaminated with environmental lectins that show similar binding to 
either ricin or cholera toxin. 
 
However, the use of these databases, in informing real-world experiments is limited 
by the poor accessibility of the data, non-uniform formatting of data sets, variations 
between data sets in experimental protocol and challenges caused by the effect of the 
spacers on lectin binding meaning. This means the data in the CFG can only be 
compared to lectin binding to exactly the same microarray platform. This is 
unfavourable as these microarrays are expensive. 
 
In conclusion, whilst there is a wealth of information available in terms of 
carbohydrate binding profiles, its use has many limitations not least of which is the 
expense of using their microarray platforms. It is favourable to combine many of the 
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analysis techniques examined within this chapter (such as linear discriminant 
analysis) with a much cheaper more customisable surface modification technique. 
Coupled with standardised techniques for assessing binding (be that fluorescence or 
other ‘label free’ methodologies) this could be used to generate a database of profiles 
that can be accessed and reproduced around the world with the aim of using the 
database for sample classification based on binding profiles. 
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2.5 Methods 
 
Consortium for functional glycomics data extraction: The following data files 
were downloaded from the consortium for functional glycomics and all data plotted 
are the average of the 6 repeats and error bars represent the standard error (Table 2.2). 
All graphs are plotted in OriginPro and binding isotherms are fitted using the 
nonlinear curve fitting function. 
Abbreviation in text Sample name in CFG database 
RCA120 RCA120 (10 µg.mL-1) 
CTxB CTxB (0.001 µg.mL-1, 0.01 µg.mL-1, 0.1 µg.mL-1, 1 µg.mL-1, 
10 µg.mL-1) 
Ag Ag I/II Vhelical-GFP: Ag I/II Vhelical-GFP 
ArtB ArtB toxin: ArtB bacterial toxin- 200 µg.mL-1 
Blon Blon 2468 mut 
BOA Burkholdeira oklahomensis agglutinin (BOA): BOA lectin 
EalB EalB-h6:EalB-h6 ADP- ribosylating toxin 
EplB EplB-h6: EplB-h6 ADP ribosylating enzyme 
EtpA recombinant EtpA glycoptorein: rEtpA 
EtxB EtxB:etxAB-100 µg.mL-1 
FimH FimH:FimH type 1 fimbriae 10 µg.mL-1 
Fm1D FimD:FimD (200 µg.mL-1) 
FliD FliD:FliD 
Msmeg MSMEG_3662:MSMEG3662-2B 
OmpA OmpA+E. coli:OmpA+E. coli 
PFL PFL:PFL 
Rv1419 Iron regulated heparin binding hemmaglutinin from 
Mycobacterium tuberculosis 
SAOUHSC SAOUHSC_00176 
SSLO SSLO:SSLO-488 (200 µg.mL-1) 
StcE StcE:StcE 
Typhoid Typhoid toxin: WT_Typhoid toxin- 20 µg.mL-1 
 
Table 2.2 Table linking the lectin abbreviation in the text to the file name within the 
CFG database. Where more than one concentration is stated then the concentration 
used for the method is stated. 
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Linear discriminant analysis: Six repeats of the relative fluorescence for each of the 
bacterial lectins binding to each of the chosen monosaccharide surfaces was extracted 
from the CFG. This data formed a training matrix which was subjected to classical 
linear discriminant analysis using the ‘dapc’ function in the ‘adegenet’ package 
(version 1.4-2)29 in the open source statistical package R (version 3.1.3).30 
 
Cross-validation was performed using the ‘xvalDapc’ function whereby 10 % of the 
data set is ‘left out’ of the model and then the model produced is used to classify the 
‘left out’ data. This is repeated multiple times with the ‘left out’ data being randomly 
selected. 
 
Random forest analysis: The dataset of six repeats of the binding of 20 bacterial 
lectins to 13 monosaccharide surfaces as extracted from the CFG database was used 
to produce a random forest model using the ‘randomForest’ function (version 
4.6.10)31 in the open source statistical package R (version 3.1.3).30 The model 
produced was the average of 500 trees. Data were cross-validated using a ‘leave-one-
out’ approach and the percentage of correct reassignment for each bacterial lectin was 
calculated. 
 
Apparent Kd calculations: Kdapp calculations were performed as described by Orosz 
and Ovadi19 but, briefly; relative fluorescence data produced upon binding of different 
concentrations of cholera toxin to the various glycans assessed was extracted from the 
consortium for functional glycomics.  
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Fluorescence levels were then modified to put them on a relative scale with 1 
indicating the maximum fluorescence with 0 indicating the lowest fluorescence. 
Points were then plotted in OriginPro and a binding isotherm fitted to the data using 
the nonlinear curve fit tool (as shown in Figure 2.13A). Concentration of cholera 
toxin at a variety of fluorescence levels (i) was extracted from the fitted curve. All 
values were then modified and plotted as shown in Figure 2.13B and the gradient of 
the fitted line (m) was extracted.  𝐾𝑑!"" = 1/𝑚            (Eq. 1) 
The Kdapp can then be determined by using Eq. 1. For any data set where the binding 
isotherm failed to converge, the Kdapp was unable to be calculated and this is reported 
as NA. 
 
Figure 2.13 Example data set showing transformation needed to calculate Kdapp as 
described by Orosz and Ovadi.19 A) Relative fluorescence (i) is plotted for various 
concentrations of cholera toxin and a binding isotherm fitted to the data. The 
modelled isotherm is then used to estimate cholera toxin concentration at various 
fluorescence (i) values. These extracted values are then further transformed and 
plotted as indicated in B. The gradient of the fitted line (m) is extracted. 
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Chapter 3 
	
Optimisation of glycan-surface conjugation 
 
 
 
3.1 Abstract 
 
Carbohydrate microarrays are an important technique for the study of pathogens such 
as bacteria and their toxins and in the generation of inhibitory compounds for anti-
adhesion therapy. Whilst carbohydrate microarrays are commercially available they 
are expensive and limited in the number of surfaces available. In this chapter, we 
examine two methods of surface functionalisation and adapt them in order to generate 
microwell based carbohydrate microarrays in a cheap and facile manner.  
Functionalisation of 96 well plates for lectin assays by using covalent attachment of 
unmodified glycans through the addition of cyanuric chloride to the surface was 
unsuccessful due to poor binding resolution. Attachment of reducing glycans to 
commercially available hydrazide funtionalised microwell plates was found to be a 
much easier technique and was shown to be successful through the use of a modified 
drop shape analysis technique and showed far better resolution for lectin binding. 
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3.2 Introduction 
3.2.1 Carbohydrate Microarrays 
Many microarrays are commercially available, for example the consortium for 
functional glycomics (CFG) have used glycans with an amino linker printed onto N-
hydroxysuccinimide (NHS) coated glass to generate a vast database of binding 
profiles for hundreds of lectins and whole cell lines to an array of 200 glycans.1 These 
carbohydrates include everything from simple mono- and di-saccharides to large and 
branched oligosaccharides. 
 
A variety of different microarray platforms have been developed to tackle a number 
of different challenges including; the detection of food-based bacterial pathogens2, the 
detection and typing of bacteria in blood samples3, the identification of human and 
avian influenza strains4 and identification of antibodies that protect against severe 
malaria.5 Grabosch et al. used carbohydrate functionalised 96 well plates in order to 
test inhibitors of type 1 fimbriae-mediated bacterial using Escherichia coli.6 
Microarrays have also been used in the development of toxin resistant cell lines by 
selecting cells that lack the surface-bound carbohydrates necessary for lectin binding 
(or were more resistant to lectin binding).7 
 
However, many of the microarrays currently available have limitations. Those that 
utilise monsaccharides either lack sensitivity due to the promiscuous nature of lectin 
binding at the monosaccharide level or are combined with expensive techniques such 
as surface plasmon resonance in order to overcome this limitation. The use of larger 
oligosaccharides in microarrays results in much better lectin specificity but these 
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compounds can be expensive or synthetically challenging, especially if the glycans 
require modification for surface attachment. As carbohydrate microarrays can play an 
important role in the detection of pathogens, the development of cheap and facile 
functionalisation techniques is crucial. 
3.2.2 Surface functionalisation 
In order to develop carbohydrate microarrays, carbohydrates have to be attached to a 
surface. There are many different methods for this and broadly speaking they can be 
split into four categories (Table 3.1).8 There are many published examples of all of 
these methods for attachment and each category has advantages and limitations when 
compared to the others. 
 
Table 3.1 Generalised methods of surface functionalisation in the development of 
carbohydrate microarrays. The pentasaccharide displayed is drawn using standard 
CFG nomenclature.  
Covalent Non-covalent
Site specific
Site non-specific
x x x
x x x
x x x
y
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3.2.2.1 Site non-specific and non-covalent attachment 
At first glance this is a very attractive technique as it allows the carbohydrates to be in 
their natural form and does not require any expensive or laborious preparation of the 
surface. Many examples of this type of method exist in the literature including the 
non-covalent absorption of polysaccharides to black polystyrene and the 
immobilisation of polysaccharides on nitrocellulose.9, 10   
 
However, it has been observed that the immobilisation process is dependent on the 
molecular weight of the compound being immobilised, where immobilisation is most 
efficient for larger molecules.9 This is a major drawback of this method as it means 
that the technique is only applicable to large polysaccharides and so smaller mono- or 
disaccharides cannot be probed. It also means that differential protein binding 
between polysaccharides may be caused by differences in polysaccharide 
immobilisation.  
 
Non-covalent (or passive) absorption of polysaccharides onto a surface also has 
another drawback; deposition of the polysaccharide will be random and us such the 
molecule will be presented on the surface in a variety of orientations the majority of 
which will not be biologically relevant thus a lower signal may just be as a result of a 
low number of molecules presented in the biologically relevant conformation.11 
 
3.2.2.2 Site non-specific and covalent attachment 
This approach is appealing as it allows the use of unmodified glycans, which are 
bound to a modified surface. An example of this mechanism is the attachment of free 
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glycans to a surface modified with 4-azido-2,3,5,6-tetrafluorophenyl under UV light 
or the photochemical ligation of perfluorophenylazide derivatised carbohydrates to a 
poly(ethylene oxide) surface.12, 13 Whilst several other examples of this technique 
exist in the literature, one of the main limitations of this technique is the site non-
specific nature of the attachment, which means that the glycans can attach in any 
orientation to the surface. 
 
In 2012, Liang and Chen described the attachment of unmodified mono- di- and 
polysaccharides to modified glass and gold slides.14 The process they described 
initially involved the hydroxylation of either a glass or gold surface followed by 
addition of cyanuric chloride, this compound contains three chlorine atoms all of 
which can undergo hydrolysis and bind to hydroxyl containing molecules. The 
cyanuric chloride binds to the surface and then carbohydrates will then bind to the 
remaining binding sites of the compound in any orientation.14 Whilst this means that 
any orientation of molecule can be presented on the surface, lectin specificity was 
retained implying that the natural presentation was present on the surface and this 
means that this technique may overcome the challenges of the other methods that 
utilise the site non-specific, covalent attachment of glycans. 
 
3.2.2.3 Site specific and non-covalent attachment 
Examples of this approach include the use of biotin-conjugated glycans coupled with 
a streptavidin surface,15 the attachment of fluorous tagged carbohydrates to fluorous 
derivatised glass slides16 and the attachment of carbohydrates conjugated to either 
bovine serum albumin or human serum albumin to epoxide functionalised microscope 
slides.17 
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Whilst this technique ensures that orientation of the glycan is controlled, it has the key 
disadvantage that it requires both a chemically modified surface and modified 
glycans, which can be expensive, and synthetically challenging, thus limiting the use 
of techniques based on this approach. Also the storage of protein functionalised 
surfaces is crucial to avoid protein denaturation and loss of surface functionalisation. 
 
3.2.2.4 Site specific and covalent attachment 
This method is the most desirable as it ensures that all glycans are presented in the 
same orientation and whilst many methods require both surface and glycan 
modifications there are some that can utilise unmodified glycans. Many methods that 
involve the modification of the surface and the glycans have been described, for 
example, the attachment of modified carbohydrates in the form of glycosylamines or 
malemide conjugated carbohydrates onto thiol modified glass slides.8 This approach 
is also utilised by the CFG in the production of a carbohydrate microarray, which uses 
glycans with an amino linker, which are covalently attached to NHS coated glass 
slides.1, 15, 18  
 
However these methods require the modification of carbohydrates which is 
challenging, time consuming and often requires multiple purification steps.19 Site-
specific and covalent immobilisation of chemically unmodified carbohydrates on a 
modified surface has also been described and this eliminates the need for modification 
of the glycan thus making it the most desirable technique. However, this technique is 
also the most challenging and few examples exist in the literature. Reductive 
animation is the most common choice for attaching unmodified carbohydrates to a 
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surface, this involves the use of a hydrazide functionalised surface which is 
commercially available in the form of 96 well plates.20 The reducing end of the sugar 
reacts with the hydrazide on the surface, after which the Schiff base is reduced. One 
example of this method is the attachment of unmodified oligosaccharides to hydrazide 
modified self-assembled monolayers on a gold surface.11 This method has also been 
used in the attachment of unmodified glycans to hydrazide functionalised polymers.21 
Whilst this technique allows the site-specific attachment of unmodified glycans (and 
thus allows biological orientation to be conserved) its key disadvantage is that only 
reducing sugars can be attached to the surface, which limits the number of glycans 
that can be analysed.  
 
Recently a new technique has come to light in which unmodified carbohydrates were 
attached to a silicon nanowire (SiNW). This has the advantage that interactions can be 
detected in a label free manner and real-time binding can be observed. The technique 
was also significantly more sensitive than any other techniques currently available 
(the authors were able to detect lectin binding down to 100 fg.mL-1). Currently the 
synthesis of these SiNW biosensors is challenging, making the technique inaccessible, 
but there is the potential to commercially produce arrays of these sensors, which 
would greatly improve the sensitivity of protein-carbohydrate interaction detection 
that is currently observed.22 
  
3.2.3 Surface functionalisation considerations 
As there are many techniques for modifying the surface it should be noted that initial 
modification of the surface before the addition of the carbohydrates is important and 
should be kept constant between different carbohydrates as the linker attaching the 
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carbohydrate to the surface can modulate lectin binding. This is also occasionally seen 
in nature so is not always a negative thing; glycophospholipids are carbohydrates 
attached to long fatty acid chains, their binding is often examined using only the 
carbohydrate sequences but it has been shown that in some instances the fatty acid 
chain plays a role in determining binding strength in biological conditions.23  
 
Linker length is also crucial as it has been shown that the length of the chain on the 
surface can have a massive impact on binding; the initial chain length should be 
between 10 and 14 carbons long to allow binding of the lectin (Figure 3.1).24 Not only 
does the spacer length and nature play a crucial role in lectin binding but surface 
density is also crucial, if the glycans are too close together then a reduction in lectin 
binding is observed but if they are too far apart then the lectins cannot utilise 
multivalent binding which would result in the protein-carbohydrate interactions being 
very weak. Multivalent binding is utilised in nature to overcome the weak protein-
carbohydrate interaction and most lectins have multiple binding domains, it has been 
shown that the simultaneous occurrence of two binding events can increase the 
strength of an interaction by between 100 and 10,000-fold.20  
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Figure 3.1 Surface functionalisation where the glycan is presented at less than 10 
carbon atoms’ distance from the surface is insufficient for lectin binding (A) where as 
at 10 carbons or more, from the surface lectin binding can occur (B).  
 
Here we describe the development of a facile surface functionalisation technique that 
allows the use of unmodified carbohydrates to be added to a modified surface for the 
production of a microwell based carbohydrate microarray. Modifications of the 
method for the attachment of native glycans to a cyanuric chloride functionalised 
surface or the addition of unmodified glycans to a commercially available hydrazide 
functionalised 96-well plate were both explored in detail.  
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3.3 Results and Discussion 
The aim of this work was to develop a surface functionalisation technique that allows 
the modification of surfaces with unmodified glycans for the production of a 96-well 
plate based carbohydrate microarray. 
 
3.3.1 Solvent Testing 
As the method described by Liang and Chen allowed the addition of any unmodified 
glycan this technique was very attractive and so work was done to attempt to modify 
this method for 96-well plates. The initial step of the Liang and Chen method involves 
the formation of a hydroxylated surface.14 The aim was to achieve this through non-
specific absorption of the carbohydrate GM1 to a high-binding plate. However the 
next step in the process involves adding cyanuric chloride (Figure 3.2) dissolved in 
acetone, which would dissolve the polystyrene high-binding plate. As such diethyl 
ether and lutidine were tested as potential solvents for the cyanuric chloride. Diethyl 
ether was able to dissolve the cyanuric chloride but was found to rapidly dissolve the 
high-binding plate. 
 
Figure 3.2 Structure of cyanuric chloride. 
Lutidine was found to both dissolve the cyanuric chloride and be relatively stable in 
the high-binding plates. The cyanuric chloride solution has to be incubated in the 
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wells for approximately 6 hours and this resulted in the formation of a tar like 
substance that proved impossible to remove from the wells and eventually corroded 
the bottom. The attempt to find another solvent to dissolve the cyanuric chloride was 
abandoned and the plate type was changed. 
 
3.3.2 Hydroxylation of Polypropylene Surface with GM1 
Polypropylene 96-well plates were then used as the surface for modification. This 
material has the benefit in that it does not react with the acetone that the cyanuric 
chloride is dissolved in. The polypropylene plates were functionalised first with GM1 
to produce a hydroxylated surface and then with cyanuric chloride followed by a 
variety of glycans. 
 
In order to confirm surface functionalisation, polypropylene slides were also 
functionalised in the same manner (initially with GM1 then cyanuric chloride 
followed by a glycan). These slides were then analysed using drop shape analysis 
(DSA) for changes in the nature of the surface angle. DSA involves adding a droplet 
of water to the surface and then using a microscope to generate an image and measure 
the contact angle of the water droplet. Changes in the nature of the surface would 
indicate that surface functionalisation had occurred. As can be seen by Figure 3.3 
there is a significant difference in the hydrophobicity of the surfaces at each step of 
the functionalisation indicating a change in the chemical composition of the surface. 
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Figure 3.3 Polypropylene slides were prepared for DSA to determine the 
characteristics of the surface. There was a difference in the hydrophobicity of the 
surface between each stage of the functionalisation indicating a change in the nature 
of the surface. 
 
After surface functionalisation had been confirmed on the slides the surface 
specificity was tested using fluorescently labelled Concanavalin A (Con A) and 
Peanut Agglutinin (PNA) in the 96-well plates. These lectins have been extensively 
studied and their binding specificity has been well characterised; PNA is a β-D-
galactose binding lectin that also binds lactose whereas ConA is a α-D-mannose 
binding lectin that also has some affinity towards α-D-glucose. As such the following 
four sugars were functionalised onto the surface of the modified plates for testing; D-
glucose, D-galactose, D-lactose and D-mannose. 
 
Comparison of differential PNA binding between these four sugars revealed there to 
be a significant difference between binding to mannose compared to binding to 
galactose but the difference was very small and there was little difference between 
maximum binding seen. This indicates the presence of sugars on the surface but the 
poor resolution limits the usefulness of this technique. 
 
Polypropylene GM1 Cyanuric chloride Dextran
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3.3.3 Surface Blocking 
Several blocking agents were trialled on a variety of the surfaces in order to try and 
improve the specificity of the surface. Initially ethanolamine was used as described by 
Liang and Chen,14 and did appear to produce some improvement in surface specificity 
(Figure 3.4) but, the improvement was not reproducible. Indeed in some instances the 
addition of ethanolamine prevented any protein binding. 
 
Figure 3.4 Blocking of a mannose surface with a variety of blocking agents prior to 
incubation with fluorescently labelled peanut agglutinin (to represent non-specific 
binding). Bars represent the average of three measurements and the error bars are the 
standard error. 
 
Bovine serum albumin (BSA) was then utilised as it is a cheap protein source 
available in large quantities and often used in blocking non-specific binding in 
biological assays. There did not appear to be much improvement in the binding 
profiles (Figure 3.4) produced and this material would be unfavourable as a blocking 
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reagent as interaction between BSA and carbohydrates has been poorly studied and 
there is some evidence to show that BSA will bind certain carbohydrates thus 
competing with any lectins being studied. 
 
Tween was also tested as a potential blocking agent as it is often used in carbohydrate 
microarrays and has the benefit that it is not a protein and does not interact with the 
carbohydrates on the surface at all but it resulted in no improvement of the specificity 
of the surface (Figure 3.4). 
 
3.3.4 Hydroxylation of Polypropylene Surface with Octanol 
As no reproducible improvement was seen after use of several blocking agents, a new 
method of surface hydroxylation was trialled. The aim of this was to increase the 
density of hydroxyl compounds on the surface, which would then increase the 
cyanuric chloride functionalisation and subsequently the number of bound sugar 
residues. Greater sugar functionalisation should reduce non-specific binding whilst 
increasing specific binding thus resulting in better resolution. 
 
A paper by Grabosch et al. describes the use of compounds with long carbon chains 
for functionalisation of polypropylene.6 It was therefore reasoned that long chain 
alcohols could be used to introduce hydroxyl functionality to the polypropylene 
plates.  
 
Alcohols have several advantages; they will be more readily bound to the 
polypropylene than the GM1 resulting in greater initial functionalisation and 
consequently greater functionalisation at later steps. They also do not interact with the 
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lectins for testing (unlike GM1 which is the target carbohydrate for cholera toxin 
lectin and has a terminal galactose that has been shown to interact with galactose 
binding lectins), they are also cheap and readily available in large quantities. 
 
Initially, octanol was added to the surface for the hydroxylation stage before the 
cyanuric chloride step and the addition of the sugars. However, there was found to be 
no lectin binding upon testing for the presence of the sugar. This does not necessarily 
mean that the sugar is not present as it has previously been shown that a chain length 
of less than ten is not optimal for lectin binding to surface carbohydrates as the 
carbohydrate would not have the flexibility to enter the binding pocket. 
 
3.3.5 Hydroxylation of Polypropylene Surface with Dodecan-1-ol 
As octanol hydroxylation was insufficient for lectin binding the chain length of the 
alcohol was increased and dodecan-1-ol was used for the initial functionalisation step 
before addition of the cyanuric chloride solution and the sugars as shown in Figure 
3.5. 
 
To test surface characteristics, polypropylene slides were prepared by initially coating 
them in dodecan-1-ol before further functionalisation with the cyanuric chloride and 
the following sugars; sucrose, galactose, lactose and cellobiose. As well as this, small 
8 x 8 mm polypropylene chips were functionalised in the same way for analysis by 
variable angle XPS. 
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Figure 3.5 Schematic showing the three steps of surface functionalisation based on 
the method described by Liang and Chen.14 Initially a hydroxylated surface was 
produced through non-specific, non-covalent addition of dodecan-1-ol to the surface. 
Cyanuric chloride was then bound to the hydroxyl groups on the surface allowing 
addition of carbohydrates in the final step. 
 
Successful surface modification was determined using variable angle XPS and DSA. 
DSA showed there to be a significant change in contact angle between all of the steps 
of the modification process indicating a change in the hydrophilicity of the surface 
(Figure 3.6).  
Dodecan-1-ol
Cyanuric chloride
Glycan
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Figure 3.6 A slide was prepared for each step of the functionalisation and DSA was 
performed. Each measurement was repeated three times and the average is shown, the 
error bars represent the standard deviation. As can be clearly seen there is a change in 
surface hydrophobicity at each step indicating that functionalisation has been 
successful. 
 
The variable angle XPS results also confirm the functionalisation of the surface 
(Figure 3.7). The polypropylene and dodecan-1-ol surfaces only contained carbon and 
oxygen (the large change in contact angle in the DSA confirms the presence of the 
dodecan-1-ol). After addition of the cyanuric chloride both nitrogen and chlorine can 
be found on the surface (indicating the presence of the cyanuric chloride) the higher 
ratios of the nitrogen and chlorine fractions at 60° also indicates that they are more 
prevalent on the top layer of the surface and the carbon and oxygen fraction 
underneath. After the addition of the sugar, the loss of the chlorine whilst no loss of 
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nitrogen indicates the loss of the chlorine groups after reaction with the 
carbohydrates. This is further confirmed by the fact that the nitrogen fraction is under 
the carbon and oxygen fractions indicating the presence of the sugar on the surface. 
 
Figure 3.7 Variable angle XPS was performed on chips after each step of 
functionalisation. The bars represent one reading.  
 
After the surface had been characterised, the surface specificity was tested using the 
same well-characterised lectins as previously described. It was found that, while again 
there was differential binding, there was little difference between maximum binding 
and no binding (Figure 3.8) and despite attempts at blocking the rest of the surface 
with either BSA (10 mg.mL-1) or TWEEN (5 %) the difference between the 
maximum and no binding did not improve.  
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Figure 3.8 Addition of a serial dilution of PNA to a galactose functionalised surface 
revealed there to be little difference between maximum binding (550 RFU) and no 
binding (350 RFU).  
 
Figure 3.9 Functionalisation of the surface with 3 different carbohydrates (galactose, 
N-acetyl-D-glucosamine and mannose) resulted in differences in PNA binding with 
the highest binding shown on the galactose surface (as would be expected for a 
galactose specific lectin). 
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Binding was shown to be specific as binding of PNA on different sugar surfaces was 
shown to be distinct, thus indicating the presence of the carbohydrate on the surface 
(Figure 3.9). This showed that whilst there was surface functionalisation it was not 
highly functionalised. It may be that the surface is functionalised but not densely 
enough to allow multivalent binding so only weak interactions are seen but, it may be 
that this technique is applicable to bacteria as they are larger and so can undergo 
multivalent binding as they can bridge the gap between sugar units (Figure 3.10). 
 
 
Figure 3.10 It is hypothesised that the functionalisation of the surface with 
carbohydrates may be insufficient for lectins to show multivalent binding due to too 
great a distance between sugar units thus resulting in only weak binding. Bacteria 
may be able to bridge this gap as they are larger and thus can still undergo multivalent 
binding. This means that the technique may be applicable as a bacterial binding assay. 
 
Despite discontinuing this technique in favour of another surface functionalisation 
method its versatility has been shown through the analysis of the surface; it could be 
applied either to 96 well plates or a sheet of polypropylene can be coated in the same 
way and can be cut to almost any size allowing the production of samples that can be 
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analysed in many different ways including microscope slide sized samples for DSA 
and small chips for variable angle XPS. 
 
3.3.6 Hydrazide Functionalised 96-Well Plates 
Commercially available hydrazide functionalised 96-well plates can be further 
functionalised with sugars (Figure 3.11A).21 Owing to the high numbers of hydrazide 
groups on the well surface this technique might be expected to result in improved 
carbohydrate functionalisation and thus greater lectin specificity. This technique has 
previously been well-characterised and results in attachment of glycans 
predominantly in the ring closed (pyranose) β-D-anomeric form.21 Modification of the 
surface in this manner has a disadvantage over the previously mentioned technique in 
that only reducing glycans can be attached to the surface. 
 
Functionalisation was confirmed by using a modified drop shape analysis technique, 
which characterised the spreading of a water droplet (containing resorufin dye) on the 
surface before and after functionalisation with either galactose or glyceraldehyde (as a 
positive control) to gain an estimate of the surface hydrophilicity. As can be seen by 
Figure 3.11B, the surface hydrophilicity was significantly increased after surface 
functionalisation with galactose (when compared to the unfunctionalised hydrazide 
surface) and this was even further increased for the surface functionalised with 
glyceraldehyde. 
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Figure 3.11 Glycosylated 96-well plates were generated through the reaction of 
commercially available 96-well plates with glycans (A). Functionalisation was then 
confirmed using a modified DSA technique where surface spreading of a droplet of 
water was determined at every step (B). The bars represent the average of 3 
independent replicates and the error bars represent the standard deviation. 
Representative images of droplet spreading shown above the bar.  
A
B
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Figure 3.12 A serial dilution of fluorescently labelled Con A was added to both a 
galactose and a mannose functionalised surface and fluorescence was measured. Con 
A was found to bind the mannose surface (1.7 µM) more strongly than the galactose 
surface (5.3 µM). This IC50 value is determined from a curve fitting to an average 
binding curve based on three triplicate measurements and error bars represent the 
standard error.  
 
Whilst the change in hydrophilicity indicates a change in the nature of the surface that 
can be explained by the presence of galactose on the surface, further probing with 
lectins was then performed in order to further characterise the surface. Fluorescently 
labelled Con A (α-D-mannose specific) and PNA (β-D-galactose specific) were 
incubated with a mannose or a galactose functionalised surface and Con A was found 
to bind the mannose surface more strongly than the galactose surface (Figure 3.12) 
and the reverse was also found to be true for PNA (Figure 3.13). This selective lectin 
binding indicated the success of the surface functionalisation step. 
Surface
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Figure 3.13 A serial dilution of fluorescently labelled PNA was added to both a 
galactose and a mannose functionalised surface and fluorescence measured. PNA was 
found to bind the galactose surface (35 nM) more strongly than the mannose surface 
(44 nM). This IC50 value is determined from a curve fitting to an average binding 
curve based on three triplicate measurements and error bars represent the standard 
error.  
 
3.3.7 Hydrazide surface blocking 
The blocking of microarray surfaces in order to prevent non-specific adhesion is 
routinely performed, as this would increase the specificity of the surface. 
Functionalised surfaces are routinely blocked with BSA and various other agents such 
as Tween to prevent non-specific binding of proteins to the underlying surface. 
However, little work has been done to identify possible interactions between the BSA 
and the carbohydrates on the surface or the lectins being tested. Blocking should only 
really be performed if it will prevent a significant amount of non-specific 
carbohydrate adhesion. 
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Addition of a serial dilution of fluorescently labelled BSA to both a carbohydrate 
functionalised surface and an unfunctionalised surface made of the same material 
highlighted that at the concentrations of lectin being analysed there was no significant 
non-specific adhesion on the functionalised surfaces (highlighted by the lack of FITC-
BSA binding on these surfaces compared to a non-functionalised surface, Figure 
3.14). Owing to the lack of knowledge about interactions the BSA may have with the 
lectins being tested and the limited amount of non-specific binding that could occur at 
the concentrations of protein being used, the hydrazide surfaces were not blocked 
during further experiments. 
 
Figure 3.14 Addition of a serial dilution of FITC labelled BSA to a hydrazide surface 
and surfaces functionlised with two different carbohydrates highlights that up until 
about 0.01 mg.mL-1 of protein there is no significant non-specific binding of the BSA 
to functionalised surfaces when compared to unfunctionalised surfaces. Points 
represent individual measurements and error bars represent machine error. 
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3.4 Conclusion 
Carbohydrate microarrays play a crucial role in the identification and classification of 
toxins and whole bacteria and they play a pivotal role in the testing of inhibitory 
compounds. Whilst commercial carbohydrate microarrays are available, they are 
expensive and the surfaces are limited to those commercially available and thus it is 
advantageous to use a surface functionalisation technique in order to be able to 
generate the surfaces of interest. 
 
Many surface functionalisation techniques exist and have been used in the generation 
of carbohydrate microarrays. The best techniques use unmodified carbohydrates 
which are attached covalently in a site-specific manner to a modified surface, this is 
because unmodified carbohydrates are significantly cheaper than modified ones and 
site-specific attachment results in one orientation of the carbohydrate being present on 
the surface. Spacers and linkers between the surface and the carbohydrate can impact 
significantly on binding so, ideally, these should be the same for all the carbohydrates 
being attached. 
 
Attempts to modify the Liang and Chen method for attachment of any unmodified 
glycan to a surface functionalised with cyanuric chloride residues for use in 96- well 
plates proved unsuccessful. The technique was shown to be adaptable to a number of 
surface analysis techniques through the use of polypropylene slides and chips and 
surface functionalisation was confirmed through the use of DSA and variable angle 
XPS. The resolution of lectin binding proved to be insufficient despite changing both 
the hydroxylation steps used and testing a number of surface blocking techniques.  
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Commercially available hydrazide functionalised microwell plates were employed to 
generate 96 well plate based carbohydrate microarrays. This method of attachment 
has been very well characterised previously and it is known that reducing glycans 
immobilised through this method are predominantly in the β-D-anomeric pyranoside 
form and all are attached in identical orientation through the reducing terminus.21 
Surface functionalisation was confirmed using a modified DSA technique and the 
carbohydrate specific adhesion of two well-characterised lectins. This simple and 
cheap method for generating carbohydrate microarrays represents a method through 
which any (reducing) glycan of interest can be immobilised for testing of either lectin 
binding, the binding of whole cells or the testing of inhibitory compounds. 
 
  
	 103	
3.5 Materials and methods 
Materials: All chemicals were used as supplied unless otherwise stated. High binding 
clear flat-bottomed polystyrene microplates were purchased from Greiner Bio-one. 
Polypropylene flat-bottomed microplates, polypropylene sheet, cyanuric chloride, 
acetone, aniline (99.5 % ACS reagent), monosialylganglioside GM1 from bovine 
brain, D- (+)cellobiose, D- (+)galactose, D- (+)mannose, DL- glyceraldehyde, bovine 
serum albumin, HEPES, lactose, α-D-glucose, N-Acetyl-D-Glucosamine, resorufin, 
octanol, dodecan-1-ol, ethanol, phosphate buffered saline (PBS) tablets, sodium 
acetate anhydrous, acetic acid glacial, fluorescein isothiocyanate isomer I (≥ 90 % 
HPLC grade), PD10 desalting columns, Tween20 and sucrose were all purchased 
from Sigma-Aldrich. FITC labelled Concanavalin A and Peanut Agglutinin from 
Arachis hypogaea were purchased from Vector Labs. 100 mM acetate buffer (pH 5.5) 
with 1 mM aniline was prepared in 200 mL of milliQ water (with a resistance >19 
mΩ.cm at 25 °C). 10 mM HEPES buffer was prepared in 200 mL of milliQ water 
(with a resistivity >18 MΩ.cm-1 at 25 °C) with added 0.15 M NaCl, 0.1 mM CaCl2 
and 0.01 mM Mn2+ (pH 7.5) and is now referred to as HEPES in the text. 
 
GM1 hydroxylation: 100 µL of GM1 solution (0.1 mg.mL-1 in PBS) was added to 
every well of the 96 well plate before incubation for 16 hours at 4 °C. Unbound GM1 
solution was then removed and every well washed three times with MilliQ water 
(resistivity >18 MΩ.cm-1 at 25 °C) before drying under N2 stream. Functionalised 96 
well plates were either used directly or stored at -20 °C prior to use. 
 
Cyanuric chloride and sugar functionalisation: Hydroxylated surfaces were further 
functionalised with cyanuric chloride by addition of 100 µL of cyanuric chloride 
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solution (100 mM in acetone) to every well and incubation at 4 °C for 6 hours. 
Unbound solution was then removed and wells were extensively washed with acetone 
and then a further three times with HEPES buffer. 100 µL of glycan solutions (30 mM 
for small glycans or 3 mg.ml-1 for polysaccharides, in water adjusted to pH 9 with 1 
M NaOH) was added to every well before incubation for 10 hours at room 
temperature. Unbound solution was then removed and wells washed three times with 
MilliQ water (resistivity >18 MΩ.cm-1) before drying under N2 stream. Functionalised 
96-well plates were then either used directly or stored at -20 °C prior to use. 
 
Cyanuric chloride blocking: After preparation of a mannose functionalised surface 
the surfaces were further incubated with either bovine serum albumin (at 10 mg.mL-1 
in PBS), 5% Tween (in PBS) at room temperature for 12 hours. Blocking with 
ethanolamine was performed by incubating with a 1 M aqueous solution of 
ethanolamine (adjusted to pH 9) for 3 hours. After surface blocking, the wells were 
incubated with fluorescently labelled PNA (0.1 mg.mL-1in HEPES) at 37 °C for 30 
minutes before removal of unbound protein solution and extensive washing with 
HEPES. Fluorescence was then measured using a BioTek Synergy HT multi-detection 
microplate reader and Gen5 software with excitation and emission wavelengths of 
485 and 528 nm respectively.  
 
Drop shape analysis: Water contact analysis experiments were performed at room 
temperature using a Krüss drop shape analysis system (DSA100) equipped with a 
moveable sample stage and a microliter syringe. Samples were placed on the sample 
stage using tweezers and aligned within the field of view of the camera. Then the 
microliter syringe was advanced until a drop of 10 µL of deionized water was formed 
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and suspended at the end of the needle. The sample stage was then elevated, until the 
sample touched the bottom of the drop, causing it to detach from the needle and form 
on the surface. The sample stage was then moved back to the initial position and an 
image of the droplet was recorded. The baseline contact angles were then computed 
from the image. 
 
Octanol and Dodecan-1-ol hydroxylation: 100 µL of either octanol or dodecan-1-ol 
solution (10 mM in ethanol) was added to every well of a polypropylene plate before 
incubation at room temperature for 24 hours. Any remaining unbound solution was 
then removed before washing of every well with ethanol and twice with PBS. 
 
Variable angle XPS: 8 x 8 mm polypropylene chips were prepared at various stages 
of functionalisation including unfunctionalised, hydoxylated with dodecan-1-ol, after 
addition of cyanuric chloride and then after addition of a glycan. All variable angle 
XPS was performed by Stephen	 Edmondson,	 School	 of	Materials	 Science	 at	 the	University	of	Manchester. 
 
Lectin binding assay: Surfaces were incubated with either fluorescently labelled 
Concanavalin A or Peanut Agglutinin in a serial dilution from a starting concentration 
of 0.1 mg.mL-1 (in HEPES) were incubated for 37 °C for 30 minutes before removal 
of unbound protein solution and extensive washing with HEPES. Fluorescence was 
then measured using a BioTek Synergy HT multi-detection microplate reader and 
Gen5 software with excitation and emission wavelengths of 485 and 528 nm 
respectively.  
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Hydrazide functionalisation: 100 µL of 30 mM glycan solutions (in 100 mM acetate 
buffer with 1 mM aniline, pH 5.5) was added to each well of a Carbo-BINDTM 96-
well plate. Plates were then covered in foil and incubated at 50 °C for 24 hours. After 
incubation, any unbound solution was removed and the well washed thoroughly with 
PBS three times. Plates were then either used immediately or stored at -20 °C prior to 
their use. 
 
Modified drop shape analysis: 10 µL drops of resorufin (0.01 mg.mL-1 in milliQ 
water) were added to hydrazide surfaces prior to functionalisaton and after 
functionalisation with either galactose or glyceraldehyde. A digital camera was then 
used to take a photograph (Figure 3.15A) and the image was then converted into a 
Hue, Saturation, Brightness (HSB) stack in ImageJ. The area of the well in pixels was 
determined initially by drawing a region of interest around the well (Figure 3.15B). A 
region of interest was then drawn around the droplet and the area that the droplet 
occupied (Figure 3.15C) was compared to the area of the well to determine the 
percentage of the surface covered by the droplet. The greater the hydrophilicity of the 
surface, the more the droplet will spread and the greater the percentage of the well 
area covered by the droplet. 
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Figure 3.15 A digital photograph is taken of the 10 µL dye droplets on the well 
surface (A), this is then uploaded into ImageJ and converted into a HSB stack. A 
region of interest is drawn around the entire well (B) and the area in pixels is 
measured. A second region of interest is then drawn around the droplet (C) and the 
area occupied by the droplet in pixels is measured. The two values are then compared 
to determine the percentage of the surface covered by the dye droplet. 
 
BSA labelling: A stock solution of 1 mg.mL-1 BSA in PBS was prepared and 30 µL 
of fluorescein isothiocyanate isomer I (at 10 mg.mL-1 in DMSO) was added to every 1 
mL of stock solution. This was then incubated at room temperature in the dark for 1 
hour, with continuous stirring. Before use, the solution was washed through a PD10 
desalting column in order to remove unlabelled protein and unbound FITC. 
 
Non-fouling surface analysis: 100 µL of FITC-BSA was added as a serial dilution 
(from 1 mg.mL-1 in PBS) to the wells of either an unfunctionalised hydrazide surface, 
or those further functionalised with either D-galactose or D-glucose. Fluorescence was 
then measured using a BioTek Synergy HT multi-detection microplate reader and 
Gen5 software with excitation and emission wavelengths of 485 and 528 nm 
respectively.  
 
HSB Stack
ImageJ
A B C
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Data analysis: All protein-binding curves were plotted in OriginPro (version 8.6) and 
the built in nonlinear curve-fitting tool was used to fit a logistic curve to the data and 
to calculate IC50 values. All other graphs were also plotted in OriginPro and averages 
and standard deviations were calculated using the open source statistical package R 
(version 3.1.3).25 
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Chapter 4 
	
Discrimination between lectins with similar 
specificities by ratiometric profiling of 
binding to glycans 
 
 
 
 
 
4.1 Abstract 
 
Carbohydrate-lectin interactions mediate a number of crucial biological processes. 
Their prevalence in nature means they are often exploited by pathogens and as such 
have recently been utilised for diagnostic applications. Whilst lectin binding to long 
chain glycans can be highly specific these compounds are challenging to access and 
often expensive. The use of readily available and cheap monosaccharides is 
complicated by the promiscuous nature of lectin binding to these compounds. Herein 
the use of monosaccharide-coated surfaces is described, coupled with a machine-
learning algorithm for the discrimination of lectins of similar binding specificities. 
This approach is then further expanded to a solution based ‘label-free’ approach and 
the use of heterogeneous glyco-environments to move towards a more ‘real-world’ 
system that can not only discriminate between lectins but can do so in a concentration 
independent manner.   
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4.2 Introduction 
Protein carbohydrate interactions are crucial for many biological processes including 
cell-cell communication, innate immunity, and fertilisation.1-4 These processes are 
mediated by carbohydrate binding proteins known as lectins. Carbohydrate-lectin 
interactions are moderated by a combination of the carbohydrate itself, the linker 
between the carbohydrate and the cell surface and the precise 3D presentation of 
carbohydrates on the cell surface.5, 6 
 
Figure 4.1 Lectin binding to six oligosaccharides extracted from the consortium for 
functional glycomics (A). Lectin binding to all mono- and di-saccharides extracted 
from the consortium for functional glycomics (B). The lectins are as follows; cholera 
toxin B subunit (CTxB), Dolichos biflorus agglutinin (DBA), peanut agglutinin from 
Arachis hypogaea (PNA), Ricinus communis agglutinin 120 (RCA120) and Soybean 
agglutinin (SBA).7 
 
Many lectins show highly specific binding at the oligosaccharide level (Figure 4.1A) 
but highly promiscuous binding on the mono- and di-saccharide level (Figure 4.1B). 
For example, Peanut Agglutinin from Arachis hypogaea (PNA) is described as being 
galactose (Gal) specific but microarray analysis reveals it will readily bind to all 
monosaccharides to one degree or another.7 Similarly, the B subunit of cholera toxin 
(CTxB) is described as binding specifically to monosialyltetrahexosylganglioside 
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(GM1) found on intestinal endothelial cells but it will indiscriminately bind all 
monosaccharides (although in a completely different order of magnitude compared to 
GM1 binding).7 
Figure 4.2 Schematic of cholera toxin action.  
 
The wide variety of roles played by glycans in the body’s innate processes and the 
prevalence of these interactions in nature means that they are readily exploited by 
pathogens. For example, FimH is a lectin that mediates the binding of uropathogenic 
Escherichia coli to mannose rich residues thus initiating infection and is a crucial 
virulence factor.8, 9 The intraerythrocytic phase of Plasmodium falciparum (the 
parasite responsible for malaria) is mediated by a lectin-like protein, which allows it 
to bind to glycans on the surface of the red blood cell.10 Cholera is caused by cell 
internalisation of an AB5 toxin secreted by the bacteria Vibrio cholera.11, 12 This toxin 
comprises of one enzymatic A subunit and 5 lectin B subunits (CTxB) which bind to 
the GM1 ganglioside present on intestinal endothelial cells.13 After binding and 
2. Endocytosis
3. Toxin cleaved 
to release the 
active A subunit
8. Efflux of ions and water
4. A subunit binding 
and activation of G 
protein
5. Activation of 
adenylate cyclase
1. Binding of 
toxin to GM1
6. Production of cAMP
7. Activation of CFTR
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internalisation of the toxin, the B subunits are cleaved from the A subunit and the A 
subunit is further cleaved to form an active enzyme. This enzyme then enters the 
cytosol of the cell where it binds to a G protein locking it in its active state so it 
continually stimulates adenylate cyclase to generate cyclic adenosine monophosphate 
(cAMP). cAMP binds to cystic fibrosis transmembrane conductance regulator 
(CFTR) causing an efflux of ions and water (Figure 4.2). Ricin is a highly toxic lectin 
extracted from Ricinus communis seeds. It comprises an A subunit and a D-galactose 
binding B subunit. After binding of the toxin to the cell surface and internalisation the 
two subunits are cleaved apart and the A subunit goes on to remove an adenine 
residue from the 28S ribosomal RNA thus rendering the cell incapable of protein 
synthesis and ultimately resulting in cell death (Figure 4.3).14 Differences in 
glycosylation have also been detected in tumour cells and can determine the 
metatastic potential of cancers whilst changes of glycosylation patterns on red blood 
cells have been linked to susceptibility towards, and severity of, diseases such as 
smallpox, cholera and malaria.2, 4, 15-17 
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Figure 4.3 Schematic of ricin action. 
 
As they are so crucial for a multitude of pathogenic processes, the rapid detection of 
lectins can aid in the early identification and prevention of diseases. Whilst proteomic 
and antibody based techniques can be used in the identification of lectins these 
techniques are not always suitable for robust point-of-care applications. These 
methods often require infrastructure for preparation and storage, expensive equipment 
and/or highly staff. To address this, multiplexed nanoparticles for biosensing have 
attracted much interest, especially for diagnostics. For example, Rotello et al. have 
developed a system using differentially functionalised gold nanoparticles, which 
allowed detection of 52 different mixtures of 7 proteins using just 6 different 
nanoparticles.18 Glycosylated magnetic particles have also been used for MRI based 
detection of cancerous cells and gold particles functionalised with three different 
thiols allowed identification of cancerous cells from normal cells.19, 20 Jayawardena et 
al. described the use of gold nanoparticles functionalised with a number of glycans. 
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These gold nanoparticles were used to discriminate between a number of different 
lectins based on the characteristic shift in SPR readings upon lectin binding to the 
gold nanoparticles. In this instance the lectins assessed had very different binding 
specificities and they could be discriminated based on binding to a single glycan so a 
multiplexed approach was not needed.21 
 
Many lectins will have similar binding specificities especially at the monosaccharide 
level where binding can be fairly promiscuous. The aim of this research was to assess 
the use of monosaccharides as multiplexed sensors to enable the discrimination of 
lectins with similar binding specificities. Rapid diagnostic techniques based on 
discriminant lectin binding would allow for rapid detection of environmental toxins 
and by utilising monosaccharides the need for a single high affinity binder for each 
target is removed. This would allow the discrimination of a broader range of targets. 
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4.3 Results and Discussion 
The key aim of this work was to evaluate the use of monosaccharides (as these are 
cheap and readily available) as multiplexed sensors to enable discrimination between 
different lectins.  
4.3.1 Lectin binding profiles 
Hydrazide functionalised 96-well plates were further reacted with a range of 
monosaccharides to produce a number of monosaccharide surfaces (as described in 
Chapter 2). To highlight the challenges faced in identification of lectins, a panel of 
five fluorescently labelled D-galactose (Gal) or N-Acetyl-D-Galactosamine (GalNAc) 
binding lectins were selected including two toxins; Ricinus communis Agglutinin-120 
(RCA120, a non-toxic surrogate for the ricin B subunit) and cholera toxin (CTxB) and 
three environmental plant lectins; Soybean Agglutinin, Dolichos biflorus Agglutinin 
and Peanut Agglutinin from Arachis hypogaea (SBA, DBA and PNA respectively). 
 
These lectins were then incubated with a D-galactose functionalised surface and after 
removal of unbound lectin and washing the fluorescence spectra were read. The 
binding profile for most of the lectins were within error of each other and as such 
identifying any one lectin based on binding to D-galactose alone would be challenging 
(Figure 4.4). 
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Figure 4.4 Addition of five fluorescently labelled lectins (at a concentration of 0.01 
mg.mL-1) to a D-galactose functionalised surface resulted in very similar binding 
profiles for most of the lectins. Bars represent the average of three measurements and 
the error bars are the standard error of the measurements.  
 
Increasing the number of monosaccharide surfaces to include D-glucose (Glc), D-
mannose (Man) and a 1:1 mixture of Gal:Man (Gal/Man) resulted in a unique binding 
profile for each lectin (Figure 4.5). For example RCA120 displayed significantly 
higher binding to Gal and the Gal/Man mixture with respect to Glc binding. 
Conversely, SBA showed depressed binding to the Gal/Man surface. 
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Figure 4.5 Addition of five fluorescently labelled lectins (at a concentration of 0.01 
mg.mL-1) to a surface functionalised with either Gal, Glc, mannose or a mixed surface 
of 1:1 Gal:Man. Bars represent the average of 4 independent replicates with error bars 
representing the standard error. 
 
Despite the differences in the binding profiles it would still be challenging to identify 
a single lectin based only on its binding profile as many of the differences between 
the carbohydrates are within error of each other and many of the differences between 
the lectins are also very small or within error. A better analysis method is needed in 
order to improve the resolution between the profiles to aid in the classification of 
unknown samples. 
 
4.3.2 Linear Discriminant analysis 
Linear discriminant analysis (LDA) is a statistical technique that can aid in the 
classification of samples as it minimises the variation within the class (in this instance 
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the lectin) and maximises the variation between classes thus increasing the resolution 
of the profiles generated. Initial binding profiles are used as a ‘training matrix’ to 
produce a model in which the resolution between lectin classes is maximised. 
 
The LDA model produced showed excellent resolution between groups (Figure 4.6A). 
Whilst it appears that all other lectin classes are well resolved from CTxB but poorly 
separated from each other this is not actually the case. Excluding CTxB, the model 
shows good separation between the other lectin classes has been achieved (Figure 
4.6B). Validation of the model in a leave-one-out manner (where a sample is left out 
and the model is generated before classification of the ‘left out’ samples) gave a 
reclassification accuracy of 100 %. 
 
Figure 4.6 The LDA model produced from the surface binding profiles showed 
excellent resolution amongst the lectin groups (A). Whilst it appears that DBA, PNA, 
RCA120 and SBA are tightly clustered, they are also well separated from each other 
(B). Each point represents the binding profile of one lectin to all 4 surfaces and the 
ellipse represents the standard deviation from the average response. 
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The LDA model was then used to classify a blind sample of each of the five lectins 
binding to each of the four surfaces. All blind samples were correctly classified by the 
model based on their binding profiles with 100 % accuracy. This highlights the 
potential of a carbohydrate based identification sensor. 
 
4.3.3 Identification of mixed samples 
The model was able to correctly identify blind samples of pure lectins but in 
environmental samples it is likely that there will be contamination of other lectins and 
as such the differentiation between a mixed sample of the two pathogenic lectins 
(RCA120 and CTxB) was investigated. 
 
Mixed samples of RCA120 and CTxB were added to the four sugar surfaces and 
binding profiles were determined (Figure 4.7). The LDA model was then used to 
classify the binding profiles in order to determine the lectin responsible. When the 
lectin was present at greater than 50 % (by mass) of the sample it was correctly 
classified, so at > 50 % CTxB the model classified the profile as CTxB with the 
reverse case also being true. 
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Figure 4.7 Binding of a variety of samples containing different ratios of CTxB to 
RCA120 to the 4 sugar surfaces. The bars show the binding of a single sample. 
 
4.3.4 Solution based assay 
Classification of non-pure lectin samples was possible with the mixed surfaces 
technique and, whilst that is a step-towards a ‘real-world’ sensing application, it still 
utilises fluorescently labelled lectins, which would not be available in all settings. As 
such LDA was applied to the binding profiles generated from a label-free solution 
based assay. 
 
This assay uses sugar functionalised gold nanoparticles (GlycoAuNPs, Scheme 4.1). 
In solution, these appear pink to the naked eye but upon addition of a lectin and 
aggregation of the GlycoAuNPs the solution undergoes a colour change from pink to 
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blue (Figure 4.8). This colour change can also be seen in the absorbance spectrum as a 
decrease in absorbance at 530 nm and an increase at 700 nm. Using these changes 
glycan binding affinity can be estimated. 
 
Scheme 4.1 Synthetic route to carbohydrate functionalised gold nanoparticles (60 
nm). Particles were synthesised by Sarah-Jane Richards. 
 
Figure 4.8 Upon addition of a lectin to GlycoAuNPs aggregation occurs which results 
in a colour change from pink to blue. 
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Addition of six lectins to 6 different GlycoAuNPs and measurement of the absorbance 
at 700 nm resulted in the production of binding profiles for all of the lectins (Figure 
4.9A). All of the lectins assessed had unique binding profiles. However, many of the 
binding profiles for one lectin fell within error of the profile of another lectin, 
consequently, binding profiles alone could not be used to predict unknown samples. 
 
The binding profiles were used as a ‘training matrix’ to produce a LDA model (Figure 
4.9B). The LDA model produced showed excellent resolution between all lectin 
classes and validation of the model using a leave-one-out approach indicated the 
reclassification accuracy of the model was 100 %. 
	  
Figure 4.9 After incubation of the lectin with each of the GlycoAuNPS absorbance 
was measured at 700 nm resulting in the production of distinct binding profiles for all 
lectins assessed where the bars represent the average of 4 independent replicates and 
the error bars are the standard error (A). The binding profiles were then used as a 
‘training matrix’ to generate a LDA model which showed excellent resolution 
between all lectins assessed (B). 
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The differential binding of lectins to monosaccharides coupled with LDA was able to 
produce a model with excellent resolution using this label free solution based 
technique. This highlights the potential of the method for application in a more 
realistic setting where lectins for detection would not be fluorescently labelled. Whilst 
we have utilised absorbance data as the ‘training matrix’ we have previously shown 
that the colourimetric change from pink to blue can also be graphically interpreted 
using a digital camera and analysis in ImageJ to determine pixel intensity, which 
correlates well with absorbance.22 This approach is label free, cheap and highly 
accessible. 
 
4.3.5 Mixed surfaces 
All of the approaches mentioned so far have used a known concentration of lectin in 
the generation of binding profiles and subsequent detection of blind samples have 
been at the same concentration. In a ‘real-world’ setting the concentration of the lectin 
in a sample would be unknown and efforts to create a concentration independent 
sensor should also be made. 
 
Increasing the number of subunits in the glycan chain could be utilised to achieve this 
sensing capability. However, the synthetic complexity and thus price of glycans 
generally increases as the chain length increases. Increasing the information density 
without increasing the number of saccharides used would be advantageous. It is 
known that the use of variable density glycan mixtures can result in non-linear 
responses in terms of glycan binding.23-25 It can therefore be rationalised that the use 
of mixed surfaces can increase the information density of a sensor without resorting to 
increasingly complex glycans.26 
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To this end GlycoAuNPs were prepared with varying ratios of N-Acetyl-D-
Mannosamine (ManNAc) and GalNAc from 100 % GalNAc to 100 % ManNAc in 
steps of 10 (Figure 4.10). Once again the shift in absorbance at 700 nm was used as 
the response and each of the different GlycoAuNPs was incubated with seven 
different concentrations of three different lectins. The binding profiles were used as a 
‘training matrix’ and a LDA model was produced (Figure 4.11). Within the LDA 
model the lectins are at several different concentrations but only the lectin class was 
considered. 
 
 
Figure 4.10 GlycoAuNPs were functionalised with varying ratios of ManNAc and 
GalNAc from 100 % ManNAc (left) to 100 % GalNAc (right). 
 
The LDA model showed good resolution between the groups but with some overlap 
between the lectin classes. Despite this, analysis in a leave-one-out manner revealed 
the reclassification accuracy to be 86 %. The overlap between the classes was due to 
very similar binding profiles for the lectins when the concentration was low.  
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Figure 4.11 Shift in absorbance at 700 nm after incubation of the lectin at various 
concentrations was used as a ‘training matrix’ to produce a LDA model where each 
point represents the binding of a single lectin (at any of the seven concentrations) to 
all GlycoAuNPs and the ellipses represent the standard deviation from the average 
response. 
 
Whilst the model only had an accuracy of 86 % it should be noted that this is based on 
the binding profiles considering only two monosaccharides (GalNAc and ManNAc). 
If we consider a LDA model containing information from only the 100 % GalNAc 
and 100 % ManNAc particles then the reclassification accuracy of the model 
decreases to 68 % and, by including the varying ratios, the information density of the 
assay has been increased. 
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Figure 4.12 The concentration dependent LDA model produced showed significant 
overlap both between different concentrations of the same lectin and between 
different lectin classes.  
 
If we separate the lectin classes into lectin and concentration then the model has the 
potential to classify a sample based on both lectin class and concentration of the lectin 
thus providing more information. A LDA model produced that is separated in this 
manner showed considerable overlap both between different concentrations of the 
same lectin and between lectin classes (Figure 4.12). The classification power of this 
model is significantly reduced when compared to the concentration independent 
model, giving an accuracy of only 27 %.  
 
Generally the predictive power of the model is higher for the higher concentrations 
and generally declines as the concentration decreases. If we consider only the profiles 
for lectin concentration of greater than 100 nM then the profiles show excellent 
resolution between the classes and reasonable resolution between the different 
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concentrations within each lectin class (Figure 4.13A). However, if we consider the 
profiles for which the lectin concentration was less than 100 nM then there is 
significant overlap between concentrations and between lectin classes resulting in the 
lower classification accuracy of this model (Figure 4.13B). 
 
The accuracy of both the concentration independent and concentration dependent 
model could be increased by increasing the number of sugars, increasing glycan chain 
length or with the addition of varying surfaces thus increasing the accuracy of the 
model. This approach has the potential for lectin sample classification in both a 
concentration independent manner and also classification of not just lectin but also 
concentration of lectin within a sample. 
		
	
Figure	4.13 The concentration dependent LDA model considering just those profiles 
with a concentration above 100 nM showed excellent differentiation of lectin classes 
but poorly resolved for different concentrations (A). At lower concentrations (< 100 
nM) the profiles for both different concentrations and different lectins overlapped (B). 
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4.4 Conclusion 
Here we have described the use of four monosaccharide-coated surfaces combined 
with linear discriminant analysis for the discrimination of five lectins of similar 
binding specificity. This technique was able to correctly identify blind samples with 
100 % accuracy and could even determine one lectin in the presence of another as 
long as the lectin was present at greater than 50 % (by mass). The coupling of 
monosaccharide binding profiles with LDA was further applied to a ‘label free’ 
solution based assay utilising glycan functionalised gold nanoparticles. The use of 
mixed glycan surfaces coupled with LDA highlighted a manner through which 
increasing information density can be achieved without using expensive 
(bio)synthetically challenging oligosaccharides. This highlighted the potential for a 
monosaccharide based, ‘label-free’ detection system that can discriminate between 
lectins of similar binding specificities in a concentration independent manner, which 
would enable rapid lectin detection in a real world situation. 
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4.5 Materials and methods 
 
Materials: All chemicals were used as supplied unless otherwise stated. Corning® 96 
well clear flat bottom polystyrene Carbo-BINDTM microplates, aniline (99.5 % ACS 
reagent), D-(+)mannose, α-D-glucose, D-(+)galactose, DMSO, phosphate buffered 
saline tablets and  FITC conjugated Cholera Toxin B subunit were purchased from 
Sigma-Aldrich. 100 mM acetate buffer with 1 mM aniline (pH 5.5) was prepared in 
200 mL of milliQ water (with a resistivity >18 MΩ.cm-1). 10 mmol HEPES buﬀer 
containing 0.05 M NaCl, 0.1 mM CaCl2 and 0.01 mM MnCl2 (pH 7.5, HEPES) was 
prepared in 200 mL of milliQ water (with a resistivity >18 MΩ.cm-1). FITC labelled 
Dolichos biflorus agglutinin, Soybean agglutinin, Ricinus communis Agglutinin I and 
Peanut Agglutinin from Arachis hypogaea were purchased from Vector Labs. 
 
Preparation of glycosylated surfaces: 30 mM monosaccharide solutions were 
prepared in 100 mM acetate buffer with 1 mM aniline. 100 µL of monosaccharide 
solution was then added to every well of a hydrazide functionalised 96 well microtitre 
plate before incubation at 50 °C for 24 hours. After incubation wells were extensively 
washed three times with MilliQ water before being allowed to dry. Plates were 
functionalised with galactose, glucose, mannose or a 1:1 solution of galactose and 
mannose and were either used immediately or stored at -20 °C. 
 
Lectin binding assays: Various fluorescently labelled lectins (DBA, CTx, PNA, 
RCA120 and SBA) were dissolved to a concentration of 0.01 mg.mL-1 in 10 mM 
HEPES with 0.15 M NaCl, 0.1 mM CaCl2 and 0.01 mM MnCl2 (pH 7.5). 100 µL of 
the lectins were then added to each well of a microtitre plate before incubation in the 
dark at 37 °C for 30 minutes. After incubation, each well was rigorously washed 3 
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times with water before fluorescence readings were taken. Fluorescence readings 
were taken using a BioTek Synergy HT multi-detection microplate reader and Gen5 
software with excitation and emission wavelengths of 485 and 528 nm respectively.  
 
Blind sample assays: Blind samples were prepared in the same method as the lectin 
binding assays. Briefly, 100 µL of each blind sample (with a lectin concentration of 
0.01 mg/mL) was added to each well and after incubation in the dark at 37 °C for 30 
minutes wells were washed with water before fluorescence readings were taken. 
Fluorescence readings were taken using a BioTek Synergy HT multi-detection 
microplate reader and Gen5 software with excitation and emission wavelengths of 
485 and 528 nm respectively. 
 
Linear discriminant analysis: Every lectin was added to each surface as described in 
the lectin binding assay section. This was repeated 4 times to generate a training data 
matrix of 4 surfaces x 5 lectin x 4 replicates, which was then subjected to a classical 
linear discriminant analysis (LDA)27 in the open source statistical package R (version 
2.14.1).28 The model produced in this analysis was used to predict the nature of the 
random samples using the predict function in R.27 
 
Linear discriminant analysis plots: LDA plots were drawn in R (version 2.14.1)28 
using the plot function. Each data point represents the fluorescence readings for a 
single lectin transformed into linear discriminants using the LDA model. Ellipses 
were added using the ellipse function and represent the mean linear discriminant 
values for each lectin category +/- the standard deviation of the linear discriminants. 
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Chapter 5 
	
Carbohydrate functionalised surfaces for 
the rapid identification of bacterial species 
to improve point-of-care diagnostics 
 
 
5.1 Abstract 
 
Antibiotic resistance remains a global health concern with deaths as a result of 
antimicrobial resistance due to outnumber those caused by cancer by 2050. There is a 
growing concern that without an increase in new treatment methods, or a decline in 
the spread of resistance amongst bacterial species, there will be a return to a ‘dark 
age’ of medicine during which procedures that are currently routine will once again 
become impossible. Current bacterial infection identification methods are often 
challenging, time-consuming or expensive and most treatment is carried out in the 
absence of microbial information. Here we describe the use of carbohydrate 
functionalised surfaces coupled with a powerful statistical technique for the rapid 
identification of a variety of bacterial species in order to improve point-of-care 
diagnostics of bacteria responsible for infection. 
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5.2 Introduction 
 
5.2.1 Bacterial infections  
 
Bacterial infections are responsible for millions of deaths a year. Although exact 
statistics are hard to come by, the number of childhood deaths is often used as a 
‘surrogate marker’ for the bacterial infection-derived mortality worldwide. It is 
estimated that bacterial infections contribute to one third of all childhood deaths, 
approximately 1.6 million deaths a year, with the majority occurring in South Asia 
and Sub-Saharan Africa.1  
 
Bacteria cause diseases such as meningitis, pneumonia, diarrhoea and are responsible 
for many hospital acquired infections such as Staphylococcus aureus2 and 
Clostridium difficile.3 Moreover, ‘old’ illnesses such as tuberculosis, caused by the 
bacteria Mycobacterium tuberculosis, for which antibiotics have proven particularly 
effective, are once again on the rise.4, 5  
 
5.2.2 Antibiotic resistance 
 
Penicillin was the first antibiotic discovered and was first used clinically in 1940 
where it revolutionised the treatment of gram-positive infections.6 Several other 
antibiotic agents came to light soon after this but, despite this early progress, bacterial 
infections are still rife today due to the adaptable nature of the bacteria. Bacteria often 
develop resistance to the antibiotics used to treat them. The spread of resistance can 
be a very rapid process within a population of bacteria, for example Methicillin was 
first clinically used in 1960 and Methicillin resistant S. aureus cases were first 
reported a short while after (Figure 5.1).7  
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Figure 5.1 Time line of antibiotic compound discoveries (shown in blue boxes) and 
development of resistant bacterial species (shown in red boxes). The resistant 
bacterial species depicted are as follows; Staphylococcus aureus (Penicillin-R, 
Methicillin-R and Ceftaroline-R), Streptococcus pneumonia (Erythromycin-R and 
Levofloaxin-R), Enterococcus faecalis (Vancomycin-R) and Pseudomonas 
aeruginosa (Imipenem-R). 
 
Resistance occurs as a result of the development of one of a number of protective 
mechanisms including efflux pumps to remove the antibiotic (such as MexXY which 
is responsible for multidrug resistance in Pseudomonas aeurginosa),8 antibiotic 
degrading enzymes (such as the β-lactamases that confer resistance to the β-lactam 
class of antibiotics),9 and antibiotic altering enzymes (resistance to aminoglycosides is 
caused by modifying enzymes),10 all of which render the antibiotics ineffective. The 
genes responsible for these mechanisms confer an evolutionary benefit towards 
bacteria living in an environment containing antibiotics and as such are readily passed 
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throughout the population through the production of daughter cells, this is known as 
vertical gene transfer. Furthermore, bacteria can undergo horizontal gene transfer, 
where plasmids containing genes responsible for antibiotic resistance can be 
transferred between both neighbouring bacterial cells and even between closely 
related species.11 This increases the spread of resistance within a population and is 
one of the reasons for the rapid spread in resistance genes with a bacterial population. 
 
Antibiotic resistance now affects almost all species of pathogenic bacteria and is 
increasingly becoming a concern in terms of treatment of infections with increasing 
numbers of resistance cases (Figure 5.2). It has been predicted that by 2050, the 
number of deaths associated with antibiotic resistance will exceed those caused by 
cancer and many medical procedures that are currently routine will be impossible due 
to the increased risk of death from infection.12, 13 
 
 
Figure 5.2 Predicted number of deaths associated with antibiotic resistance every 
year by 2050 where colour indicates mortality per 10,000 population. Figure adapted 
from reference 12. 
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5.2.3 Point-of-care diagnostics 
 
The problem of antibiotic resistant bacteria is being propagated by the lack of rapid 
point-of-care diagnostic tools for detection of the bacterial species responsible for an 
infection. Whilst current tools such as culturing are accurate they are often time 
consuming and detection of certain species can be complicated by the fact that they 
enter a viable but not-culturable (VBNC) phase; meaning that they are un-culturable 
and thus un-detectable by conventional methods.14 As a result, treatment decisions are 
often made in the absence of microbiological information. 
 
Whilst several current methods exist for identification of bacterial species, most of the 
Food and Drug Administration (FDA) approved detection methods are based on 
culturing techniques with some exceptions for specific bacteria, which are known to 
be challenging to culture. These bacteria are detected through the use of Polymerase 
Chain Reaction (PCR) based methods. 
 
Culturing for the purpose of identifying bacteria was first described over 140 years 
ago by Robert Koch, for the identification of planktonic bacteria responsible for acute 
epidemic infections and the technique has hardly changed since.14, 15 These types of 
bacterial infections are now very uncommon due to the production of vaccines and 
their susceptibility to broad-spectrum antibiotics.16 Biofilm based infections (e.g. 
tuberculosis, vide infra) are now a widespread problem with these bacteria proving 
incredibly challenging to culture. It is estimated that only 1 % of bacteria are 
culturable in standard culture media and several of the common species that cause 
infection in a hospital setting can enter a VBNC phase where they are not detectable 
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through culturing techniques. This has been shown to occur in enterohemorrhagic 
Escherichia coli, Salmonella enterica and S. aureus.14, 17 
 
PCR based processes include: (i) analysis of the full genome of microbial species and 
identification through comparison with a database18, 19 and (ii) IBIS a novel method 
which involves selective PCR of a species-specific element of DNA which is flanked 
by highly conserved regions of DNA. This section of DNA is then analysed with mass 
spectrometry and compared to a database in order to identify the species. PCR based 
techniques can be rapid, with IBIS reportedly taking only 6 hours, but they can also 
be incredibly expensive and often large numbers of bacterial cells are required for 
good PCR analysis. PCR techniques also rely on extraction of nucleic acids from 
within bacteria, which can be problematic in Gram-positive bacteria due to their thick 
peptidoglycan wall, which is difficult to lyse.16 
 
With most approved detection methods unable to detect a multitude of the bacteria 
responsible for biofilm based infections there is increasing interest in the discovery of 
new, facile and rapid techniques for point-of-care bacterial detection. Developing 
countries are also likely to be hardest hit in terms of deaths associated with antibiotic 
resistance. For example, it is predicted that by 2050 one in every four deaths in 
Nigeria12 will be due to antibiotic resistant microorganisms and, new techniques 
should be cheap in order to make them accessible to all countries. 
 
5.2.4 Bacterial Biofilm formation 
 
Biofilm based bacterial infections are becoming increasingly common. They are 
responsible for chronic bacteria associated conditions such as pneumonia20 and 
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tuberculosis21 and result in millions of deaths every year (tuberculosis caused 1.3 
million deaths in 2012).22 As previously discussed, detection of these bacteria using 
current detection methods is challenging and, even upon detection, treatment can be 
difficult as the biofilm protects the infection from both the host’s immune system and 
penetration by antibiotics. The process of biofilm formation is an important area of 
research in the hope that greater understanding will result in increased treatment 
options. 
 
The initial step in bacterial infection is the process of adhesion, mediated by bacterial 
proteins (adhesins), which bind to carbohydrates on cells. After adhesion, a 
proliferation step occurs resulting in biofilm formation once the colony reaches a 
certain size. Once the population in the biofilm reaches this critical level, some of the 
bacteria leave the biofilm and travel further around the body to start new colonies in 
other places (Figure 5.3). Biofilm formation is a biomedically important step in 
infection as it allows the bacterial population to expand whilst offering protection 
from both the hosts immune system and antibiotics.23  
 
Figure 5.3 Schematic depicting bacterial biofilm formation. The example shown is 
the bacterial adhesin FimH interacting with a mannose rich tetrasaccharide.24 
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5.2.5 Role of protein-carbohydrate interactions in bacterial infection 
 
Protein-carbohydrate interactions are a target for the prevention of bacterial infection. 
If the initial adhesion phase (mediated by these interactions) does not happen then a 
biofilm cannot be formed, so any bacteria in the body will be exposed to antimicrobial 
agents. This is of interest owing to the increase in bacterial antibiotic resistance; if 
critical bacterial adhesins could be identified and targeted then the initial adhesion 
phase could be prevented (anti-adhesion therapy).25-28 This mechanism is also used in 
nature to protect cells from bacterial infection.29 Carbohydrates known as mucins 
found on epithelial cells have been shown to be targets for pathogens. However, these 
cells also secrete the same carbohydrates on their surface thus trapping pathogens 
before they can invade the underlying tissue.30 
 
Adhesins are thus essential for bacterial pathogenicity and detection through the 
initial adhesion phase could be key to selectively identifying pathogenic bacteria, 
because binding specificity is intrinsically linked to bacterial virulence.20 The adhesin 
FimH is a crticial virulence factor found in uropathogenic E. coli and among 
enterobacteriaceae (a large family of bacteria including many pathogenic bacteria 
such as E. coli).31 FimH is a mannose binding adhesin and so targets cells coated in 
mannose-rich carbohydrates. Upon binding, colonisation and biofilm production can 
occur.32 Inhibitors of FimH have been identified, containing a mannose-based 
structure.33 These inhibitors were then further assessed for cytotoxicity where their 
potency in inhibiting bacterial cells binding to highly glycosylated mammalian cells 
was found to be very different from that on a surface coated in mannan 
(polysaccharide of repeating D-mannose units). For all compounds tested, a narrow 
range between the IC50 of the drug (the concentration at which the drug prevented 
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adhesion of half of the bacterial cells) and the concentration at which 50 % cell death 
occurred (in the mammalian cells used) was observed thus potentially limiting their 
therapeutic potential.31 
 
Identification of bacterial adhesins that are crucial for pathogenicity could result in 
faster detection of potentially pathogenic bacteria. They may also reveal potential 
drug targets to prevent bacteria from binding to mammalian cells, thereby preventing 
biofilm formation. However, whilst for some bacteria (such as E. coli) these adhesins 
have been well characterised for others (such as those found in M. tuberculosis) very 
little research has been done. Despite the existence of cheap and readily available 
drugs to cure tuberculosis, there were 8.6 million new cases and 1.3 million deaths 
reported in 2012 (figure 5.4A).34 Increasingly, drug resistant strains have been 
identified and recently there have been several outbreaks of multi-, extensively- and 
totally-drug resistant (and thus incurable) tuberculosis and these strains (along with 
co-infection with HIV) are largely responsible for the resurgence of tuberculosis as a 
global health epidemic (figure 5.4B).35, 36  
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Figure 5.4 (A) Estimated number of new tuberculosis cases diagnosed in 2011. 
Colours depicted show the number of cases per 100 000 people (B) The number of 
new tuberculosis cases that are multi-drug resistant (the year the percentage was 
reported varies from country to country and the colours represent the percentage of 
new tuberculosis cases reported as being multi-drug resistant).37 
 
Genotyping of the bacteria in an attempt to elucidate those antibiotics which are 
effective before treatment has demonstrated limited success. It has been shown that 
A
B
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strains of M. tuberculosis that are supposed to be susceptible to an antibiotic (after 
genotyping) can grow on media containing that antibiotic, and a better mechanism for 
identifying drug resistance in tuberculosis infection is needed.38  
 
Carbohydrate adhesion patterns could provide a better detection system and any 
changes could help identify differences amongst the drug resistant strains not 
necessarily present in their genotype. Glycosylation patterns may be different 
amongst the different strains and presentation of adhesins on the bacterial surface will 
also be important. The bacteria may all express the same adhesins but as the 
interactions are reliant on multivalency to achieve strong adhesion it may be that 
those that present certain adhesins in patches will be reliant on one type of adhesin for 
infection where as others may rely on other adhesin proteins.  
 
5.2.6 Carbohydrate interactions for bacterial detection 
 
Detection of bacteria through their carbohydrate binding specificity is a promising 
area of research. As discussed earlier, the interactions between surface carbohydrates 
and bacterial lectins is a crucial initial step in infection and adhesins are crucial for 
pathogenicity. Detection of bacteria through these interactions could allow specific 
detection of pathogenic bacteria. 
 
Initial studies in the use of these interactions as a method for detection have shown 
some promise. It has been shown that different species show distinct adhesion 
specificities. For example, E. coli strains contain different adhesins, which allow them 
to target different organs. E. coli containing type 1 pili are responsible for initial 
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colonisation and infection in the bladder whereas those species with P-pili are 
responsible for infection in the kidneys.20  
 
Modification of systems with known carbohydrate binding targets of specific bacteria 
can allow the production of cheap detection systems. For example, functionalisation 
of streptavidin coated magnetic beads with biotin-linked galabiose (α-D-Galactose (1-
4) β-D-Galactose) resulted in the detection of Streptococcus suis (a zoonotic pathogen 
commonly associated with meningitis and pneumonia in pigs, human infection with 
this bacteria is life-threatening and an emerging public health concern) down to a 
detection limit of 104 bacterial cells per mL.20, 39  
 
Mannose conjugated gold nanoparticles have been shown to selectively detect FimH 
positive strains of E. coli down to a detection limit of 1.5 x 107 colony forming units 
per mL.40 This detection was selective for FimH positive strains and did not detect 
other strains of E. coli without this adhesin. This system showed selective detection of 
uropathogenic E. coli through appropriate selection of the carbohydrate unit used in 
the detection system.  
 
Whilst these systems are all particle-based, it highlights the potential for 
carbohydrates in detection of both pathogenic bacteria and bacterial toxins. Several 
examples of bacterial detection through the use of carbohydrate microarrays exist, 
though many utilise expensive commercially available microarrays and as the 
importance of appropriate carbohydrate units for detection has been highlighted, this 
is not always possible if using commercially available surfaces. Thus utilising a 
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surface functionalisation technique would increase the choice of carbohydrate units 
allowing for production of a targeted detection system. 
 
Here we describe the combination of hydrazide coated 96-well plates, which have 
been further functionalised with a variety of glycans, and a powerful machine learning 
algorithm for the rapid identification of five bacterial species (both pathogenic and 
non-pathogenic), Gram-positive and Gram-negative and surrogates for 
Mycobacterium tuberculosis, for which there is an urgent need for low cost, point of 
care diagnostics to address the emerging resistance time bomb. 
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5.3. Results and discussion 
 
The key aim of this work was to identify whether differential binding to carbohydrate 
functionalised Carbo-BINDTM surfaces can be used as a rapid tool for identifying 
bacterial species. 
 
5.3.1 Bacterial cell membrane labelling 
 
In order to develop a detection system, bacteria first needed to be labelled, which was 
achieved using a two-step process. Initially bacterial cells were biotinylated through 
reaction of primary amines found in proteins in the cell membrane with (+)- Biotin N-
hydroxysuccinimide ester (Biotin-NHS). Biotinylated cells were then incubated with 
fluorescein conjugated to streptavidin resulting in fluorescent labelling of the cell 
membrane (Scheme 5.1). 
 
 
Scheme 5.1 Reaction of Biotin-NHS with primary amines (found in proteins on the 
cell membrane of bacterial cells) results in the formation biotinylated proteins and N-
hydroxysuccinimide.  
 
 
FITC
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Labelling of all the bacterial species was confirmed using a number of techniques. 
Biotinylation of the cells was confirmed through detection of a side product of the 
reaction between Biotin-NHS and the primary amine groups. During this process, N-
hydroxysuccinimide is produced as a side product. This compound shows absorbance 
in the region of 260-280 nm and as such samples were removed and absorbance 
readings were recorded. Absorbance was found to increase for after incubation 
(Figure 5.5). 
 
 
Figure 5.5 Absorbance at 280 nm for P. putida after a 2.5 hour incubation with 
Biotin-NHS at room temperature was significantly higher than an unlabelled sample. 
Bars represent the average absorbance of three repeats and the error bars represent the 
standard error. Significance is indicated by an asterix above the bar where ** 
indicates p<0.01 as determined by a Student’s t-test. 
 
After incubation of the biotinylated cells with the fluorescein-streptavidin conjugate 
the labelled cells were viewed under ultraviolet light as fluorescein is known to 
**
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fluoresce at this wavelength. Prior to washing, the solution containing the biotinylated 
bacteria and the fluorescein-streptavidin conjugate appeared yellow when compared 
to biotinylated bacterial cells (Figure 5.6A, left and right respectively), when viewed 
under UV light the sample containing the fluorescein-streptavidin fluoresced (Figure 
5.6B). After washing three times with PBS to remove unconjugated fluorescein-
streptavidin neither the fluorescein labelled cells or the biotinylated sample were 
found to fluoresce under UV light (Figure 5.6C). Pleasingly the fluorescein labelled 
cells did appear a more yellow colour when compared to biotinylated cells (Figure 
5.6D) indicating the success of the labelling procedure. 
 
 
Figure 5.6 Samples under normal lighting (A and D) and UV lighting (B and C). A 
and B represent labelled (left) and unlabelled (right) samples under normal and UV 
lighting (in solution). The labelled sample glows under UV light showing the 
presence of fluorescein. Samples pictured in C and D are the same samples after 3 
wash steps to remove unbound fluorescein. As can be seen they do not glow under 
UV lighting but the bacteria in the labelled sample under normal lighting (D, left) is 
visibly more yellow than unlabelled (D, right). All images shown are for Top10 
(OD=1). 
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This was then further confirmed by comparison of the fluorescence intensity of a 
blank well, biotinylated bacteria and bacteria after the addition of the avidin-
fluorescein conjugate. The fluorescence was found to be significantly higher for those 
bacterial cells that had been incubated with the avidin-fluorescein conjugate when 
compared to either the biotin labelled cells or the blank well indicating the success of 
the fluorescence step (Figure 5.7). 
 
Figure 5.7 Comparison of the fluorescence of a blank unfunctionalised well to a well 
after incubation with biotinylated bacterial cells (and subsequent washing and 
removal of unbound cells) or fluorescein conjugated bacterial cells shows a 
significantly higher fluorescence reading for those that had been incubated with the 
fluorescein-avidin conjugate. Bars are the average of four replicates, the error bars 
represent the standard error. A Student’s t-test was performed to determine 
differences, ** represents p<0.01. 
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5.3.2 Bacterial differential binding 
Binding of 5 different bacterial species to 9 functionalised surfaces was analysed. The 
bacterial species chosen were; two strains of E. coli Top10 and K12, Pseudomonas 
putida, Mycobacterium smegmatis and Mycobacterium marinum. Of the two E. coli 
strains, Top10 is FimH negative and K12 is FimH positive and thus pathogenic. P. 
putida is similar in nature to Pseudomonas aeruginosa,  which is the pathogenic 
organism responsible for pneumonia (particularly in cystic fibrosis patients).41, 42 M. 
marinum and M. smegmatis are both model organisms for Mycobacterium 
tuberculosis, the causative agent of tuberculosis, with M. marinum sharing around 
3000 orthologs with over 85 % amino acid identity with M. tuberculosis.43 The 
species assessed include Gram-positive and Gram-negative species, pathogenic and 
non-pathogenic species and different strains for one species of bacteria. 
 
The binding profiles produced after incubation of fluorescently labelled bacteria with 
the surfaces revealed unique binding profiles for each of the bacterial species (Figure 
5.8). However most of the differences observed are within error or other species for 
each surface and so it would be challenging to identify an unknown sample based on 
its binding to these surfaces. As such linear discriminant analysis was utilised to 
improve the discrimination. 
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Figure 5.8 Binding profiles for a variety of carbohydrate functionalised surfaces with 
one of five fluorescently labelled bacterial species: E. coli K12 (black), 
Mycobacterium smegmatis (red), E. coli Top10 (blue), Pseudomonas putida (pink) or 
Mycobacterium marinum (green). The carbohydrate surfaces analysed are as follows; 
L-arabinose (Ara), cellobiose (Cel), dextran (Dex), D-galactose (Gal), N-Acetyl-D-
glucosamine (GlcNAc), D-glucose (Glc), DL-glyceraldehyde (Gly), lactose (Lac) and 
D-mannose (Man). Bars represent an average of 8 replicates and the error bars 
represent the standard error. 
 
5.3.3 Specificity of bacterial binding 
Specificity of bacterial binding to the surfaces was determined by addition of a serial 
dilution of bacteria to a sugar coated surface and then measurement of fluorescence. 
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The bacterial binding at various concentrations confirmed that bacterial adhesion was 
specific and not random deposition (Figure 5.9). 
 
Figure 5.9 Binding of a serial dilution of E. coli Top10 (red circles) and K12 (black 
squares) to a glucose functionalised surface showed that the greatest binding of 
bacteria corresponded to the greatest concentration of added bacteria. Every point 
represents the average of 3 measurements and the error bars represent the standard 
deviation. 
 
To further determine if the affect was specific and not due to charge interactions with 
the surface, bacteria were incubated with a glucose surface in the presence of glucose 
in the buffer (from 100 mM) as an inhibitory compound. High glucose showed the 
lowest bacterial binding and vice versa thus indicating a specific interaction (Figure 
5.10). 
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Figure 5.10 Binding of M. smegmatis to a glucose functionalised surface in the 
presence of inhibitory glucose in the buffer (a serial dilution of glucose from 100 mM 
in PBS). Each point is the average of 3 repeats and the error bars represent the 
standard error. 
 
5.3.4 Bacterial species discrimination 
The binding profiles were utilised as a training matrix for linear discriminant analysis 
(LDA). This analysis separates the data based on class in order to achieve the best 
possible separation between all classes of data in the training matrix (see Chapter 2). 
All five bacterial species analysed were shown to have excellent resolution between 
species in the model produced (Figure 5.11).  
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Figure 5.11 The binding profiles were used to generate a linear discriminant model, 
which showed good discrimination between bacterial species and was able to predict 
unknown samples with an accuracy of 92 %. Each point represents one full binding 
profile, the colour represents the species responsible and the ellipses represent the 
standard deviation from the average for each species. 
 
The validity of the model was further assessed by using a ‘leave one out’ protocol, in 
which each binding profile is removed from the training matrix in an iterative manner 
and the LDA model produced was then used to predict the bacterial species 
responsible for that profile. This was performed for all repeats, all bacterial species 
and the model was found to correctly identify the bacteria responsible 92 % of the 
time. The only false classifications were classifications of K12 as Top10 and as both 
of these are strains of the same species that is not surprising. 
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Random Forest was also used as a comparative classification technique, but this 
produced worse classification than the LDA model. The overall correct classification 
after a ‘leave one out’ analysis was performed was 71 % and the only bacterial 
species correctly predicted for all samples was M. smegmatis (Figure 5.12). 
 
 
Figure 5.12 The binding profiles were used to generate a Random Forest model, 
which showed poor discrimination between bacterial species and was only able to 
predict unknown samples with an accuracy of 71 %. Only M. smegmatis was correctly 
predicted 100 % of the time for all samples. 
 
5.3.4 Blind sample identification 
As the LDA model showed greater predictive power than the model produced with 
Random Forest, this model was used to determine the bacterial species responsible for 
% reassignment to actual group
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Escherichia coli  Top10
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a blind sample of one of the five bacterial species in the model. Addition of the 
sample to each surface in triplicate was used to determine an average reading for the 
binding of the sample to the surfaces. The response was correctly classified by the 
LDA model as E. coli Top10 with 96 % certainty. The turquoise dot in Figure 5.13 
represents the blind sample and whilst it appears to fall between several categories it 
should be noted that the model shown is only a 2 dimensional representation of a 
multidimensional model and the certainty in the classification was still very high. 
 
Figure 5.13 The LDA model was used to classify a blind sample of one of the 5 
bacterial species present in the model. The turquoise circle represents the average 
profile of the blind sample added in triplicate to every surface. The blind sample was 
classified as being E. coli Top10 with 96 % confidence. 
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5.4 Conclusions 
Antibiotic resistance is a growing global health concern and the numbers of deaths 
associated with it are on the rise, coinciding with a reduction in the number of new 
antibiotics being identified each year. There is a concern that without a change in 
current medical practice there will be a return to the ‘dark age’ of medicine during 
which procedures that are standard with only limited risk currently will become far 
too risky in the future due to the high chance of infection. 
 
Current bacterial identification methods either involve culturing, which is time 
consuming and thought to be only applicable to around 1 % of all bacterial species, or 
expensive PCR based techniques. Owing to these limitations, antibiotics are often 
prescribed in the absence of microbial information. There is a high likelihood that 
antibiotics will be prescribed when the bacteria causing the infection are resistant to 
that particular antibiotic, this would also further propagate the spread of resistance to 
other bacterial species which may be present in the body (although not at a clinically 
pathogenic level). The development of rapid point-of-care diagnostics tools is an 
important area of research in combating this. 
 
We have shown that by combining carbohydrate functionalised 96-well plates with a 
powerful machine-learning algorithm we can exploit the mechanism through which 
bacteria achieve their initial adhesion (prior to establishing infection and biofilm 
formation) in order to detect bacterial species present in samples. The binding of five 
bacterial species to nine different functionalised surfaces was used to develop a linear 
discriminant analysis model that could identify bacterial species responsible for 
carbohydrate binding profiles with 92 % accuracy. The model was then utilised to 
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correctly classify the bacterial species present in a blind sample as Escherichia coli 
Top10 with 96 % certainty. Whilst this is only a limited number of bacterial species, it 
highlights the potential for this method in rapid point-of-care species identification as 
the entire procedure from labelling to identification can be achieved in under five 
hours. Furthermore, it requires no prior knowledge of the bacterial species to achieve 
in that all steps are identical for all bacterial species. 
 
  
	 162	
5.5 Materials and methods 
Materials: All chemicals were used as supplied unless otherwise stated. Corning® 96 
well clear flat bottomed polystyrene Carbo-BINDTM microplates, ExtrAvidin®-FITC, 
(+)-Biotin N-hydroxysuccinimide ester, DMSO, L-arabinose, D-(+)-cellobiose, 
Dextran from Leuconostoc mesenteroides, D-(+)galactose, N-Acetyl-D-glucosamine, 
α-D-glucose, DL-glyceraldehyde, lactose, D-(+)mannose, phosphate buffered saline 
tablets, sodium acetate anhydrous, acetic acid glacial and aniline (99.5 % ACS 
reagent) were all purchased from Sigma-Aldrich. 100 mM acetate buffer (pH 5.5) 
with 1 mM aniline was prepared in 200 mL of milliQ water (with a resistivity >18 
MΩ.cm-1). K12 JM109 (referred to as K12 in the text) and Top10 were both grown in 
LB media from frozen stocks prior to use. 
  
Functionalisation of hydrazide surfaces: 100 µL of 30 mM sugar solutions (in 100 
mM acetate buffer with 1 mM aniline, pH 5.5) was added to each well of a Carbo-
BIND 96-well plate. Plates were then covered in foil and incubated at 50 °C for 24 
hours. After incubation, any unbound solution was removed and the well washed 
thoroughly with PBS three times. Plates were then either used immediately or stored 
at -20 °C prior to their use. 
 
Biotinylation of bacterial species: Bacterial species in cell culture media were 
centrifuged at 6800 rpm for 10 minutes and then resuspended in PBS with a final OD 
of 1. Then 2.5 µL of (+)-Biotin N-hydroxysuccinimide ester (10 mg.mL-1 in DMSO) 
was added to every 1 mL of bacterial solution before incubation at room temperature 
for 2.5 hours. A 200 µL sample was then removed and absorbance at 280 nm 
measured using a BioTek Synergy HT multi-detection microplate reader to determine 
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the success of the biotinylation procedure. The remaining bacterial solutions were 
then centrifuged at 6800 rpm for 10 minutes and resuspended in PBS three times to 
remove unbound (+)-Biotin N-hydroxysuccinimide ester. 
 
Carbohydrate binding assay: 50 µL of biotin labelled bacterial cells was added to 
every sugar functionalised surface in triplicate before incubation at 37 °C for 30 
minutes. Unbound solution is then removed from each well prior to washing three 
times with PBS. 100 µL ExtrAvidin®-FITC (in a 1 in 200 dilution in PBS) was then 
added to every well prior to incubation at 37 °C for 1 hour. Unbound solution was 
then removed and each well washed thoroughly three times with PBS before 
fluorescence readings were taken using a BioTek Synergy HT multi-detection 
microplate reader with excitation and emission wavelengths of 485 and 528 nm 
respectively. 
 
Linear discriminant analysis: Every bacterial species/strain was added to every 
surface as described in the carbohydrate binding assay section. This was repeated 8 
times for K12, Top10, M. smegmaits, P. putida and M. marinum to generate a training 
matrix, which was then subjected to classical linear discriminant analysis using the 
‘dapc’ function in the ‘adegenet’ package (version 1.4-2)44 in the open source 
statistical package R (version 3.1.3). 45 
 
Random Forest model: The carbohydrate binding profiles were used to produce a 
random forest model using the ‘RandomForest’ function (version 4.6.10) in the open 
source statistical package R (version 3.1.3). The model produced was the average of 
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500 trees and the percentage of correct reassignment for each bacterial species was 
calculated.45 
 
Blind culture identification: A blind culture of one of the bacterial species was 
prepared and biotinylated as described. Biotinylated samples were then added to all 
the functionalised surfaces in triplicate and incubated at 37 °C for 30 minutes. 
Unbound solution is then removed from each well prior to washing three times with 
PBS. 100 µL ExtrAvidin®-FITC (in a 1 in 200 dilution in PBS) was then added to 
every well prior to incubation at 37 °C for 1 hour. After fluorescence measurements 
were taken as described the average binding profile of the blind sample was classified 
by using the ‘predict.dapc’ function in the adegenet package.  
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Chapter 6 
Differential glycan binding for the detection 
of Plasmodium falciparum infected 
erythrocytes and identification of drug 
resistance. 
 
    
6.1 Abstract 
 
Malaria is one of the main causes of global death from disease and with the spread of 
resistance to Artemisinin (the basis for most modern malaria treatment) this looks set 
to remain unchanged. Microscopy currently remains the gold standard for diagnosis 
of malaria, but this offers no information about potential drug resistance of the 
parasite thus allowing the spread of drug resistance through administration of 
ineffective treatment. There are four species of parasite that are responsible for 
malaria in humans, but most of the deaths are associated with Plasmodium falciparum 
infection due to the complications caused by cytoadhesion in the later stages of the 
parasite development cycle. This cytoadhesion mechanism is highly complex and it is 
poorly understood. Here we highlight the use of facile carbohydrate functionalised 
surfaces for detection of P. falciparum infected red blood cells. These differential 
binding patterns were used in the life-stage specific detection of parasites in a sample 
and allowed identification of drug resistance strains. 
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6.2 Introduction 
 
Malaria is one of the main causes of global death from disease with approximately 
198 million cases occurring in 2013 resulting in 584,000 deaths predominantly among 
African children. It is estimated that one African child dies of malaria every minute.1 
Malaria is caused by parasites of the genus Plasmodium of which there are five 
species that can infect humans; P. falciparum, P. malariae, P. vivax, P. ovale and P. 
knowlsei. Plasmodium falciparum and Plasmodium vivax are the main causes of 
disease and deaths from malaria with P. falciparum responsible for almost all deaths 
associated with malaria.2  
 
P. falciparum is the most lethal of the Plasmodium spp. that can infect humans as the 
parasites can infect red blood cells (RBCs) at all stages whereas the other species can 
often only infect red blood cells at specific erythrocyte developmental stages. For 
example, P. vivax can only infect reticulocytes.3 P. falciparum also has a very high 
replication rate. Both of these factors result in a higher parasite burden within the 
blood, which is associated with high mortality levels.4 In addition to this, whilst both 
P. falciparum and P. vivax can cause severe anaemia, only P. falciparum can cause 
cerebral malaria, which has many complications including; hypoglycaemia, 
respiratory distress and metabolic acidosis.3 
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Figure 6.1 P. falciparum life cycle. During the ~48 hour intraerythrocytic life stage, a 
single cell (merozoite) invades a red blood cell (RBC) and takes on a ring-shaped 
form (early trophozoite: ring) that rapidly expands and drastically changes in 
morphology resulting a vastly enlarged nucleus, which divides into up to 36 daughter 
cells. A small fraction of these differentiate into gametocytes that continue the malaria 
life cycle in the mosquito. Images shown for the intraerythrocytic stages are 
microscopy images. 
 
Parasites (sporozoites) are mainly injected into the body through the bite of the female 
Anopheles mosquito. Once in the body, sporozoites travel directly to the liver where 
they enter hepatocytes5 until the parasites develop into merozoites. Merozoites are 
then released from the liver where they go on to infect RBCs (Figure 6.1). Within the 
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RBC, the parasite enters the asexual cycle where initially they are known as the ring 
stage as the parasite engulfs some cytoplasm upon entering the RBC giving it a ring 
like appearance (Figure 6.1). Ring stage parasites then develop into trophozoites and 
finally merozoites (Figure 6.1). These merozoites are released back into the blood 
stream to infect uninfected RBCs. Some of the asexual parasites go on to form 
gametocytes, which are essential for transmission of the disease by mosquitoes 
(Figure 6.1). From initial infection to lysis of the RBC and release back into the blood 
stream as merozoites takes approximately 48 hours, the final phase coinciding with 
the characteristic paroxysms associated with malaria (sudden onset of chills, followed 
by fever and sweating).6  
 
Figure 6.2 Schematic showing the cytoadhesion of P. falciparum. Initial infection 
occurs in the liver where sporozoites develop into merozoites, which go on to infected 
red blood cells thus beginning the intraerythrocytic life stage. During this stage, 
infected cells undergo adhesion to the endothelium and the placenta. Reprinted with 
permission from reference 3. 
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Once P. falciparum parasites reach the mature trophozoite stage the infected RBCs 
can be cleared by the spleen. To prevent this from occurring P. falciparum infected 
erythrocytes undergo cytoadherance (Figure 6.2) during this phase as is evinced by 
the fact that none of the cells in this stage of infection will be detected in peripheral 
circulation in an infected person but ring-stage infected RBCs will be present.7 RBCs 
in this advanced stage of the parasite growth cycle undergo membrane alterations 
resulting in the formation of knob like protrusions which act as points of attachment 
for these cells to tissue vascular beds and endothelial cells.8  
 
The knob like protrusions are the site of localisation of many parasite derived proteins 
including those from the var gene family. The var gene family encodes for 200-350 
kDa proteins responsible for antigenic variation and cytoadherance of P. falciparum 
and accounts for an estimated 2-6 % of P. falciparum genomic DNA with between 50 
and 150 copies per parasite. A number of different proteins are encoded by the var 
gene family and differences in gene transcription have been shown to correlate with 
changes in cytoadherance and antigenic phenotypes (resulting in waves of parasitemia 
in infected people).  
 
The expressed proteins are collectively known as P. falciparum erythrocyte 
membrane protein 1 (PfEMP1). Many of these proteins have not been fully 
characterised, but have been shown to have domains homologous to the binding 
domains of a glycophorin binding molecule and ligands involved in the invasion of 
Duffy blood group positive erythrocytes.8-10 Other proteins (which interact with host 
receptors) not encoded by the var gene family have also been indicated to be involved 
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in cytoadherance but these proteins are relatively consistent amongst parasite lines 
and don’t show antigenic variation.7 
 
Cytoadherance to the microvasculature results in reduced blood flow to organs and 
causes the symptoms associated with severe malaria.3 Whilst the role of PfEMP1 in 
cytoadherance of the parasitised RBCs has long been known, it is still not understood 
why some strains of P. falciparum result in sequestering and adhesion in the 
microvasculature of the brain causing cerebral malaria whereas others are localised to 
different tissue types.3 One mechanism through which this could occur is through 
protein-carbohydrate interactions. Many of the proteins in PfEMP1 have lectin like 
properties and it is known that a lectin like protein plays a key role in the initial 
infection of erythrocytes by merozoites.9-11 It may also highlight a mechanism 
through which infected RBCs sequester to different tissue types. Whilst endothelial 
cells all have fairly similar carbohydrates on their surface there are known differences 
between tissue types both in density of the carbohydrate residues and the linkages 
involved.12 For example, whilst many of the endothelial surface carbohydrates contain 
terminal sialic acid residues, it has been shown that there are tissue differences in 
whether the sialic acid residues are attached through an α(2-3) linkage or an α(2-6) 
linkage.7  
 
Very little work has been done looking at parasitised red blood cell binding to 
carbohydrates previously, but they form a potential mechanism for tissue specificity 
of the parasitised erythrocytes. Some research has been done looking at glucose 
transport in infected RBCs. As the parasite lives within a host erythrocyte, it is 
dependent on the hosts ability to provide nutrients, most specifically glucose 
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(although there is some evidence that fucose can replace glucose in the parasites 
metabolic pathways). During infection, P. falciparum increases glucose transport into 
the red blood cell by up to 50 fold, this increase is maximal at the trophozoite stage.13, 
14 From as little as 6 hours post infection the very nature of the erythrocyte membrane 
is modified in order to support this increase.15 The membrane dramatically increases 
in permeability to small molecules such as sugars, sugar-alcohols, amino acids and 
nucleotides all to support the growing parasite.16 It is possible that these changes in 
permeability could be detected through the use of carbohydrate microarrays, which 
may elucidate some of the important carbohydrate residues for RBC sequestering and 
may also form an important tool for malaria diagnosis. 
 
Malaria must be promptly recognised in order to rapidly begin treatment thus 
maximising the possibility of a positive patient outcome and preventing further 
spread. Currently, treatment is based on Artemisinin-based combination therapies, but 
resistance to Artemisinin is on the rise and threatens global efforts to control and 
eliminate malaria.17, 18 As such, rapid diagnosis of malaria and identification of drug 
resistance is crucial in order to stop the spread of resistance and ensure positive 
patient outcome. 
 
However, diagnosis of malaria can be challenging and is usually based upon clinical 
symptoms such as fever, muscle pain and exhaustion, which are not specific to 
malaria and are common among many other diseases. Currently microscopy remains 
the gold standard for identification of malaria This method is both cheap and sensitive 
with a detection limit as low as 4 parasites per µL of blood.19 However, transport of 
microscopes to remote areas can be difficult and it takes considerable skill to achieve 
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such a good level of sensitivity and the diagnostic power of this technique depends on 
operator performance and so prone to errors.20 This technique also provides no 
information about drug resistance and so may increase the likelihood of the spread of 
resistant malaria due to ineffective treatment. 
 
In addition to this it can be challenging to identify the species involved in the 
infection through microscopy. The Centre for Disease Control (CDC) provides a 
detailed chart, which involves looking at characteristics of infection throughout the 
parasites life-cycle in order to definitively identify species involved.21 Species 
identification is crucial as some strains, such as P. falciparum, are more dangerous 
than others. Differential carbohydrate binding may be a mechanism by which species 
identification can be improved as P. falciparum exploits very different binding 
pathways from the other malaria strains and is also the only species that has a 
cytoadhesion phase.22 
 
Microscopy is not the only diagnostic tool available for the detection of malaria. 
Immunochromatography based ‘dipstick’ tests are also available. These techniques 
detect the presence of malarial antigens in the blood rather than infected RBCs and 
are rapid and easy to use, but their sensitivity is significantly below that achieved 
through microscopy (at 100 parasites per µL of blood), the technique is expensive and 
sensitivity can be affected by adverse field conditions.20 The output of the test does 
not provide a quantitative indication of the level of infection (as the strength of the 
response to the test varies from person to person).23 The level of antigens in the blood 
also declines as the infection progresses and this method cannot be used to determine 
whether a treatment is effective, but can be used to detect recurring waves of 
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infection. Whilst some immunochromatography methods exist which detect host 
antibodies, as they remain in the blood stream even after the infection has passed, this 
method cannot be used to determine an infection in someone who may have suffered 
a previous infection.24 
 
There is also a growing investment in molecular diagnosis tools. These techniques 
have comparable sensitivity to microscopy and can give quantitative signals, which 
correlate with level of infection. Additional information such as species and drug 
resistance can also be determined using this technique thus making it significantly 
more powerful than microscopy. This technique is currently being used for the 
tracking of Artemisinin resistant malaria cases.25 However, this technique requires 
careful sample preparation, is expensive and the results are often not rapidly 
available. Technique sensitivity may also suffer due to the field conditions.26 
 
All of the current methods that exist have limitations and, with the rise of population 
movement from areas of high malaria transmission to low transmission due to tourism 
and socioeconomic factors, has resulted in a rise in the number of cases of malaria 
with a parallel rise in mortality due to late or misdiagnosis there is a need for a rapid, 
facile and cheap diagnostics method.27, 28 It would be advantageous for new methods 
to be able to detect drug resistance in order to combat its spread. 
 
In this chapter, we describe a number of carbohydrate moieties for which differential 
binding is observed upon incubation with parasitised RBCs when compared to native 
uninfected erythrocytes. This is the first time such a technique has ever been used in 
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the detection of the presence of P. falciparum in RBCs. This technique was further 
expanded to the detection of drug resistant strains of P. falciparum. 
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6.3 Results and discussion 
The key aim of this work was to determine differential carbohydrate binding of RBCs 
infected with P. falciparum and native uninfected RBCs as a potential diagnostic tool, 
to highlight a mechanism through which tissue specific sequestering of P. falciparum 
infected RBCs may occur and to identify whether differing levels of drug resistance 
can be detected through glycan binding. As such we employed facile coupling 
chemistry to functionalise commercially available Carbo-BIND™ 96-well plates to 
generate a number of different glycan functionalised surfaces as previously 
described.29 
 
6.3.1 Level of infection in infected red blood cell samples 
Prior to use on surfaces all samples, were checked for contamination and an estimate 
of the percentage of infected cells was determined (Figure 6.3). The developmental 
stage of the parasite was also confirmed. Four stages of infected cells were analysed 
and the level of infection was found to be 10 % for all stages. 
   
Figure 6.3 Giemsa stained RBCs (viewed under 100 X oil immersion objective) 
showing uninfected (left), ring stage (centre) and mature trophozoite (right) stages of 
infection. 
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6.3.2 Labelling techniques 
A number of techniques for the detection of RBCs were analysed. Initially, two label-
free methodologies were assessed (Figure 6.4A and 6.4B) before comparing two 
fluorescent labelling methodologies (Figure 6.4C and D). 
 
Figure 6.4 Schematic highlighting the four detection strategies assessed. 
Autofluorescence of haem under certain wavelengths of light (A). At various dilutions 
of RBCs the red colour changes and this can be used to estimate the RBC 
concentration (B). Biotinylation of the RBC was followed by addition of fluorescein-
labelled streptavidin, which results in fluorescent labelling of the RBC membrane (C). 
Direct labelling of the RBC membrane through reaction with fluorescein 
isothiocyanate (FITC) (D). 
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6.3.2.1 Autofluorescence 
Firstly, RBCs undergo a phenomenon known as autofluorescence due to the haem 
component (Figure 6.5A). However, upon incubation with the surfaces and 
subsequent wash steps the autofluorescence methodology was found to be insufficient 
for detecting differences in binding upon addition of red blood cells in a serial 
dilution to a glucose functionalised surface (Figure 6.5B). This method also had the 
additional complication that autofluorescence of red blood cells increases with cell 
age, so all samples added to the surface would have to be the same age in order to 
ensure that differences observed are due to changes in sugar binding during parasite 
phases and not to cell age. Additionally, during the trophozoite phase of infection 
(also known as mature infected cells) the haem component of the red blood cells 
becomes surrounded by the parasite and its daughter cells. This may result in changes 
in autofluorescence and as such this technique was not used. 
 
Figure 6.5 Autofluorescence of RBCs where bars represent an average of three 
measurements and error bars are the standard error (A). Autofluorescence analysis of 
a serial dilution of red blood cells on a glucose surface (B). 
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6.3.2.2 Colorimetric analysis 
The second label free methodology analysed was the use of ImageJ to compare 
changes in colour upon binding of red blood cells to the cell surface. An addition of a 
serial dilution of RBCs to a 96-well plate results in different shades of red, which can 
be analysed in ImageJ to produce a rough dilution curve (Figure 6.6). 
Disappointingly, there was no observed colour change after wash steps in sugar 
functionalised surfaces following addition of red blood cells, thus ruling this out as a 
potential detection technique. 
 
Figure 6.6 A photograph of the colourimetric dilution (A) can be converted into a 
Hue, Saturation, Brightness (HSB) stack in ImageJ (B). The saturation image in this 
stack can then be used and the pixel intensity in each well measured to give an 
approximate measurement of the colour in the well, error bars represent the standard 
error  (C). 
 
6.3.2.3 NHS-Biotin:Avidin-FITC labelling 
As neither of the label free methodologies were successful, two labelling methods 
were utilised in order to aid in the detection of differential binding. Initially the NHS-
Biotin:Avidin-FITC system for labelling of the cell surface was used for cell 
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detection. This method has been successfully utilised in Chapter 5 for the detection of 
bacterial cells. This method failed in the labelling of RBCs. This was due to the fact 
that the reaction involves a 2.5 hour incubation step with the NHS-Biotin. For this 
duration the parasites would have died if they had been in PBS and thus had to be 
kept in cell culture media. However, cell culture media also contains primary amines, 
which would have competed with those in proteins on the cell surface for the NHS-
Biotin label thus reducing the overall efficiency of the labelling of the cells. 
Increasing the concentration of NHS-Biotin added to the cells may have improved the 
labelling efficiency but RBCs are very sensitive to DMSO, in which the NHS-Biotin 
is dissolved, so addition of more NHS-Biotin would have resulted in increasing levels 
of cell lysis. 
 
6.3.2.4 FITC labelling 
Finally, direct labelling of RBCs with fluorescein isothiocyanate (FITC) was used. 
This technique is commonly used for labelling RBCs in blood flow experiments in 
animals and it was theorised that it would be successful in cell culture media.30 A 
serial dilution of FITC labelled RBCs added to glucose and galactose surfaces showed 
differential binding that was detectable (Figure 6.7).  
 
Further to this, successful FITC labelling of each stage was also confirmed through 
the use of fluorescence microscopy (Figure 6.8). There appeared to be some 
differences in the labelling efficiency seen in the fluorescence microscopy images 
with parasitized cells labelling much more than uninfected cells, which was further 
confirmed by the measurement of fluorescence of samples. All samples were 
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corrected to account for labelling efficiency and this labelling method was utilised for 
all further experiments. 
 
Figure 6.7 Addition of a serial dilution of FITC labelled uninfected (RBC) and 
trophozoite stage infected (pRBC) cells to a glucose or galactose surface showed 
increases in binding as concentration increased. The concentration shown is from 1, 
which represents the concentration of cells in a pellet of RBCs (~1.9x106 cells per µL) 
and the serial dilution was performed in cell culture media. Error bars represent 
machine error. 
 
Figure 6.8 Fluorescence microscopy images of FITC labelled uninfected RBCs (A), 
ring stage infected RBCs (B), trophozoite stage infected RBCs (C), early stage 
gametocytes (D) and late stage gametocytes (E). 
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6.3.3 Differential binding on carbohydrate surfaces 
With the RBC labelling method in hand, surfaces were functionalised with six 
different carbohydrates; D-galactose, D-glucose, N-Acetyl-D-Galactosamine 
(GalNAc), N-Acetyl-D-Glucosamine (GlcNAc), α(2-3) Sialyllactose and α(2-6) 
Sialyllactose. Galactose was selected as permeability of the RBC membrane to small 
molecules is known to drastically increase upon infection. Glucose would also be 
affected by this, and it is known that the intraerythrocytotic stage of parasite 
development is characterised by a 50-100 fold increase in glucose absorption to meet 
the metabolic demands of the parasite.13, 14 This increase is maximal during the 
trophozoite stage. Rosetting (the process whereby infected RBCs bind to uninfected 
RBCs) is known to occur during the later stages of infection, GlcNAc, GalNAc and 
galactose were selected as these saccharides are found on the surface of RBCs. Both 
α(2-3) sialic acid and α(2-6) sialic acid residues are found on the surface of 
endothelial cells in varying ratios. As late stage infected RBCs undergo cytoadhesion 
to the endothelial surface of the vasculature α(2-3) sialyllactose and α(2-6) 
sialyllactose were also selected to represent α(2-3) sialic acid and α(2-6) sialic acid 
residues. 
 
RBCs infected with Plasmodium falciparum 3D7, at four different stages in the 
intraerythrocytotic development cycle of the parasite and uninfected RBCs were 
fluorescently labelled and incubated with a carbohydrate functionalised Carbo-
BINDTM plate. Differential binding was observed for many different carbohydrates at 
different stages in the development cycle despite the level of parasitemia being only 
around 10 % for all stages (Figure 6.9). 
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Figure 6.9 Binding of FITC labelled ring stage infected RBCs (green), uninfected 
(red) RBCs and trophozoite stage infected RBCs (blue) to several carbohydrate 
surfaces showed differential binding. Significance is indicated by an asterix above the 
bar where * indicates p<0.05 relative to uninfected RBCs. Error bars represent the 
standard error. 
 
Ring stage RBCs are the initial stage immediately after parasite infection and these 
showed increased binding to both the glucose surface and the α(2-6) linked sialic acid 
surface. The metabolic demand of hosting the parasite would increase the absorption 
of glucose by the infected RBCs and thus an increase in glucose binding during 
infection would be expected (vide infra). 
 
It has been shown that whilst endothelial cells in macrovascular structures, such as the 
pulmonary artery contain terminal α(2-3) and α(2-6) linked sialic acid residues, 
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pulmonary microvascular structures only contain α(2-3) linked sialic acid residues.31 
As such differential binding to these surfaces may indicate a mechanism for targeted 
sequestering of infected RBCs in the microvasculature. 
 
Ring stage infected RBCs are generally found in peripheral circulation and are not 
thought to undergo cytoadhesion and as such the increase in binding to α(2-6) linked 
sialic acid residues is surprising. The lack of increase in binding to α(2-3) linked sialic 
acid residues would prevent binding of these cells in the microvasculature and, whilst 
adhesion in the microvasculature may be possible, it is possible that binding to α(2-6) 
alone is insufficient to support binding to the microvasculature and so RBCs in the 
ring stage of infection are found in circulating blood.  
 
Trophozoite stage RBCs also showed increased binding to α(2-6) linked sialic acid 
residues as well as an increase in α(2-3) linked residues. This may indicate a 
mechanism for binding of RBCs in the trophozoite stage to the vasculature. 
Specifically, the increase in α(2-3) binding may allow adhesion of these cells to the 
microvasculature. 
 
Gametocytes are split into five distinct phases, but extraction of gametocytes at very 
specific stages is challenging and just two samples were assessed; early gametocytes 
(stages I to III of gametocyte development) and late gametocytes (stages IV and V). 
The early gametocytes showed increased binding to both α(2-3) and α(2-6) linked 
sialic acid residues. It is known that, similarly to trophozoites, early stage 
gametocytes undergo cytoadhesion and sequestering in order to escape eradication by 
the spleen.32 Increased binding to α(2-3) and α(2-6) residues may indicate a 
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mechanism for cytoadhesion and sequestering of gametocytes in this early 
developmental stage. 
 
Late stage gametocytes (stages IV and V) showed significantly higher binding to 
glucose, GlcNAc, α(2-6) and α(2-3) linked sialic acid. As only mature stage V 
gametocytes are found in peripheral blood it is not surprising that these samples still 
showed adhesion to α(2-3) and α(2-6) residues, as this would allow sequestering of 
the stage IV parasites present within the sample. It would be expected that this 
binding would be lost in stage V RBCs, as this would allow release of the parasite 
into the circulation where it can be taken up by mosquitoes (vide infra). 
 
6.3.4 Differential binding for diagnostics 
Whilst several of the stages showed statistically significant differences for some 
glycans, classification of a sample based on binding profile can still be assisted by use 
of linear discriminant analysis (LDA). LDA is a statistical tool, which can be used for 
the classification of samples. Since it maximises the difference between groups in the 
original data set and minimises differences within the groups, it is sensitive to picking 
up small differences in binding profiles that are not necessarily statistically 
significant.  
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Figure 6.10 Linear discriminant analysis model produced shows good discrimination 
between most cell types. 
 
As can be seen, the LDA model produced shows excellent discrimination between 
RBCs at different stages in the parasite life cycle (Figure 6.10). During cross-
validation the model was able to correctly classify samples with an accuracy of 96 % 
and the model was able to correctly identify the nature of two blind samples (Figure 
6.11). Whilst the samples do not seem to fall into any of the categories in the model it 
should be noted that the model is a two-dimensional representation of a 
multidimensional model and a high classification accuracy was still achieved. 
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Figure 6.11 Linear discriminant analysis model correctly classified two different 
blind samples as ring stage and trophozoite respectively. Blind samples represent the 
average glycan binding profile of four repeats. 	
Clinically relevant levels of parasitemia vary wildly, a patient with 1 % parasitemia 
could die but a patient with 40 % parasitemia could be fine. This large disparity is 
often caused by the complications associated with the trophozoite adhesion phase.4 10 
% parasitemia is generally described as ‘hyperparasitemia’ and as such differential 
binding was determined for two lower levels of parasitemia (5 % and 1%). All 
parasitemia levels were for the ring stage only, as this is generally the only stage 
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present in peripheral circulation in patients infected with P. falciparum.22 Mature 
stages are sometimes found in peripheral circulation, but it is thought that this is 
linked to disease severity.33 In this system neither of these samples were correctly 
classified thus limiting the potential as a diagnostic tool. In order to improve the 
sensitivity of the model, increasing the number of glycans or the chain length of the 
glycans could increase the differential response of the different cell types, which 
would improve the sensitivity of the system. 
 
Whilst this lack of sensitivity would limit the use of this system in terms of a 
diagnostic tool, it still represents the first time that differential glycan binding in 
parasitized RBCs has ever been investigated and the ability of this technique to 
classify blind samples in a stage specific manner highlights the potential of this 
system. This methodology is only really a proof of principle and there is significant 
potential for the expansion of the system and increasing sensitivity through coupling 
to other current glycan based techniques such as a label-free gold nanoparticle-based 
system. 
 
6.3.5 Detection of drug resistance 
 
Whilst sensitivity of the system was too low to be of real use diagnostically, drug 
resistance is becoming a real problem amongst P. falciparum and detection of drug 
resistance clinically is currently achieved using molecular markers.25 Artemisinin 
based treatments are currently the main treatment for P. falciparum infections (due to 
high levels of drug resistance to other drugs). Artemisinin treatment results in 
increased clearance of ring stage parasites by the spleen thus reducing the number of 
parasitized RBCs in circulation.34 Resistance is increasingly becoming a concern and 
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is being found in increasing numbers of countries thus endangering the eradication of 
malaria.17, 35-38 Resistance is known to be associated with very specific single 
nucleotide polymorphisms occurring in the K13 gene. This results in mutations in the 
primary amino acid sequence of the propeller region of the kelch domain-carrying 
protein K13.18 It is currently not known how this affects Artemisinin sensitivity but 
resistance is characterised by reduced clearance of ring stage parasites by the spleen.39 
 
As trophozoites also escape eradication by the spleen and seem to show increased 
glycan binding which may mediate tissue cytoadhesion and sequestering then it can 
be reasoned that perhaps glycan binding plays a role in Artemisinin resistance. Tissue 
sequestration of the ring stage parasites that display resistance to Artemisinin may 
explain why ring stage parasites are not eradicated by the spleen. 
 
P. falciparum 3D7 is a purely laboratory strain of P. falciparum and as such there is 
no data concerning drug resistance so a different strain was used for the drug 
resistance experiments. Four strains of P. falciparum TH004 with differing levels of 
resistance to Artemisinin were selected with strain 4 representing clearance time (and 
thus Artemisinin susceptibility) closest to the wild type P. falciparum. Both strains 23 
and 36 show roughly the same clearance times, which are approximately three fold 
higher than 4. Strain 64 showed the highest levels of resistance with a clearance time 
over four fold higher than the wild type (personal communication with Matthew 
Phanchana). 
 
The different strains showed differential binding at both the ring stage (Figure 6.12) 
and the trophozoite stage of parasite development (Figure 6.13). At the ring stage 
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those with the lowest level of resistance (4) showed increased binding to glucose, 
galactose, α(2-3) and α(2-6) sialic acid residues when compared to uninfected RBCs. 
This may indicate that these RBCs can adhere to both the macro and 
microvasculature, which would allow them to escape eradication by the spleen. 
Increased glucose would occur due to the increased metabolic demands of the host 
and increased galactose may occur as a result of the increase in permeability of the 
RBCs membrane to small molecules, which is associated with infection. 
 
Figure 6.12 Differential binding seen between strains with different drug resistance 
levels at the ring stage. Significance is indicated by an asterix above the bar where * 
indicates p<0.05 relative to uninfected RBCs. Error bars represent the standard error. 
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Figure 6.13 Differential binding seen between strains with different drug resistance 
levels at the trophozoite stage. Significance is indicated by an asterix above the bar 
where * indicates p<0.05 relative to uninfected RBCs. Error bars represent the 
standard error. 
 
Ring stage RBCs infected with parasites 23 and 36 showed significantly reduced 
binding to almost all glycans assessed. As these parasites have similar clearance times 
(and thus similar levels of drug resistance) it is possible that they escape spleen 
clearance through another mechanism that does not involve glycan binding. Whilst 
genetically the main mutational difference between these strains and 4 is within the 
K13 gene, it is possible for glycan binding to be disrupted purely by re-patterning of 
glycan binding proteins within a membrane (as this would disrupt multivalent 
binding) and this could explain the decrease in glycan binding observed for these 
strains. 
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The most drug resistant strain (64) showed increased binding to glucose and GlcNAc. 
Increased glucose could be explained by the metabolic demand of hosting the parasite 
whereas GlcNAc binding may indicate binding to uninfected RBCs. This would 
protect the parasitized cell from the immune system and also prevent eradication by 
the spleen. 
 
For P. falciparum 3D7, the development of the parasite from the ring stage to the 
trophozoite stage was characterised by a reduction in binding to glucose and an 
increase in binding to sialic acid residues (when compared to uninfected RBCs). Once 
again, strains 23 and 36 showed reduced binding to many of the glycan residues 
highlighting that other mechanisms may be involved in sequestering of RBCs infected 
with these strains. 
 
Strain 4 trophozoites retained the ring-stage characteristic of increased α(2-3) and 
α(2-6) sialic acid residue binding which would allow them to sequester in the 
microvasculature thus escaping the spleen. Whilst glucose binding remained high for 
the trophozoite stage, there was a reduction in galactose binding that may indicate a 
loss of ring stage membrane permeability. 
 
Similarly to 3D7, strain 64 showed a reduction in glucose binding when in the 
trophozoite stage. GlcNAc binding was also significantly reduced and there was an 
increase in binding to α(2-6) sialic acid residues, which may indicate targeting of 
these cells towards the vasculature system. Although this strain lacks the increased 
α(2-3) sialic acid binding shown by 3D7 it may be that this strain does not bind in the 
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microvasculature during the trophozoite stage as not all strains of P. falciparum 
display this characteristic. 
 
As many of the development stages showed differential binding for different strains 
(summarised in Table 6.1) the power of LDA as a diagnostic tool was assessed in 
order to determine whether drug resistant strains could be identified based on their 
glycan binding profiles. The LDA model produced when considering all strains and 
the two separate parasite development stages showed good separation between groups 
(Figure 6.14A). The model was able to classify samples with an accuracy of 78 %, 
with overlaps generally limited to the different development stages of the same strain. 
 
Table 6.1 Summary of differential glycan binding for all resistance strains of P. 
falciparum in which an upward arrow indicates a significant increase and a downward 
arrow a significant decrease in binding relative to uninfected RBCs. 
 
Development 
stage Strain
Glycan on surface
Galactose Glucose GalNAc GlcNAc α2-3 Sialic 
acid
α2-6 Sialic 
acid
Ring
3D7
4
23
36
64
Trophozoite
3D7
4
23
36
64
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This is further highlighted when we split the model into development stages. 
Considering just the ring stage, the classification power of the model can be increased 
to 85 % (Figure 6.14B). 100 % reclassification can be achieved if just the binding 
profiles of trophozoites are considered (Figure 6.14C) but, these late stages in the 
parasites development generally sequester themselves within tissues and are only 
rarely found in circulation. The ring stage model is most useful for classification of 
samples. 
 
Whilst ring stage parasites are most likely to be found in circulation, other 
developmental stages may be present in samples especially in cases of severe malaria. 
Identification of the developmental stage of the parasites within a sample would not 
be as important as identifying drug resistance and so a model was developed using the 
binding profiles of resistant strains at either the ring or trophozoite stage. The LDA 
model only considered the strain and contained no information about the 
developmental stage of the parasite that produced that binding profile. This was able 
to increase the accuracy of the initial model (which considered both developmental 
stage and strain) to 83 % classification of strain based on binding profile alone 
(Figure 6.15). 
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Figure 6.14 Linear discriminant analysis model produced shows good discrimination 
between all resistance strains and was able to correctly identify both strain and stage 
with an accuracy of 78 % (A). Further splitting into ring stage (B) and trophozoite 
stage (C) allowed prediction of resistance strain with an accuracy of 85 and 100 % 
respectively. 
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Figure 6.15 Linear discriminant analysis model in which only the strains and not the 
development stage were considered showed reasonable separation between resistant 
strains and was able to re-classify data in a ‘leave-one-out’ method with an accuracy 
of 83 %. 
 
The ability of this facile system to detect differences between resistance strains 
highlights its power as a diagnostic tool. Whilst the sensitivity of the system is still 
low this is a proof of principle study and sensitivity could be improved through a 
number of different methods such as increasing the number of glycans studies, 
increasing glycan chain length or coupling with another detection system such as gold 
nanoparticles. 
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6.4 Conclusion 
 
We have developed a rapid and simple diagnostic tool for the detection of RBCs 
infected with the malaria parasite through binding to carbohydrate functionalised 
surfaces, the first time such a method has ever been used for the detection of malaria. 
Uninfected and parasitised RBCs were successfully labelled using FITC to allow 
detection of binding.  
 
Ring stage RBCs were found to bind glucose and α(2-6) sialic acid residues 
significantly more than uninfected RBCs. Trophozoites and early gametocytes 
showed increased binding to α(2-3) and α(2-6) sialic acid residues. Late stage 
gametocytes showed increased binding to glucose, GlcNAc, α(2-3) and α(2-6) sialic 
acid residues.  
 
Moreover we have shown that these differences fit within the supporting literature 
evidence and may indicate a mechanism through which trophozoite infected RBCs 
can sequester specifically to the microvasculature through adhesion to α(2-3) linked 
sialic acid residues found predominantly within the microvasculature. 
 
These differential binding profiles were used as a training matrix to produce a LDA 
model with a classification accuracy of 96 % and was able to correctly classify two 
blind samples in a developmental stage specific manner. Furthermore, ring stage 
samples exhibiting reduced parasitemia (5 % and 1 %) were also analysed to 
determine whether more clinically relevant levels of parasite infection could be 
detected. Disappointingly, neither of these samples were correctly classified. The 
detection limit of this system was found to be ~2.4 x104 parasitsed cells per µL of 
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blood. Whilst other currently available techniques are more sensitive, the detection 
limit could be improve through the incorporation of more complex glycan structures 
onto the surfaces, the use of a wider range of sugars or the use of mixed sugar 
surfaces. 
 
Further to this we analysed the ability of this system to detect differences in glycan 
binding between Artemisinin resistant strains of P. falciparum. Differential binding 
was observed both between different strains and between life stages of the same 
strain. A LDA model produced using these binding profiles was analysed in a ‘leave-
one-out’ manner and was correctly able to classify a sample based on both life stage 
and strain with an accuracy of 78 %. Accuracy at classifying strain increased 
markedly to 85 % and 100 % when samples were separated into either ring or 
trophozoite stage respectively. A further model was produced in which only the strain 
of the sample was considered (and thus all samples included were either ring or 
trophozoite stage) and this was able to classify strain (and thus resistance level) with 
an accuracy of 83 %. 
 
As Artemisinin is currently the basis of almost all standard malaria treatment regimes, 
the increase in Artemisinin resistance amongst P. falciparum is of great concern but, 
current malaria diagnosis uses microscopy, which provides no information about drug 
resistance. The spread of resistance is currently monitored using molecular markers, 
but this technique requires careful sample preparation, is often expensive and results 
can take time to process. As such this glycan based detection system offers a much 
more accessible technique that can identify differences between infected and 
uninfected RBCs as well as identifying drug resistant strains in under two hours. 
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Whilst sensitivity is currently a limitation of this assay, there are many routes through 
which this could be improved and this work represents a proof of principle. This 
represents the first time that differential glycan binding has been used to detect the 
presence of a parasite. Although the technique is in its early stages, we have presented 
a cheap, facile and stage specific technique for the identification of P. falciparum 
infected red blood cells and detection of drug resistant strains. 
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6.5 Materials and methods 
Materials: All chemicals were used as supplied unless otherwise stated. Corning® 96 
well clear flat bottomed polystyrene Carbo-BINDTM microplates, ExtrAvidin®-FITC, 
(+)-Biotin N-hydroxysuccinimide ester, Fluorescein isothiocyanate isomer I (≥ 90 % 
HPLC), aniline (99.5 % ACS reagent), sodium acetate anhydrous, acetic acid glacial, 
phosphate buffered saline tablets, D- (+)galactose, N-Acetyl-D-galactosamine, N-
Acetyl-D-glucosamine, α-D-glucose and DMSO were all purchased from Sigma-
Aldrich. α(2-3) D-sialyllactose and α(2-6) D-sialyllactose were both purchased from 
Carbosynth. 100 mM acetate buffer with 1 mM aniline was prepared in 200 mL of 
milliQ water (with a resistivity of >18 MΩ.cm-1). Plasmodium falciparum 3D7 were 
cultured in RPMI 1640 R8758 (Sigma-Aldrich) supplemented with 25 mM HEPES 
(pH 7.4, Amresco), 0.25 % Albumax I (Sigma-Aldrich), 0.4 mM hypoxanthine 
(Sigma-Aldrich) and 0.020 mM gentamycin sulphate (Sigma-Aldrich). Plasmodium 
falciparum TH004 were cultured in RPMI 1640 supplemented with 25 mM HEPES 
(pH 7.4, Amresco), pooled human AB+ serum (50 mL per 500 mL of RPMI 1640), 
0.4 mM hypoxanthine (Sigma-Aldrich) and 0.020 mM gentamycin sulphate (Sigma-
Aldrich). Parasite work was carried out with Eva Caamaño-Gutiérrez in the 
Department of Parasitology at the Liverpool School of Tropical Medicine with the 
assistance of Ahmed Saif and Matthew Phanchana.  
 
NHS-Biotin:Avidin-FITC labelling of red blood cells: 50 mL of infected and 
uninfected RBCs in cell culture media were spun down by centrifugation at 2000 rpm 
for 5 minutes before being resuspended in 10 mL of cell culture media. 2.5 µL of 
NHS-Biotin (10 mg.mL-1 in DMSO) was then added to every 10 mL of cell 
suspension. RBCs were then added to cell culture flasks and incubated at 37 °C for 
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2.5 hours before washing and resuspension in cell culture media. 50 µL of biotin 
labelled red blood cells were then added in a serial dilution (in cell culture media) to 
every well of various sugar functionalised 96-well plates from a maximum 
concentration of that achieved in the pellet formed post-centrifugation.  
 
96-well plates with RBCs were then incubated at 37 °C for 30 minutes before removal 
of unbound cells and washing of every well with PBS. 100 uL of ExtrAvidin®-FITC 
(0.5 % in PBS) was then added to every well before incubation at 37 °C for 1 hour. 
Unbound ExtrAvidin®-FITC was then removed from every well before washing with 
PBS. All wells were then incubated with cell lysis buffer for 1 hour prior to 
fluorescence detection. Fluoresence measurements were conducted on a Thermo 
Electron Varioskan spectral scanning multimode reader using excitation and emission 
wavelengths of 475 and 525 nm respectively. 
 
Fluorescein Isothiocyanate labelling of red blood cells: 50 mL of infected and 
uninfected RBCs in cell culture media was spun down by centrifugation at 500 g 
before being resuspended in 12 mL of cell culture media. Subsequently FITC was 
added to produce a final concentration of 0.1 mg.mL-1 (and 0.35 % DMSO). The cells 
were then incubated for 30 minutes at 37 °C as previously described by Fujii et al.30 
before centrifugation and resuspension of cells in fresh cell culture media at 11 % 
haematocrit. 
 
Autofluorescence: 50 uL of RBCs were added in a serial dilution (in cell culture 
media) from the maximum pellet concentration to every well of a sugar functionalised 
96-well plate. This was then incubated at 37 °C for 30 minutes prior to removal of 
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unbound red blood cells and washing with PBS. Fluorescence was then measured 
with excitation and emission wavelengths of 485 nm and 645 nm respectively.  
 
Colorimetric assay and ImageJ analysis: Dilution assays of RBCs in culture media 
were photographed using a camera and images were uploaded into ImageJ. Each well 
had a region of interest drawn around it before conversion of the image into a HSB 
(Hue, Saturation, Brightness) stack. The region of interest was added to the saturation 
image from the HSB stack and pixel intensity in each well was measured before 
exporting the data into Excel and plotting in OriginPro.  
 
Fluorescence microscopy: Smears of blood drops from either infected cells (early or 
late trophozoite stage) or uninfected cells after incubation with FITC were observed 
under a fluorescence microscope (Olympus b x-60) with a blue filter (495-570 nm) 
and digitalised with the aid of a Nikon camera. 
 
Carbohydrate surface preparation: 100 µL of 30 mM sugar solutions (in 100 mM 
acetate buffer with 1 mM aniline, pH 5.5) was added to each well of a Carbo-BIND 
96-well plate. Plates were then covered in foil and incubated in the dark at 50 °C for 
24 hours. After incubation, any unbound solution was removed and the well washed 
with PBS. Plates were either used immediately or stored at -20 °C prior to their use. 
 
Carbohydrate binding assay: FITC labelled RBCs were diluted to one third of the 
pellet concentration (~6.3x105 cells per µL) and 50 µL of this cell suspension was 
added to every well of a sugar functionalised Carbo-BINDTM plate and incubated for 
30 minutes at 37 °C, followed by removal of unbound cell suspension and washing 
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with PBS. Finally 1X dilution of lysis buffer consisting of 5 mM EDTA, 0.08 % 
Triton x100, 20 mM Tris and 0.08 % saponin was added to each well and the 
fluorescence was measured using SkanIt in a Thermo Electron Varioskan spectral 
scanning multimode reader (excitation and emission wavelengths of 475 and 525 nm 
respectively). 
 
Cell culturing method: Plasmodium falciparum 3D7 were cultured in RPMI 1640 
R8758 supplemented with 25 mM HEPES (pH 7.4), 0.25 % Albumax I, 0.4 mM 
hypoxanthine and 0.020 mM gentamycin sulphate. Plasmodium falciparum TH004 
were cultured in RPMI 1640 supplemented with 25 mM HEPES (pH 7.4), pooled 
human AB+ serum (50 mL per 500 mL of RPMI 1640), 0.4 mM hypoxanthine and 
0.020 mM gentamycin sulphate. Cultures were grown under a gaseous headspace of 3 
% O2 and 4 % CO2 in N2 at 37 °C.40 Parasite growth was synchronised by treatment 
with sorbitol. 41 
 
Gametocyte preparation: Plasmodium falciparum 3D7 were cultured in RPMI 1640 
culture media containing L-glutamine and sodium bicarbonate. Media was 
supplemented with 25 mM HEPES (pH 7.4), 0.4 mM hypoxanthine, pooled human 
AB+ serum (50 mL per 500 mL of RPMI 1640) and 0.020 mM gentamycin sulphate. 
For the first 4 days the media was supplemented with 50 mM N-Acetyl-D-
glucosamine. For late stage gametocytes, complete culture media was used for the 
remaining 3 days and for early stage gametocytes complete media supplemented with 
50 mM N-Acetyl-D-glucosamine was used. Cultures were grown under a gaseous 
headspace of 3 % O2 and 4 % CO2 in N2 at 37 °C.40 
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Slide preparation for red blood cells: Samples of RBCs in culture media were 
prepared on slides for light microscopy. Each slide was fixed with methanol, dried 
and then stained with Giemsa before washing and drying again. Slides were viewed at 
100X magnification using an oil immersion objective. 
 
Statistical analysis: Differences in carbohydrate binding were analysed using a two-
sample one-sided Student’s t-test performed in the open source statistical package R 
(version 3.1.3) 42 after equal variance was confirmed by performing a Fisher test for 
variance and normality of data was confirmed using the Shapiro-Wilk normality test. 
For those samples were equal variance was not observed a Welch t-test was 
performed and for those where data was not normally distributed, the Wilcoxon Rank 
Sum test was employed. All graphs were produced in OriginPro. LDA was performed 
using the ‘dapc’ function in the ‘adegenet’ package (version 1.4-2)43 in R.  
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Chapter 7 	
Conclusions 	
 
Carbohydrate arrays represent a powerful tool for the detection and identification of 
pathogenic organisms in point-of-care diagnostics. Currently the poor sensitivity of 
binding at the monosaccharide level has limited the potential of these devices as 
increased sensitivity is achieved by using expensive and synthetically challenging 
oligosaccharides or by coupling to more sensitive detection methods. These methods 
include; surface plasmon resonance, quartz crystal microbalance and mass 
spectrometry to name but a few. Such techniques are often challenging, require high 
sample purity, highly skilled technicians, expensive machinery and processing of 
results can be both challenging and time-consuming. 
 
In this work, we have described the use of simple and synthetically accessible glycans 
as multiplexed sensors after analysis with linear discriminant analysis (LDA). LDA 
not only improved the resolution between groups based on binding but allowed the 
identification of unknown samples based on binding.  
 
The huge wealth of binding data that is already available from the consortium for 
functional glycomics has been achieved using an expensive microarray. Such 
information density can be matched by the coupling of a multiplexed monosaccharide 
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sensor with LDA. Cheap and facile surface chemistry allowed the production of a 96-
well based carbohydrate array through coupling of reducing glycans to a 
commercially available hydrazide functionalised 96-well plate. Functionalisation was 
confirmed using a modified drop shape analysis technique where the spreading of a 
droplet of dye within a well was compared at each stage of the functionalisation in 
order to determine surface hydrophobicity. Functionalisation was further confirmed 
by the specific binding of two well-characterised lectins to carbohydrate 
functionalised surfaces. Concanavalin A (α-mannose specific) was found to bind 
more strongly to the mannose surface than the galactose surface and the reverse was 
found to be true for peanut agglutinin (a β-galactose specific lectin). 
 
This functionalisation methodology was then used to generate four monosaccharide 
surfaces (galactose, mannose, glucose and a 50 % galactose 50 % mannose mixed 
surface) and the binding of five galactose specific lectins was assessed. Whilst 
binding profiles alone were not sufficient for lectin discrimination (due to the 
similarity in their binding), combination of these profiles with LDA allowed excellent 
resolution between all lectin groups and 100 % correct classification of blind samples 
for all the lectins. 
 
This methodology was also able to correctly identify the presence of a toxin when 
mixed with another lectin as long as it was present at greater than 50 % of the sample 
thus paving the way towards identification of toxins in impure samples. Fluorescently 
labelled lectins were used for this method but as these are not going to be present in 
real biological samples, the use of LDA for the analysis of lectin binding couple with 
a label-free detection method was also examined. Gold nanoparticles were coupled to 
	 214	
monosaccharide functionalised polymers (GlycoAuNPs) for label free detection of 
lectin binding. The characteristic absorbance shift in response to lectin binding for six 
different monosaccharide functionalised particles was measured. Identification of any 
of the six lectins assessed based on binding to the surfaces would be challenging 
based purely on their binding profile but the LDA model showed excellent resolution 
between lectins thus allowing clear identification of any of the lectins assessed.  
 
Combining GlycoAuNPs with varying rations of N-Acetyl-D-Mannosamine and N-
Acetyl-D-Galactosamine functionalisation, highlighted the potential for ratiometric 
surfaces to improve the information density of the sensor without increasing glycan 
number or complexity. This approach allowed concentration independent lectin 
discrimination (with an accuracy of 86 %) that was significantly more accurate than 
considering just 100 % mannose and 100 % galactose functionalised particles (which 
had an accuracy of 68 %). This would allow classification of biological samples with 
unknown levels of lectin thus highlighting the potential for this methodology in a 
‘real-world’ situation. 
 
The combination of facile monosaccharide functionalised surfaces and LDA was also 
utilised in the discrimination of bacterial species. Identification of bacterial species to 
determine appropriate point-of-care treatment is crucial to avoid the spread of 
antibiotic resistance strains. Five bacterial species, encompassing pathogenic and non-
pathogenic strains, gram positive and gram-negative species and strains of the same 
species were successfully fluorescently labelled. After labelling and incubation with 
nine different functionalised surfaces and production of a LDA model it was shown 
that each bacterial species showed good resolution from the other species and the 
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model could be utilised in the identification of a blind bacterial sample of one of the 
species assessed. 
 
This approach also allowed the life-stage specific identification of red blood cells 
(RBCs) infected with Plasmodium falciparum (the most lethal of the parasite species 
responsible for human malaria). RBCs infected with parasites at different stages of 
development showed distinct binding patterns when compared to uninfected RBCs. 
Production of an LDA model highlighted distinct profiles for all life-stages and 
allowed not just the identification of infected versus uninfected but the identification 
of the life stage of the parasite within the RBC. Furthermore, the application of this 
methodology to P. falciparum strains of differing levels of Artemisinin (a drug that 
underpins many malarial treatment therapies) resistance allowed the identification of 
differing resistance levels based on their carbohydrate binding profiles. This allowed 
not just the identification of resistance but was able to detect differences between 
strains with differing levels of resistance with a high accuracy. This represents the 
first time P. falciparum infection has been detected based on carbohydrate adhesion 
and a promising avenue of research for a simple method for identification of drug 
resistant strains. 
 
One of the key limitations of this approach is the lack of techniques available for 
surface characterisation. Due to this, the exact conformation of the glycans on the 
surface is unknown, the topology of the surface and their exact surface density. This 
results in the possibility for false negatives in binding whereby a lectin or cell fails to 
bind a surface that it binds to natively due to non-optimum surface presentation of 
glycans. Despite this, the technique represents a facile methodology for surface 
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coupling of glycans and further optimisation of the reaction conditions and 
development of surface characterisation techniques may aid in improving the level of 
characterisation of the surface. 
 
Point-of-care detection would currently be limited by the sensitivity of the technique, 
especially when considering contaminated biological samples. Whilst a significant 
amount of work would have to be done in order to improve the technique to the point 
where it could be used as a diagnostic tool, it represents a powerful tool for research 
in other fields. For example, this tool could be used to look at differential glycan 
binding characteristics of bacteria at different growth phases or in different nutritional 
conditions. This may elucidate some potential binding targets that occur only in 
specific growth phases or in certain nutrient availability conditions that may be more 
similar to that found within the host. 
 
Whilst much current work in this field is focused towards improving specific binding 
interactions through improved surface functionalisation (specifically with longer 
chain glycans), this combined technique highlights a mechanism through which better 
analysis of low resolution data (such as monosaccharide binding) can still provide 
information in the discrimination of samples. As such, future work within this field 
should focus on the use of more powerful statistical tools such as linear discriminant 
analysis and Random Forest for the analysis of binding data to ensure maximum 
information density of glycan binding is utilised. Whilst sensitivity is currently a 
limitation for the real-world application of this approach we have shown methods for 
improving this through the use of mixed glycan surfaces and coupling to a ‘label-free’ 
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approach such as gold nanoparticles further improves the real world application of 
this methodology. 
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Appendix 1: Gold nanoparticle-linked analysis of 
carbohydrate-protein interactions and polymeric 
inhibitors, using unlabelled proteins; easy 
measurements using a ‘simple’ digital camera 
	
Gold nanoparticle-linked analysis of carbohydrate–
protein interactions, and polymeric inhibitors, using
unlabelled proteins; easymeasurements using a ‘simple’
digital camera†
Lucienne Otten,a Sarah-Jane Richards,a Elizabeth Fullam,bc Gurdyal S. Besrab
and Matthew I. Gibson*a
Traditional methods of measuring the aﬃnity of lectins (or other carbohydrate-binding proteins) to their
target carbohydrate ligand rely on the use of chemically/recombinantly modiﬁed proteins in sorbent
assays, microarrays or the use of expensive label-free methods such as surface plasmon resonance
spectrometry. In this work we exploit the extremely high extinction coeﬃcient (i.e. colour) of gold
nanoparticles as resolving agents in sorbent assays. The anionic nanoparticles adhere strongly to
immobilized proteins, but not to the carbohydrate-surfaces allowing investigation of protein binding
and screening of novel multivalent inhibitors. Furthermore, the use of a simple digital camera (or mobile
phone) to obtain the data is shown, providing a simple ultra-low cost route to the detection of
unmodiﬁed, carbohydrate-binding proteins.
Introduction
Carbohydrate–protein recognition events are responsible for a
plethora of biological processes including host–pathogen
interactions, immune signaling, fertilization, cancer metas-
tasis, blood group markers and many more. Pathogenic
infection is oen driven by an initial carbohydrate–protein
binding event such as neuraminic acid/hemagglutinin (inu-
enza),1,2 GM-1 ganglioside/cholera toxin (cholera)3 and GP-120/
DC-SIGN (HIV),4 oen through binding to lectins: a subset of
carbohydrate-binding proteins which are neither enzymes nor
antibodies. Inhibition of these binding events, to prevent
infection, is termed anti-adhesion therapy and has been
extensively studied for both mono- and multi-valent carbohy-
drate derivatives.5–9 The binding aﬃnity of carbohydrates to
lectins (and hence their potential utility) is oen enhanced by
the multivalent presentation of individual carbohydrates on a
polymeric/dendritic scaﬀold (‘glycopolymer’),10 due to the
‘cluster glycoside eﬀect’,5,11 where the polymer's binding
aﬃnity increases to an extent greater than the linear sum of
the individual carbohydrates' binding aﬃnities. The mecha-
nisms and applications of these materials are currently under
intensive investigation, but are oen only focused on model
plant lectins which are widely available and have well-char-
acterized interactions. Despite many carbohydrate–protein
interactions being known, there still remains a huge number
of carbohydrate-mediated processes (covering recognition,
uptake, traﬃcking and binding) which are poorly character-
ized and hence causes a bottle-neck in the design of new
therapeutics or diagnostics.12 For example, the structure of the
oligosaccharide responsible for human sperm binding was
only recently elucidated despite many years of intense study.13
In part, this is due to the challenge associated with obtaining
usable quantities of complex glycans or their derivatives,
compared to other biomacromolecules (DNA, proteins) which
can be recombinantly amplied and/or expressed and
obtained by solid-phase chemical synthesis.14,15 In order to
evaluate carbohydrate–protein interactions, there is also a
need to isolate and characterize usable quantities of the
protein prior to any analysis. Standard methods for evaluating
these interactions include both solution and solid phase based
assays. Isothermal titration calorimetry (ITC) provides
detailed information about the energetics of the binding
interactions, but is time consuming, not high-throughput and
can consume a relatively large amount of material and
requires specialized equipment.16 Sometimes, direct uores-
cence assays probing tryptophan/tyrosine residues can be used
but this is not always the case. A further problem of only
probing solution interactions is that many carbohydrates are
immobilized on the surface of a cell/virus, providing an
adhesion site, rather than as mobile solutes. To address this,
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Surface Plasmon Resonance (SPR) is frequently employed. SPR
allows direct measurement of the binding of a bio-
macromolecule onto an appropriately functionalized gold
surface using minimal quantities of each compound.17,18
However, SPR equipment is specialized, oen not high-
throughput, is expensive and not routinely available in all
laboratories. Other surface methods such as Quartz-Crystal
Microbalance (QCM) and Optical Waveguide Spectroscopy
(OWLS) have similar problems and benets.19 It should be
noted that immobilization of proteins on surfaces, rather than
carbohydrates is convenient but limited by the signal detec-
tion (which is essentially proportional to mass) which cannot
detect small molecule binding. ELISA (Enzyme-Linked
Immuno-Sorbent Assay) and uorescence-linked assays have
found wide-spread use due to their lower equipment level
requirement (microplate reader) and excellent sensitivity
limits.20,21 A key challenge of sorbent assays is the need to use
labelled proteins, rather than unmodied versions. Recombi-
nant methods can introduce enzymatic or antigen tags which
themselves can alter the function of the protein and direct
chemical labeling of isolated proteins with uorophores (such
as uorescein isothiocyanate) can provide detection, but gives
rise to heterogeneous distributions of labels which leads to
well known problems in terms of altering ligand binding-
aﬃnities.22–24 Fluorescent labels are oen not photostable
presenting challenges in quantitative analysis.25 The chal-
lenges associated with carbohydrate-immobilisation, or the
generation of labelled carbohydrates should also not be
underestimated.26
Considering that monitoring of these interactions has huge
potential in the development of novel anti-adhesion therapies
or diagnostics, any technology which simplies this process, is
compatible with native proteins and relies on readily available
imaging platforms could have profound benet. Gold nano-
particles (AuNPs) which display an extremely strong coloration
due to their surface plasmon band (similar, but distinct from
the analytical equipment discussed above) have been shown to
strongly adhere to proteins by electrostatic interactions. For
example, colloidal gold has been used to stain native proteins
separated by electrophoresis on gels,27 or those onmicroplates28
allowing colorimetric detection. While useful, this technique
has not found wide-spread use, has not been optimized in terms
of particle size, nor has it been used to screen for novel inhib-
itors of lectin-binding. Other uses of AuNPs in imaging has also
been reviewed extensively,29–31 especially with regard to their
aggregation-sensitive properties,32 contrast agents in biological
electron microscopy33 and photothermal imaging.34
Here the use of AuNPs as resolving agents to allow quanti-
cation of protein absorption onto carbohydrate functionalized
microplate surfaces and to use it as an accessible tool to probe
multivalent inhibitors which are potential prophylactic anti-
bacterial agents without the need for uorescence detection is
investigated. This visualization should reduce the need for
expensive, complicated and low throughout analytical facilities
and inaccessible, labelled, protein samples. The use of a simple
digital camera to probe these interactions is also studied as an
ultra-low cost, alternative.
Materials and methods
General
Concanavalin A (ConA), uorescein isothiocyanate (FITC)
labelled ConA, peanut agglutinin (PNA) from Arachis hypogaea,
FITC labelled PNA, monosialotetrahexosylganglioside (GM-1),
bovine serum albumin (BSA), cholera toxin subunit B (CTx-B),
FITC labelled CTx-B, mannan, preformulated phosphate buﬀ-
ered saline tablets (PBS), calcium chloride (CaCl2), sodium
chloride (NaCl), HEPES, Tris buﬀer, trisodium citrate dihydrate
and chloroauric acid (HAuCl4) where all purchased from Sigma-
Aldrich, UK. 96-well high binding microtitre plates were
purchased from Greiner Bio-one. Galactose-functional poly-
mers used in this study have been previously reported and their
synthesis is summarised in the ESI.†35 Phosphate buﬀered
saline (PBS) was prepared using preformulated tablets dissolved
in 200 mL of Milli-Q water (with resistance >18 mOhms) to give
nal concentrations of [NaCl] ¼ 0.138 M, [KCl] ¼ 0.0027 M and
pH ¼ 7.4. 10 mmol Tris buﬀer containing 0.1 mmol CaCl2 and
0.5 mmol NaCl (pH 8, TBS) was prepared in 250 mL of Milli-Q
water (with a resistance >19 mOhms), and 10 mmol HEPES
buﬀer containing 0.1 mmol CaCl2 (pH 6.5, HEPES) was
prepared in 250 mL of Milli-Q water (with a resistance >19
mOhms).
Physical and analytical methods
Absorbance and uorescence measurements were made using a
BioTek Synergy HT multi-detection microplate reader and Gen5
soware. Dynamic light scattering was conducted using a Nano-
Zs from Malvern Instruments, UK. Scattered light was detected
at 173" and the observed count rates recorded. Hydrodynamic
radii (where appropriate) were determined using the manu-
facturer's soware. Diameters are an average of 3 measure-
ments using at least 10 scans. All protein binding curves were
plotted in OriginPro (version 8.6) and the built in nonlinear
curve tting tool was used to t a logistic curve to the data and
to calculate the MIC50 values. MIC50 values in this report are
dened as being the concentration of inhibitor required to
reduce the binding of the lectin to the carbohydrate surface by
50% of its maximal value. The graphs showing absorbance
spectra and the optimization lines were produced in Excel.
Absorbance graphs were produced by plotting the absorbance
measurement at 530 nm against concentration. All standard
error values were calculated in Microso Excel and then
imported into OriginPro and used to produce the error bars. A
linear regression analysis for the paired cholera toxin data was
performed in the open-source statistical package R (version
2.14.1).36 Pictures of AuNP modied wells were taken using a
Nikon D60 camera with automatic exposure settings from a
distance of 30 cm using ambient light conditions.
Functionalization of multiwell plates
Greiner high binding 96-well plates were incubated for 16 h
with 180 mL of 0.1 mg mL#1 mannan dissolved in PBS per well.
Aer incubation, unbound mannan, GM-1 or BSA was removed
by washing vigorously with distilled water, aer which the
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plates were dried and stored under an inert atmosphere at 4 !C.
The same procedure was also used for GM-1 (0.1 mg mL"1),
bovine serum albumin (BSA) (0.1 mg mL"1).
Gold nanoparticle synthesis
Sodium citrate capped gold nanoparticles were produced by
chemically reducing chloroauric acid (HAuCl4) with trisodium
citrate dihydrate as the capping and reducing agent. An
aqueous solution of trisodium citrate dihydrate (2 mL,
0.13 mmol) was added to a boiling solution of HAuCl4 (35 mL,
0.35 mmol) under reux and vigorous stirring producing a ratio
of 3.5 : 1 (HAuCl4 to sodium citrate). Aer addition of the tri-
sodium citrate dihydrate the solution went from pale yellow to
dark blue before eventually turning deep red (about 30 minutes
aer addition of the trisodium citrate dihydrate). Aer which
the solution was cooled and then stored in the dark at 4 !C.
Solutions were also produced using the ratios 2.5 : 1 and 1.5 : 1
following the same procedure but using diﬀerent ratios of
HAuCl4 to trisodium citrate dihydrate.
Lectin binding assays
Lectin solutions were made up as serial dilutions in TBS from
1mgmL"1 stocks apart from ConA–FITC which was made up in
HEPES at 1 mg mL"1. The lectin solutions were then added to
96-well plates functionalized with their target carbohydrate and
incubated at 37 !C for 30 min. Unbound lectin was removed by
washing extensively with buﬀer, followed by Milli-Q water. For
FITC-labelled lectins, uorescence was then measured at exci-
tation/emission wavelengths of 485/528 nm. Alternatively, 50 mL
of AuNP solution was added to each well and then incubated at
37 !C for 30 min. Aer extensive washing with Milli-Q water, the
absorbance in each well was measured between 450 and 700 nm
in 1 nm steps. All experiments were carried out in triplicate.
Competitive inhibition assay
96-well microtitre plates were incubated for 16 h with 180 mL of
100 mg mL"1 GM-1 dissolved in PBS, per well. Unbound GM-1
was removed by washing extensively with PBS and then water.
Polymer solutions were made up as serial dilutions (up to
10 dilutions per sample in TBS from 1 mg mL"1). 20 mL of
12.5 mg mL"1 CTx-B in TBS was added to 100 mL of each polymer
solution to result in a nal concentration of 2 mg mL"1 CTx-B
per well. 100 mL of the polymer/CTx-B solutions were then added
to the GM-1-coated wells and incubated at 37 !C for 30 min.
Aer this time, they were extensively washed with Milli-Q water.
50 mL of AuNP solution was then added to each well before
incubation at 37 !C for 30 min. Aer extensive washing with
Milli-Q water, absorbance in each well was measured between
450 and 700 nm in 1 nm steps. All experiments were carried out
in triplicate.
Digital camera-linked assay and image analysis
Microplates were prepared as described above, and the CTx-B
lectin applied, washed and AuNP added following the above-
described procedures. A digital photograph of the AuNP-
modied plates was taken from a distance of 30 cm using
ambient light and the tiﬀ image le uploaded into the open-
source image processing package ImageJ37 (version 1.46a) where
a region of interest was drawn around every well. The colour
(RGB) image was then converted into a hue saturation and
brightness (HSB) stack of images and the saturation image
used. The regions of interest drawn on the original image were
added to the saturation image using the ROI manager and
average pixel intensity in each region of interest was measured
using an inbuilt function in ImageJ. An example image showing
the colour change achieved by gold binding to protein bound to
GM-1 is shown in Fig. 6.
Results and discussion
The aim of this work was to use citrate-stabilized AuNPs as
resolving agents for direct measurement of (unlabelled) protein-
binding onto carbohydrate-functional surfaces, taking advan-
tage of the extremely strong coloration of AuNPs. Here it is
exploited to screen novel anti-adhesion therapies without the
need for labelled proteins and to test the validity of direct
‘visual’ analysis of protein binding using a simple digital
camera as an ultra-low cost platform.38 The concept is outlined
in Fig. 1.
A small panel of citrate-stabilized AuNPs were obtained
using the standard citrate/HAuCl4 reduction approach.39,40 This
method was chosen as it is simple, scalable and gives rise to
charged nanoparticles, which are essential for strong non-
specic protein interactions (vide infra). Table 1 summarises the
synthesis of AuNPs used in this study which were characterized
by UV-visible spectroscopy and dynamic light scattering to
Fig. 1 Overview of the approach used to allow direct measurement of lectin–
carbohydrate binding by visualization of surface-bound protein using AuNPs on
microtitre plates.
Table 1 Citrate-stabilized AuNPs used in this study
Code
[Citrate] :
[Gold]a
lspr
b
(nm)
Particle sizec
(UV) (nm)
Particle size
(DLS) (nm) PDId
AuNP1 3.5 : 1 526 36 nm 36 0.35
AuNP2 2.5 : 1 541 76 nm 76 0.58
AuNP3 1.5 : 1 545 70 nm 130 0.38
a Molar ratio of trisodium citrate to HAuCl4 used in the synthesis of the
nanoparticles. b Location of the surface plasmon peak in the UV-visible
spectrum of the particles. c Particle size estimated by the method of
Haiss et al.41 d Polydispersity index of the particles, obtained by DLS.
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provide an estimate of their dimensions, which were in the
range of 30–70 nm. The polydispersities were quite large, as is
common with direct citrate-only reduction methods.
The key requirement of this study is that the citrate-coated
AuNPs interact with proteins that have bound to carbohydrates
immobilized onto the surface of microtitre plates, providing the
necessary visualization (red colour) to determine the extent of
protein binding. To test the hypothesis, two diﬀerent surfaces
were prepared in 96-well microtitre plates designed to promote
or inhibit AuNP binding. BSA was directly adsorbed onto high-
binding microtitre plates to provide a ‘protein rich’ surface and
the GM-1 ganglioside, which presents a carbohydrate-surface,
was also immobilized (see Experimental section for details).
These surfaces were subsequently exposed to a 0.3 mg mL!1
solution of AuNP1 for 30 minutes, washed with Milli-Q water,
and then their UV-Vis spectra measured, Fig. 2A. The BSA
surface clearly shows absorbance at "520 nm, attributable to
AuNP absorbing to the protein surface, whereas the GM-1
surface shows no signal. The branched oligosaccharide
component of GM-1 presents a highly hydrated (‘non-fouling’-
type42) surface which will not interact electrostatically with the
anionically charged AuNPs. The 3 diﬀerent AuNPs listed in
Table 1 were subsequently evaluated with BSA surfaces as a
function of AuNP concentration to determine the optimum
conditions and detection limits, Fig. 2B. Across the AuNP
concentration range of 0–1mgmL!1, the smallest nanoparticles
(3.5 : 1 [citrate] : [Au]) gave the largest signal intensity. To
maximize the signal intensity, all subsequent tests were
undertaken by exposing the protein-bound surfaces to AuNP1 at
1 mg mL!1 (total Au mass).
To evaluate the utility of AuNP as a reliable, scalable,
accessible and economic alternative to standard SPR/QCM/
ELISA type measurements of carbohydrate–protein interactions
a representative panel of lectins were selected with, and
without, uorescent labels to allow us to validate this approach.
Mannose-functional surfaces were obtained by coating micro-
titre plates with mannan and galactose-functional plates by
coating with GM-1. Concanavalin A (ConA) was used as a
mannose-specic lectin, and peanut agglutinin (PNA) and the
B-subunit of the cholera toxin (CTx-B) as distinct galactose-
specic lectins, Table 2. Fig. 3 shows the dose-dependent
binding of PNA to GM-1 as a function of PNA concentration,
Fig. 2 Evaluation of AuNP surface interactions. (A) UV-visible spectra of BSA-coated surface (black trace) and GM-1 coated surface (red trace) following addition of
AuNP1. (B) Absorbance intensity of protein-bound wells at 525 nm as a function of added AuNP concentration, onto BSA-coated microplates. Legend shows ratio of
[citrate] : [Au] used in preparation of the nanoparticles.
Table 2 Coatings and lectins used in this study
Coating Carbohydrate–ligand Lectin
Mannan a-D, 1–6 linked mannose Concanavalin A
GM-1 b-D-Galactose Cholera toxin
B-subunit
GM-1 b-D-Galactose Peanut
agglutinin
Fig. 3 Dose dependant binding curves of PNA onto GM-1 functional surfaces. (A) Fluorescence measurements (FITC – excitation/emission 485/528 nm); (B) AuNP
absorbance at lmax. Errors bars represent # standard deviation from a minimum of 3 repeats.
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with binding measured by uorescence (A) or by addition of
50 mL of 1mgmL!1 AuNP1 (B). Both binding curves have similar
proles and give calculated dissociation constant (Kd's) of
72.7 nM (AuNP) and 90.9 nM (uorescence) respectively. The
strong agreement between the two methods shows that the
AuNPs are useful and can be used to analyse complex interac-
tions without the need for specialised equipment, or labelled
proteins. Similar results were obtained when the ConA/mannan
system were analysed (ESI†). Furthermore, the AuNP-resolved
microtitre plates were not observed to degrade over time. Aer 2
weeks storage, identical data was obtained in contrast to uo-
rescence or enzymatic methods which suﬀer from photo-
bleaching or denaturation, respectively. It should be noted that
although the AuNPs will most likely bind each protein to a
diﬀerent extent, this does not aﬀect the measurements shown
here, which are probing equilibrium process and hence all that
is required is a dose–response curve with clear start and end
points.
A more clinically relevant subset of lectins for study are those
secreted by pathogenic bacteria which are targets for prophy-
lactic anti-adhesion therapy. The toxin secreted by the pathogen
Vibrio cholera binds to GM-1 on epithelial cells and is the
causative agent of cholera infection. The native cholera toxin
contains 5 carbohydrate binding units (‘B-subunits’). In this
study a single B-subunit is used as a non-toxic analogue and the
interactions probed in the same manner as PNA, Fig. 4. Kd
values obtained for CTx-B by uorescence was 0.19 mM and by
AuNP 0.18 mM again showing exceptional agreement.
The data presented above shows that AuNP based measure-
ment of protein binding is comparable to uorescence
Fig. 4 Dose dependant binding curves of CTx-B onto GM-1 functional surfaces. (A) Fluorescence measurements (FITC – excitation/emission 485/528 nm); (B) AuNP
absorbance at lmax. Errors bars represent " standard deviation from a minimum of 3 repeats.
Fig. 5 Inhibition of CTx-B binding by b-D-galacto-functional glycopolymers. (A) Structure of glycopolymeric inhibitors; (B–D) inhibitory curves of polymers 1, 2 and 3
respectively, with CTx-B, measured using AuNP method. Errors bars represent " standard deviation from a minimum of 3 repeats.
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methods. We are ultimately interested in probing for inhibition
of pathogenic toxins, and therefore the Au-system was applied
to a competitive binding experiment. We and others have
demonstrated that synthetic glycopolymers, presenting many
copies of a single carbohydrate on their side chain display high
binding aﬃnities to lectins due to the cluster glycoside
eﬀect.35,43 Recently we demonstrated that modulation of the
distance between polymer backbone and carbohydrate can
improve the aﬃnity of poly(galactoside)s for CTx-B due to an
improved t to its (relatively) deep binding site. Here, three
synthetic glycopolymers which were prepared by tandem post-
polymerization modication44 with precise control over valency
and linker length were assayed for their ability to inhibit CTx-B
binding, Fig. 5.
P1 with a short linker showed the highest MIC50 value
(lowest aﬃnity) of 56 mg mL!1 whereas the polymers with longer
linkers (P2/P3) had approximately identical MIC50 values of 23
and 24 mg mL!1 respectively which is in strong agreement with
previously published observations.35 On a per-polymer (molar)
basis, P3 was the most active, but this is biased by its higher
molecular weight and hence lower molar concentration. MIC50
corrected to carbohydrate concentration indicates that P3 and
P2 have identical activity and therefore in the case of CTx-B,
there is no additional benet of increasing chain length above
18 units (although further benet of even larger polymers
cannot be discounted). Compared to free galactose, all polymers
were at least 100"more active highlighting the cluster glycoside
eﬀect (Table 3). This method is therefore suitable, and
amenable to high-throughput screening of lectin inhibition
using un-labelled proteins.
Measuring binding using digital photography
During the above described experiments, it was observed that
upon addition of AuNPs to the protein-functional plates, suﬃ-
cient gold was deposited to allow visual examination of protein
binding, due to the intense red colouration of AuNPs (their
extinction coeﬃcients are typically 100–1000 larger than uo-
rescence dyes). Fig. 6A shows a photograph of a GM-1 microtitre
plate following incubation with a dilution series of CTx-B,
revealed by addition of AuNPs. Strong red colouration can be
seen at high concentrations of CTx-B, with the colour
decreasing in line with decreasing protein concentrations. This
visual read-out is potentially useful for low-cost diagnostic
applications, rapid protein-binding assays in laboratories or 3rd
world countries, particularly if it can be linked to a mobile
phone or digital camera system. This would remove the need for
a plate reader or similar whilst maintaining the ability to obtain
relevant data.38 The AuNP-exposed plates were photographed
using a standard digital camera (see Experimental section) and
imported into image analysis soware. The average pixel
intensity of each well was measured and plotted against
concentration of protein added, Fig. 6B. Impressively, near
identical binding curves were obtained compared to those in
Fig. 5 (Ctx-B by either absorbance/uorescence), with Kd values
close to that obtained by either uorescence or absorbance.
Fig. 7 shows the correlation between average pixel intensity and
both total uorescence or absorbance. This analysis gave a
strong positive correlation linear ts with R2 values above 0.98.
This oﬀers the opportunity for evaluation of lectin binding/
inhibition in laboratories lacking in dedicated glycomics facil-
ities and would be compatible with a cellular-phone based
analytical system.
Table 3 Inhibitory potency (MIC50) of glycopolymers against CTx-B determined by gold nanoparticle colorimetric method
Polymer DPna Linkerb MIC50 MIC50c [polymer] MIC50d ([galactose])
P1 18 Short 56 # 2.4 mg mL!1 9.4 # 0.4 mM 0.169 # 0.072 mM
P2 33 Long 23 # 18 mg mL!1 1.6 # 1.2 mM 0.055 # 0.43 mM
P3 18 Long 24 # 11 mg mL!1 3.2 # 1.46 mM 0.057 # 0.027 mM
a Number average degree of polymerization of polymer (¼ galactose/chain). b Refers to length of spacer between polymer and carbohydrate shown
in Fig. 5. c MIC50 adjusted in terms of concentration of polymer chains. d MIC50 adjusted in terms of total galactose concentration. The polymers
used were reported in a previous study.35 Error bars represent the standard deviation in the individual MIC50 from each individual measurement
(minimum of 3 repeats).
Fig. 6 Direct optical analysis of protein binding. (A) Digital photograph of GM-1
functional microplates treated with a dilution series of CTx-B and following
developing with AuNPs for 30 minutes. (B) Binding curve obtained by pixel-
counting direct from digital photographs.
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Conclusions
In this study, we have investigated the use of citrate-coated
AuNPs as resolving agents to analyse protein binding to
carbohydrate functionalized surfaces, as a low-cost, accurate
glycomics tool. Carbohydrate-coated surfaces were incubated
with their corresponding lectins and their binding isotherms
were measured by direct uorescence-linked assays and by
absorbance measurements based on gold nanoparticle
absorption. Strong correlation was found between the two
methods, with the gold particle method having the advantage
that it removes the need to use labelled proteins and can be read
with a standard microplate reader, without the need for uo-
rescence measurements. To demonstrate the applicability of
this, a series of multivalent glycopolymers were screened for
their ability to inhibit the binding of B-subunit of the cholera
toxin, as a model of a pathogenic infection process. Finally, due
to the extreme strong colouration of the gold-nanoparticle
functionalized surfaces, it was possible to use a digital camera
to simply image the microplates and use image analysis so-
ware to extract binding isotherms, which showed strong corre-
lation to those obtained by uorescence or absorbance
measurements. This presents the opportunity to use gold
nanoparticle resolving agents for label free, low cost, high-
throughout evaluation of carbohydrate–protein interactions
which may have diagnostic or screening applications. In
particular, it allows rapid testing of inhibitors and concentra-
tions ranges prior to more detailed biophysical analyses (e.g.
SPR/QCM). Current work is focussed on exploiting this meth-
odology to identify new carbohydrate-binding proteins, and to
rapidly screen for novel anti-adhesion therapies.
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Appendix 2: Glycopolymers with secondary binding 
motifs mimic glycan branching and display bacterial 
lectin selectivity in addition to affinity.  
  
Glycopolymers with secondary binding motifs
mimic glycan branching and display bacterial lectin
selectivity in addition to aﬃnity†
M. W. Jones, L. Otten, S.-J. Richards, R. Lowery, D. J. Phillips, D. M. Haddleton
and M. I. Gibson*
Theapplicationof syntheticglycopolymers toanti-adhesive therapieshasso farbeen limitedby their lackof lectin
speciﬁcity. Here we employ a macromolecular engineering approach to mimic glycan architecture. A new,
3-step tandem post-polymerisation methodology was developed which aﬀorded precise control over both
chain length and carbohydrate (galactose)-polymer backbone linker distance. This route also allowed a
secondary binding (branched) motif to be introduced onto the linker, increasing speciﬁcity and aﬃnity
towards bacterial toxins without the need for extensive carbohydrate or organic chemistry. Sequential
variation of this motif was found to dramatically alter both the aﬃnity and the speciﬁcity of the glycopolymers
towards two lectins, CTx and PNA, by up to 20-fold either via direct binding, or increased steric constraints.
Using this method, a glycopolymer that showed increased speciﬁcity towards CTx was identiﬁed.
Introduction
Protein–carbohydrate interactions dictate the outcomes of a
large and varied number of cellular recognition processes,
controlling immune responses, tumour metastasis, gamete
fertilisation and many more.1 The structure, function or even
identity of many glycans remains unknown. It is estimated that
50% of human proteins are glycosylated and there remains
signicant analytical challenges associated with the isolation
and characterisation of complex glycans.2 Proteins which
recognise and process the signals associated with carbohy-
drates are termed lectins: carbohydrate binding proteins which
are neither antibodies nor enzymes and they are widely
distributed in nature.3 Despite their role in normal physiology,
lectins/glycans can also act as a potential site for infection,
which can be exploited by pathogenic organisms to interface
with their host. For example, pathogenic Escherichia coli, E. coli,
expresses the FimH adhesin, which can bind mannose residues
in the urinary tract, inuenza has sialic acid binding lectin
(heamaglutinins) for adhesion to erythrocytes and Vibrio chol-
erae secretes a toxin which binds to intestinal epithelial
cells.1,4–6 Conversely, HIV expresses high-mannose structures on
its capsid that enables it to bind to DC-SIGN lectin on the
surface of dendritic cells in the human immune system.7 With
the widespread emergence of antibiotic resistance, new inter-
ventions to prevent and detect infectious disease are urgently
required.8,9 Anti-adhesion therapy, which seeks to use
compounds that have higher aﬃnity than the pathogen for the
target binding site, thus preventing the adhesion step and
hence reducing the infectivity, has emerged as a promising
potential treatment.4,10–14 As this process does not involve killing
the pathogen, there should be no evolutionary stress, hence
reducing resistance development and could be administered
prophylactically.
The binding aﬃnity of a carbohydrate to its target lectin is
typically very weak (Kd¼ 103–106 M"1), limiting their use in anti-
adhesion therapy. The sugars' weak aﬃnity is overcome in
nature by the presentation of multiple copies on cell surfaces
which gives rise to an increase in aﬃnity which is greater than
the linear sum of the individual sugars, the so-called cluster
glycoside eﬀect.15–19 Lee et al. rst demonstrated that multiva-
lent N-acetyllactosamine with one to four carbohydrates showed
progressively increasing binding aﬃnities, over several orders
of magnitude, towards rabbit hepatocytes.15 Kiessling and
coworkers have elegantly shown that polymer architecture
(linear, branched, dendritic) has profound eﬀects on lectin
binding aﬃnity, with particular focus on their ability to cluster
receptors.20 Ambrosi et al. found that galacto-functional poly-
mers have a 100-fold increase in binding aﬃnity compared to
free galactose.21 STARFISH-based monodisperse glycoden-
drimers were shown by Kitov et al. to neutralise Shiga-like
toxins, with a measured aﬃnity over 106-fold greater than the
monovalent carbohydrate.22 Exploitation of the high aﬃnity of
glycopolymer–lectin interactions also has applications in
biosensing.23,24
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Advances in controlled (radical) polymerisation
methods11,25,26 together with the development of highly eﬃcient
and orthogonal ‘click’27 reactions has facilitated the synthesis of
glycopolymers by pre- and post-polymerisation modication
thus widening the chemical and architecture diversity of gly-
copolymers.25,28 Despite the interest in developing synthetic
glycopolymers with high aﬃnity for their respective lectins,
there has been signicantly less focus placed on their speci-
city.6 What is oen not studied is the relative aﬃnity of the
glycopolymer for various lectins with similar specicities, which
is essential to avoid unwanted therapeutic side eﬀects or to
enable precise diagnostics. An important target for multivalent
anti-adhesion therapies/diagnostics is the toxin CTx, secreted
by Vibrio cholerae, the causative agent of cholera infection which
is estimated to cause over 100 000 deaths per year, and infects
more than 3 million people.29 b-Galactose functional inhibitors
have been shown to have high aﬃnity to CTx, but there is a need
to avoid unwanted interactions with other mammalian lectins,
such as the galectins, which also bind b-galactose and could
lead to immune responses such as cytokine production.30 Lectin
targets for which selective anti-adhesive therapies have been
studied include DC-SIGN/Langerhin in HIV therapy, or BmbL/
DC-SIGN to treat Burkholderia ambifaria.31–34 The relative aﬃnity
of a series of bivalent galactosides towards chicken galectins
has also been studied.35 Moreover, selectivity presents a chal-
lenge when identifying biological warfare agents based on lec-
tins such as ricin.36 Oligosaccharide-mimetic agents have also
been developed with high specicity based on tuning their 3-D
structure to t the lectin binding site but without the need for
total oligosaccharide synthesis.37
Examples of synthetic polymers that have demonstrated
lectin selectivity are rare, despite the obvious benets of their
multivalent nature.38 We have demonstrated that galactose-
functional polymers can be engineered to have increased
selectivity for cholera toxin B-subunit (CTxB).39 This was ach-
ieved by modulating the distance between backbone and
carbohydrate to match the relatively deep cle of the CTx
binding domain, compared to other galactose-binding lectins
with shallower domains.40 Selectivity is required here to
discriminate between other pathogenic lectins (or bacteria) that
bind galactose including ricin36 or indeed dietary lectins which
can reduce the inhibitor's potency as this would need to func-
tion in the intestinal tract.
In this work, we present a macromolecular engineering
approach to introduce specicity into glycopolymers, inspired
by glycan branching and guided by structural biology infor-
mation. In particular, we were motivated to achieve selectivity
without resorting to multi-step total glycan synthesis, which is
non-trivial. Using a new, 3 step-tandem post-polymerisation
process, secondary binding (branched) motifs are introduced to
the polymer side chain, to increase specicity and aﬃnity
towards bacterial toxins.
Results and discussion
As the rst step, microarray data were extracted from the
Consortium for Functional Glycomics database to enable a
short bioinformatics study to probe lectin specicity/aﬃnity.41
The relative aﬃnity of CTx and a model galactose-binding non-
pathogenic lectin, PNA (peanut agglutinin), to several oligo-
saccharides was measured and the most relevant results are
shown in Fig. 1A (full analysis in ESI†). PNA was found to bind
the disaccharide Gal-b-GalNAc 100-fold more than CTx.
However, changing this to a branched oligosaccharide (GM1),
which retains the Gal-b-GalNAc unit but also introduces a
neuraminic acid branch results in the CTx aﬃnity increasing
approximately 100-fold, but with no change in PNA aﬃnity. The
increased binding aﬃnity of CTx to the branched saccharide is
attributable to allosteric interactions of the neuraminic acid
with a secondary binding pocket within CTx, which is not
present in PNA.42 We therefore reasoned that if a secondary-
binding motif could be installed on the linker between galac-
tose and backbone on a polymer it would be possible to atten-
uate the binding aﬃnity of the polymer to CTx as shown by Tran
et al.,43 but also selectivity towards the CTx over PNA. Fig. 1B
shows the crystal structure of CTx binding to the branched
glycan unit from GM1 showing both the primary and secondary
binding pockets, which is simplied in Fig. 1C using standard
glycan notation. Fig. 1D shows the proposed polymer, with a
suﬃciently long linker to penetrate the cle in CTx and a
secondary motif to target the allosteric neuraminic acid site.
To enable installation of the branched motifs in a semi-
combinatorial manner, we have developed a new synthetic
methodology based on three tandem post-polymerisation
modications.19,44 This introduces large chemical diversity that
is not normally found on glycans, but ensures chain length (and
hence valency) homogeneity across all samples overcoming a
common challenge in functional polymers, Fig. 2.
The synthetic method fullled the following criteria: (i)
suﬃcient separation between backbone and carbohydrate to
enable penetration into the CTx binding site; (ii) an azide group
Fig. 1 (A) Glycan microarray analysis showing relative aﬃnity of CTx
and PNA to two related glycans; (B) crystal structure of CTx (blue)
binding to the oligosaccharide portion of GM1; (C) CTx crystal struc-
ture with glycan drawn in standard ball/stick notation (ESI† for key); (D)
synthetic polymer design concept with idealised polymer shown
(schematic, not simulation).
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for subsequent glycosylation with b-D-propargyl galactose; (iii)
esterication of the hydroxyl group, generated during epoxide
ring-opening. Poly(glycidyl methacrylate) was synthesised by
Cu(I)-mediated polymerisation to produce a well-dened poly-
mer with a degree of polymerisation !100 and Mw/Mn ¼ 1.2.
This molecular weight was targeted as our previous results have
shown that above a DP of !30, no further increase in avidity
towards CTx was observed.39 The polymer was produced by
controlled radical polymerisation to ensure a lack of low
molecular weight tail which would confuse the interpretation of
the activity measurements (vide infra). Installation of the azide
was achieved by addition of sodium azide in DMF at 50 #C,
which simultaneously, and quantitatively, installed the neces-
sary orthogonal handle and produced a secondary alcohol as
conrmed by infrared spectroscopy (IR), Fig. 3. In the second
step a range of acyl chlorides were reacted with the alcohol to
install secondary motifs as conrmed by the disappearance of
the OH stretch at 3400 cm$1 and the addition of a second
carbonyl stretching frequency. The acyl chlorides were chosen
based on evidence that aromatic groups can bind the sialic acid
site.43 In the nal modication reaction, b-D-propargyl galactose
was installed by Cu(I)-catalysed cycloaddition, which could be
monitored by the reduction in the azide vibration at 2100 cm$1.
Table 1 summarises the polymer library obtained, the side
chains installed and the calculated log P values of a single repeat
unit of the polymer (vide infra). Log P values are included as an
estimate of the relative hydrophobicity of the binding units.
With this panel of sequentially modied glycopolymers in
hand, a sorbent assay was used to evaluate the aﬃnity of the
polymers towards each of the lectins.24,39,45 Briey, the glyco-
polymers were incubated at various concentrations with uo-
rescently labelled lectins. The solutions were then added to
galactose-functionalised microtitre plates. The concentration of
polymer required to inhibit 50% of binding to the plates was
reported as the MIC50 value. Upon initial testing it was found
that several members of the library were insuﬃciently soluble in
buﬀer to be used in the assays. It was possible to solubilise the
polymers in 5% (v/v) aq. DMSO, but we found this compromised
the CTx-assay giving false positive results and hence only the
polymers which could be directly dissolved into buﬀer were
tested. The less soluble polymers are still shown in Table 1 to
highlight the synthetic diversity achieved by this approach. As
predicted, addition of the branched motifs had a dramatic
inuence on the inhibitory potential of the glycopolymers
against both of the lectins, Fig. 4.
Fig. 4 reveals some general trends between molecular
structure and lectin aﬃnity. Three of the secondary units, P8, P9
and P10 gave rise to large 10-fold decreases in the MIC50
towards both lectins, compared to P1. Whilst these groups were
relatively diverse, the common theme was that they did not
contain an aromatic group, but P8 and P10 did contain halo-
genated alkanes. P8 and P10 side chains are signicantly larger
than in P9 which suggests that their aﬃnity modulation was not
entirely due to steric constraints and may indicate that
branching at the side chain increases aﬃnity to CTx. Polymers
P11, P5 and P6, led to either no changes, or signicantly
increased the MIC50 values. Due to the size and rigidity of these
functional groups, steric constraints might be crucial, prevent-
ing access of the polymer to both lectins, or limiting confor-
mational exibility. Polymer P4, which had a linear, but exible,
hexamethylene group gave modest improvements (lower MIC50)
in binding to both lectins. Our observations are in contrast to
those of Bundle and coworkers who have observed that pendant
aromatic units can enhance the binding to CTx via interactions
with the neuraminic acid binding pocket, but they used poly-
mers with a very low density of carbohydrate side chains and
diﬀerent length side chains on polydisperse scaﬀolds, making
comparisons diﬃcult.43 Here we have densely packed side-
chains that impose additional steric restraints. The high aﬃnity
of CTx to GM1 in nature is attributable to the intrinsic rigidity of
GM1, which has also been found to be important in small-
molecule GM1 mimics and is probably contributing here.46,47
Comparison of the observed inhibitory values against the
calculated partition coeﬃcient did not reveal any obvious trend
suggesting simple hydrophobic/hydrophilic interactions are not
responsible (ESI†).
As indicated in the introduction, the key aim of this study
was to use glycan-mimetic branching to introduce specicity/
selectivity as well as aﬃnity into synthetic glycopolymers.
Analysis of the data in Fig. 4 revealed that P1 and P5 (chlor-
obenzyl) showed the most dramatic diﬀerences in terms of
relative aﬃnities for each lectin. Fig. 5 shows the relative aﬃnity
(shown as 1/MIC50 for convenience), for P1 and P5 against
the two lectins. P1 shows similar aﬃnity for both PNA and
CTx indicating that it cannot discriminate/select between
two diﬀerent galactose-binding lectins. However, addition of
Fig. 2 Glycopolymer design principle and the newly developed
synthetic route. Glycan structure is shown in standard notation (ESI†).
Fig. 3 Infrared analysis of the 3-stage, glycan mimetic, tandem post-
polymerisation strategy used here. IR analysis was of puriﬁed product.
This journal is © The Royal Society of Chemistry 2014 Chem. Sci., 2014, 5, 1611–1616 | 1613
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4-chlorobenzyl unit (P5) leads to dramatic diﬀerentiation in
response to PNA and CTx, with a signicant decrease in aﬃnity
towards PNA, but essentially no change in aﬃnity to CTx. This
demonstrates that P5 displays lectin selectivity, using biomi-
metic macromolecular engineering, but without multistep
carbohydrate chemistry. The exact mechanism of binding
which leads to selectivity cannot be rationalised at this stage,
but the additional bulk of the chlorobenzyl group may prevent
access to the PNA binding site, but still be of correct dimensions
to t the neuraminic acid site in CTx. This will be the subject
of future investigations. Furthermore, the inuence of
substituting the chloro- for bromo-group (P5 – P6) cannot be
explained. P6 has vastly increased MIC50 values towards CTx
relative to P5, but less eﬀect on PNA binding. The additional
steric bulk of a bromide might simply be too large for a good t
into the binding cle in CTx. P1/P5 also displayed similar
aﬃnities for RCA120, another galactose-binding lectin indi-
cating that the structural motifs added here only aﬀect the
target lectins (ESI†). This supports our hypothesis that the
secondary motif is giving us the specicity based on interac-
tions with the neuraminic acid binding site in CTx, which is not
present in either RCA120 nor PNA, and hence the polymers' have
decreased aﬃnity to both of these lectins. These observations
rule out non-specic hydrophobic association between poly-
mer/lectins as this would be expected to give enhancements to
all tested lectins.
Conclusions
We have demonstrated a new bio-inspired approach to
mimicking glycan architecture by using macromolecular engi-
neering, guided by structural biology, and without the need for
multi-step oligosaccharide synthesis. Bioinformatics revealed
that the addition of branched side chains to galacto-terminal
carbohydrates could increase binding aﬃnity to their corre-
sponding lectins, relative to simple monosaccharides. Tomimic
this branched structure a new, 3 step, tandem post-polymeri-
sation methodology was developed. This enabled precise
control over not only chain length, but also carbohydrate-poly-
mer backbone linker distance and the introduction of
secondary binding (branched) motifs onto the linker. Sequen-
tial variation of this motif was found to dramatically (up to
Table 1 Side chains installed onto the polymers and log P valuesa
Code Structure log P Code Structure log P Code Structure log P
P1 !1.57 " 0.61 P5 1.3 " 0.7 P9 !0.17 " 0.6
P2 1.96 " 0.68 P6 1.48 " 0.75 P10 !0.36 " 0.82
P3 1.70 " 0.7 P7 0.81 " 0.75 P11 0.73 " 0.68
P4 3.08 " 0.6 P8 0.22 " 0.63
a log P values are calculated based on a single repeat unit of the polymer, with methyl capping groups at each chain end.
Fig. 4 Inhibition of lectin binding by synthetic glycopolymers. Values
shown are the average of at least 3 measurements, and errors are the
standard deviation.
Fig. 5 Relative aﬃnity (1/MIC50) of P1 and P5 for CTx and PNA.
1614 | Chem. Sci., 2014, 5, 1611–1616 This journal is © The Royal Society of Chemistry 2014
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20-fold) alter both the aﬃnity and the selectivity of the glyco-
polymers towards two lectins; CTx and PNA. Using this method,
a glycopolymer was identied which showed increased speci-
city towards CTx. Glycopolymers with high selectivity may
feature in the development of sensitive and precise sensors or
anti-adhesive therapies, which has so far limited the application
of synthetic glycopolymers. These results show that combining
structural biology tools with macromolecular chemistry enables
the creation of synthetic glycans which can mimic, or outper-
form their natural counterparts and will nd applications in
anti-adhesive therapy and bimolecular sensors.
Experimental
Example acylation reaction using benzoyl chloride
Poly(2-hydroxy-3-azidopropyl methacrylate) (200 mg, 8.73 mmol)
was dissolved in anhydrous THF (50 mL), along with triethyl-
amine (0.45 mL, 3.24 mmol – 3 eq. for each polymer repeat
unit). Benzoyl chloride (0.46 g, 3.24 mmol – 3 eq. for each
polymer repeat unit) was dissolved in 50 mL of anhydrous DCM
and added dropwise to the solution over a period of 30 minutes.
Following complete addition, the solution was le to stir at
room temperature for 24 hours. A further portion of triethyl-
amine (0.45 mL, 3.24 mmol) and benzoyl chloride (0.46 g, 3.24
mmol) were added to the solution and allowed to stir for a
further 24 hours. The solution was then diluted with 100 mL of
DCM and quenched with 100mL of water. The organic layer was
washed with water (2 ! 50 mL), dried over anhydrous MgSO4,
ltered and the solvent removed. The crude polymer solution
was then redissolved in 50 mL of THF and twice precipitated
into a 1 : 1 mixture of diethyl ether–petroleum ether. The solids
were isolated by centrifugation and dried under vacuum to yield
the product as a oﬀ-white powder.
Example 1,3-dipolar cycloaddition reaction of benzoyl
chloride-modied polymer with galactose alkyne
Polymer (100 mg, 345.67 mmol), Cu(I)Br (4.9 mg, 34.16 mmol)
and galactose alkyne (226 mg, 1.04 mmol) was dissolved in
DMSO (8 mL) in a Schlenk tube. This solution was degassed by a
minimum of 3 freeze–pump–thaw cycles and frozen with liquid
nitrogen. The Schlenk tube was then opened, 2,20-bipyridyl (10.8
mg, 69.15 mmol) was added and the tube re-sealed. The frozen
solution was evacuated three times, back-lled with dry
nitrogen and le to defrost. Aer stirring at ambient conditions
for 4 days, the solution was diluted with distilled water and
dialysed against water for 3 days. The resulting suspension was
centrifuged and the supernatant was lyophilised to leave an oﬀ-
white powder.
Example uorescence-linked sorbent assay for inhibitory
activity against cholera toxin B subunit (CTx)
96-well microtitre plates were incubated for 16 h with 150 mL of
100mgmL"1 GCS (in 95%ethanol, 5%water andheated to 45 #C).
Unbound GCS was removed by washing extensively with water.
Polymer solutions were made up as serial dilutions (up to 10
dilutions per sample from either 1 mg mL"1 or 0.1 mg mL"1 in
water). 10mLof100mgmL"1CTx–FITC in10mMTriswith0.1mM
CaCl2 and 0.5 mM NaCl (pH 8) was added to 90 mL of polymer
solution to anal concentrationof 11mgmL"1. 100mLof the PNA/
polymer solutions were then added to GCS coated wells and
incubated at 37 #C for 30min. Aer this the wells were extensively
washed with water and uorescence was measured at excitation/
emission wavelengths of 485/528 nm. All experiments were
carried out in triplicate. Percentage inhibition was compared to
relative to controls of pure CTx–FITC (with no polymer).
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Discrimination between lectins with similar
speciﬁcities by ratiometric proﬁling of binding to
glycosylated surfaces; a chemical ‘tongue’
approach†
L. Otten and M. I. Gibson*
Carbohydrate–lectin interactions dictate a range of signalling and
recognition processes in biological systems. The exploitation of these,
particularly for diagnostic applications, is complicated by the inherent
promiscuity of lectins alongwith their low aﬃnity for individual glycans
which themselves are challenging to access (bio)synthetically. Inspired
byhowa ‘tongue’ can discriminate betweenhundredsofﬂavours using
a minimal set of multiplexed sensors and a training algorithm, here
individual lectins are ‘proﬁled’ based on their unique binding proﬁle
(barcode) to a range of monosaccharides. By comparing the relative
binding of a panel of 5 lectins to 3monosaccharide-coated surfaces, it
was possible to generate a training algorithm that enables correct
identiﬁcation of lectins, even those with similar glycan preferences.
This is demonstrated to be useful for discrimination between the
cholera and ricin toxin lectins showing the potential of this minimalist
approach for exploiting glycan complexity.
Introduction
Protein carbohydrate interactions are essential for many bio-
logical processes including cell–cell communication, fertilisa-
tion and innate immunity.1 They are also readily exploited by
pathogens during adhesion steps. These adhesion steps are
mediated by carbohydrate binding proteins known as lectins. In
nature, multivalent presentation of glycans at cell surfaces
increases the aﬃnity towards its binding partner which has
been widely exploited to create synthetic glycomimetics, such as
glyco-polymers2 and particles.3–5 This strategy however does not
necessarily maintain or improve the selectivity complicating the
design and application of multivalent glycoconjugates.2,5–8
Lectin interactions are mediated by the carbohydrate itself
but also the linker between the carbohydrate, the cell surface and
precise 3D presentation of carbohydrates on the cell surface.6,9
Many lectins show highly specic binding to oligosaccharides
but show much more promiscuous binding characteristics on a
mono- and di-saccharide level. For example, peanut agglutinin
(PNA) is generally described as being b-galactose specic but
microarray analysis shows that it will readily bind all mono-
saccharides with very little diﬀerence between them.10 The same
is also true for cholera toxin, this toxin is highly specic to the
GM-1 ganglioside in the body and thus is described as being
galactose specic but this lectin will indiscriminately bind all
monosaccharides to one degree or another.10
This wide variety of roles played by glycans in the body's
innate processes and their prevalence in nature means the
interference or detection of these interactions could have an
impact in combatting infectious diseases.11 For example, FimH
is a lectin involved in the binding of uropathogenic Escherichia
coli to mannose rich residues and is a crucial virulence factor.
Cholera is caused by cell internalisation of an AB5 toxin,
mediated by the 5 lectin subunits of the toxin initiating binding
to GM-1 on epithelial cells in the small intestine. Ricin is a toxic
protein extracted from Ricinus communis seeds, it consists of
one subunit responsible for cleaving an adenine residue from
the 28S ribosomal RNA (thus rendering the cell incapable of
protein synthesis) and one subunit responsible for binding to
galactose rich residues.12 Diﬀerences in glycosylation of cells
have also been implicated in tumour cells and determining
metastatic potential of cancers13,14 and the ABO blood system is
also determined by diﬀerent antigenic oligosaccharides.11,15
Serological blood groups have been implicated in individual
susceptibility to many diseases and the severity of others
including small pox, cholera and malaria.15–17 As such rapid
detection of lectins can aid in the early identication and
prevention of diseases and also in the design of therapeutics.
This broad window of binding partners means that the design
of a sensor for a lectin based on glycans alone is immensely
challenging.
Whilst proteomic and antibody based techniques can be
used for identication of lectins these are not always suitable
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for robust, point of care applications, and require infrastructure
for preparation, storage, distribution and deployment of the
sensor. Such a challenge is indeed not unique to glycobiology,
and the detection of cell phenotypes, which oen have dynamic
surface ligand displays which change with their environment.
To address this nanoparticles multiplexed biosensing has
attractedmuch interest especially for diagnostics.18 Rotello et al.
have developed the use of diﬀerentially functionalised gold
nanoparticles for multiplexed diagnostics. For example, 52
diﬀerent mixtures of seven diﬀerent proteins could be identi-
ed using just six distinct nanoparticles.19 Gold particles coated
with 3 diﬀerent thiols enabled cancerous and healthy cells to be
discriminated without the requirement for any specic binding
epitopes.20 Detection of pathogenic bacteria using a related
system in under 5 minutes has also been demonstrated21 as
have MRI based detection of cancerous cells with diﬀerential
lectin expression levels.22 Jayawardena et al. have described the
use of glycosylated gold nanoparticles and their characteristic
shi in SPR frequencies upon protein binding to characterise
lectins based on their response to a panel of sugars.23 In this
case, lectins with very diﬀerent glycan specicities were used
(e.g. concanavalin A/soybean agglutinin) and discrimination
was also possible without the need for multiplexing and just
using individual glycans making it a less challenging analysis.
The goal of the present research was to evaluate the use of
simple and synthetically accessible mono-saccharides as mul-
tiplexed sensors to enable discrimination between diﬀerent
lectins which have similar binding specicities. Such a system
would have widespread application especially for low-cost
selective detection/monitoring of toxins.
Results and discussion
The key aim of this work was to probe the diﬀerential response
of lectins to simple carbohydrates (monosaccharides), so it was
essential to employ accessible (/facile) coupling chemistry. 96-
multiwell plates with hydrazide functionality were used to
couple a range of monosaccharides, and mixtures of diﬀerent
monosaccharides using an aniline catalyst at 50 !C to give gly-
cosylated surfaces (Fig. 1A). This coupling mechanism is known
to result in attachment of the monosaccharides predominantly
in their ring closed (pyranose) b-anomeric form.24 It should be
noted that the presence of some acyclic species does not aﬀect
our later analysis using a training algorithm (vide infra). It was
not possible to interrogate the functionalised polypropylene
surface of the microwell plate using traditional surface analysis
techniques (such as elipsometry). As an alternative to contact
angle, droplet spread was measured. Hydrophobic surfaces,
when viewed from above should give reduced surface coverage
at equal volume, compared to a hydrophilic surface with a low
contact angle. The native, and glycosylated surfaces were
therefore interrogated by addition of a drop of ultra-pure water
with resorun (a dye) added to enable visualisation of the
droplet spread, and subsequent image analysis. The native
surfaces resulted in only 30% of the surface being covered by
the drop, but the galactose functional surface resulted in
droplet spreading over 50% of the surface (Fig. 1B). As a positive
control, glyceraldehyde was added to generate very hydrophilic
surface coating, and this resulted in spreading over"90% of the
surface, conrming this (unconventional) analytical approach.
Glycan-modied surfaces should also present an uncharged,
non-fouling surface, compared to the native hydrazide/
polypropylene surface. Therefore, non-specic fouling
(adsorption) was tested using FITC-labelled bovine serum
albumin. Compared to the native surface, the glycosylated
surfaces showed signicantly less binding than the native
surface, with no signicant absorption observed at concentra-
tions below 0.2 mg mL#1 again conrming the surface modi-
cation (Fig. 1C).
To highlight the challenges faced in identication and
proling of lectins with similar binding specicities, a panel of
5, uorescently labelled, galactose (or GalNAc) binding lectins
were selected, exposed to a galactose microwell plate, washed
and total uorescence measured. Fig. 2 shows the results of
this, indicating that at any given concentration the total
response recorded is not unique to any given lectin. Cholera
toxin B subunit (CTx) gives higher binding than the others, but
the absolute uorescence intensity is obviously dependent on
the concentration applied, which is not ideal for any realistic
biosensory format as it requires signicant prior knowledge of
the solution being probed.
Considering the low information content of these single
sugar assays, we proceeded to extract information for a series of
Gal-binding lectins from the CFG database (consortium for
functional glycomics) to a range of small mono/disaccharides
(gure of this analysis included in ESI†). The CFG data
revealed that any single glycan cannot predict the identity of the
lectins (i.e. a single peak is not present) due to their inherent
promiscuity. However, if many diﬀerent glycans are included,
there is a unique pattern of binding of each lectin to the
carbohydrates (a ‘barcode’). Guided by this data, we rationalised
Fig. 1 Fabrication of glycosylated 96-well plates. (A) Hydrazide–
carbohydrate coupling; (B) dye spreading assay showing relative
hydrophilicity of surfaces; (C) non-speciﬁc binding of ﬂuorescently-
labelled bovine serum albumin onto diﬀerent surfaces following 30
minutes incubation and washing.
53912 | RSC Adv., 2015, 5, 53911–53914 This journal is © The Royal Society of Chemistry 2015
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that if we could identify the ‘minimum basis set’ of glycans that
can provide a unique barcode for each lectin, it would be
possible to distinguish between these, enabling protein iden-
tication without proteomics or associated methods. Using the
hydrazide coupling chemistry described above, we generated 4
diﬀerently glycosylated surfaces; Gal, Man, Glc and a 1 : 1
mixture of Gal : Man (the latter was added as in our hands this
improves the resolution of our subsequent analysis. Variable
density glycan mixtures are known to give non-linear
responses7). Pleasingly, these relatively low-aﬃnity mono-
saccharides produced very unique binding proles for each
lectin, as shown in Fig. 3. For example, Ricinus communis
Agglutinin (RCA120) had signicantly higher binding to galac-
tose, and the Gal/Man mixtures, than compared to Glc binding.
Conversely, Soybean Agglutinin (SBA) had signicantly
depressed binding to the mixed surface. A summary of the
relative binding of the lectins can be shown in a heat map to
give a ‘bar-code’ which is unique to each protein.
Analysis of the individual binding of one lectin to a sugar
does not give much information, but when combined together,
this diﬀerential response provides suﬃcient information to
enable a linear discriminant analysis. Linear discriminant
analysis is a training algorithm that inputs a matrix of data and
produces a model in which all of the categories in the initial
training matrix are grouped into distinct categories based on
their linear discriminant factors (which are a linear combina-
tion of the initial inputs-in this case the surfaces used). Due to
the high degree of separation between categories within the
model produced it allows for greater condence in the identi-
cation of lectins responsible for binding in unknown samples
when compared to the raw data alone.
Fig. 4A shows the results of a linear discriminant analysis of
these lectins to the four glycosylated surfaces, revealing highly
resolved groupings for each lectin. The circles around each are
indicative of a 95% condence boundary. Fig. 4B shows the LD
analysis for the lectins without CTx, as when this is included the
other four lectins appear more tightly bunched (but are still
perfectly resolved) due the generally increased binding of CTx to
all surfaces employed here. This simple, but powerful, multi-
plexed method enables separation and identication of lectins
with similar binding proles, but without the need for complex
carbohydrates, in much the same way as a tongue has evolved to
identify complex tastes based on only 5 diﬀerent inputs. To test
the predictive power of this, blind analysis of unknown lectin
samples was also conducted, revealing 100% predictive accu-
racy from this training matrix.
As a nal test of this sensing approach, the diﬀerentiation
between two diﬀerent gal-binding, pathogenic, lectins was
investigated. CTx is the toxin secreted by the bacteria Vibrio
cholera, which causes cholera and is a huge problem in devel-
oping countries and disaster zones. RCA120 is a surrogate for
ricin, which can be weaponised as a biological warfare agent. A
training algorithm was again employed, but this time the
RCA120/CTx solutions were applied as mixtures of the two lec-
tins, rather than as pure protein solutions. This provides a far
more challenge test, which is closer to a real world sensing
Fig. 2 Relative binding of a panel of 5 lectins to a galactose-functional
surface as judged by ﬂuorescence intensity. All lectins applied at 0.01
mg mL!1, with FITC labels.
Fig. 3 (A) Relative lectin binding to glycosylated surfaces determined
by ﬂuorescence; (B) heatmap, demonstrating that each protein has a
‘barcode’ of responses to each glycan, each lectin displayed contains
at least 4 independent replicates.
Fig. 4 Linear discriminant analysis of lectin binding to the 4 diﬀerent
glycosylated surfaces. (A) Lectins with CTx, and (B) lectins without CTx.
This journal is © The Royal Society of Chemistry 2015 RSC Adv., 2015, 5, 53911–53914 | 53913
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application. When CTx was present at > 50% (by mass) the LD
model correctly indicated its presence, and when the RCA120
concentration was above 50%, this was correctly scored (see
ESI† for full details and LDA graphs).
Conclusions
Here we have reported the new concept of a ‘chemical tongue’
for multiplexed biosensing, and discrimination between
carbohydrate-binding proteins (lectins). We show that using
only simple monosaccharides, which have very low intrinsic
aﬃnity and specicity, it is possible to discriminate between a
panel of lectins with extremely similar binding preferences. The
power of this method lies in the scalability, enabling manymore
(oligo)saccharides to be employed, and the use of the large
glycan databases (which are freely available) to guide the design
of each system. Using this approach we demonstrated that the
chemical tongue can even distinguish the presence of cholera or
ricin, in complex mixtures of the two lectins. Current and future
work is focused on establishing the limits and scope of this
method, and translating it into realistic sensory surfaces/
components which would remove the need for labelled
proteins.
Experimental
Full experimental detail including microplate functionalization
LDA analysis is provided in the ESI.†
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